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Summary 
 
Pulmonary arterial hypertension (PAH) is fatal disease of the small 
pulmonary arteries which is characterised by medial hypertrophy causing an 
increase in pulmonary vascular resistance and pulmonary artery pressure 
resulting in right ventricular failure and death. The pathogenesis of PAH has 
not been fully elucidated to date and there is no current curable 
pharmacological treatment.   
Inflammation is thought to play an important role in the pathogenesis 
of PAH. The work undertaken in this thesis aimed to investigate the role of T 
cells in the pathogenesis of PAH by characterising lymphocyte subsets (T 
and B cell distribution) in treatment-naïve patients with PAH and animal 
models of disease. I found that the relative frequency of CD8+ cytotoxic T 
cells in treatment-naïve Scleroderma associated-PAH patients was 
significantly decreased compared to corresponding controls. A negative 
correlation was also noted between the relative frequency of CD4+ T cells 
and several clinical parameters. To investigate cause or effect of changes in 
T cell frequency, I examined a time course of the paigen diet-fed ApoE-/-/IL-
1R1-/- mouse model of PAH, but noted no difference in circulating T cell 
subset distribution. CD4+ T cell depletion rendered these animals more 
susceptible to the development of PAH. 
Collectively, these findings suggest that subtypes of PAH are 
associated with distinct T cell profiles. Alterations in circulating T cell and B 
cell subsets in clinical PAH, particularly CD8+ T cells suggest a dysfunctional 
immune system which could contribute to disease pathogenesis. In 
experimental models, the propagation of disease progression by depletion of 
CD4+ T cells suggests an anti-inflammatory nature of these cells within this 
disease setting. Future studies are needed to fully understand the exact role 
that T cells play in the pathogenesis of PAH. 
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Chapter 1  General introduction 
 
1.1  Pulmonary circulation  
 
 The cardiovascular system can be broadly divided into three parts: 
the pulmonary circulation, the systemic circulation and the coronary 
circulation. The coronary circulation is the circulation of blood in the blood 
vessels of the heart muscle, whilst the systemic circulation supplies the body 
with oxygenated blood from the heart, delivering deoxygenated blood back to 
the heart. In the pulmonary circulation, deoxygenated blood returning from 
the body enters the heart through the inferior and superior vena cavae and 
flows into the right atrium, then the right ventricle. The blood is then pumped 
out through the pulmonary artery through a complex network of dividing 
branches towards the capillaries in the lung, where gas exchange occurs. 
The oxygenated blood then leaves the capillaries via the pulmonary vein to 
re-enter the left atrium of the heart. Characteristics of a healthy pulmonary 
circulation include an network of highly compliant blood vessels which have 
low luminal pressure and high flow rates which encourage gas exchange 
(Harris, 1986).  
  
1.2  T cell immunobiology 
 
T lymphocytes (T cells) are a subset of leukocytes that are involved in 
both pro- and anti-inflammatory immune responses. T cells can be 
distinguished from other lymphocyte subsets by the presence of a T cell 
receptor (TCR) on their cell surface which is involved in recognising antigens 
bound to major histocompatibility complex molecules (MHCs). Specific co-
receptors including CD4 and CD8 found on the T cells along with accessory 
molecules, aid in the formation of a T cell receptor complex which transduces 
signals between the T cell and antigen presenting cell (APC).  
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T cells originate from haematopoietic stem cells in the bone marrow, 
but then populate the thymus where they mature and expand into immature 
thymocytes. A mechanism called central tolerance occurs in the thymus in 
which self-reactive T cells are removed via positive and negative selective 
processes. The remaining cells that have not been removed emerge as 
CD4+/CD8+ cells (T cell precursors) and under the influence of certain 
transcription factors such as T-bet and cytokines such as IL-2, differentiate 
and proliferate into specific lineages of T cell (Table 1.1).   
 
Subset Function 
CD4+ T cells 
Can mature into effector, memory or Treg cells and are 
involved in Th1, Th2 and Th17 responses. 
CD8+  T cells 
Destroy virally infected cells and tumor cells via the 
secretion of perforin and granzymes, which cause 
apoptosis of target cells. 
Regulatory T cells Maintain immunological tolerance. 
CD4-CD8- T cells 
Pro- and anti-inflammatory properties and can protect 
against allograft rejection. 
Memory T cells 
Have previously encountered antigen and can rapidly 
proliferate and differentiate into effector T cells following 
antigen stimulation. 
 
Table 1.1 T lymphocyte cell subsets. 
T cell subsets found within peripheral blood and their functions. CD= cluster of 
differentiation, Th= T helper type, Treg= T regulatory. 
 
CD8+ T cells express the CD8 glycoprotein on their cell surface which 
can bind to MHC class 1 molecules on the surface of target cells. They can 
rapidly proliferate in response to IL-2 and destroy target cells via Fas and 
perforin dependent mechanisms, but do not require co-stimulatory signals 
unlike CD4+ T cells (Broere et al, 2011). Memory T cells can be found in 
secondary lymphoid organs such as lymph nodes or spleen and can mount 
fast and effective responses to antigens that they have previously 
encountered. Memory T cells can rapidly proliferate and differentiate into 
effector T cells and typically express the cell surface protein CD45RO. These 
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cells can either be CD4+ or CD8+ and can be central or effector subtype 
(Sallusto et al, 2004). Double negative (CD4-CD8-) T cells are found in low 
numbers in the peripheral blood and do not express CD4 or CD8 
glycoproteins. They are thought to have pro- and anti-inflammatory 
properties, producing both IL-4 and IL-17 and inducing immunogloblulin (Ig) 
and anti-DNA antibody production, however their exact function is still 
unknown (Alluno et al, 2012; Zlotnik et al, 1992).  
The largest population of T cells are those defined by the expression 
of a protein named CD4 on their cell surface (CD4+). These cells become 
activated when presented with antigens via MHC class 2 molecules which 
are expressed on APCs. These cells (Th0) can then differentiate into many 
other cell types depending on the signals they receive. These include Th1, 
Th2, Th17 and Treg cells which all have different functions. Th0 cells 
differentiate into Th1 cells in the presence of IL-12 and IL-18 released from 
dendritic cells (DCs) and can then secrete IL-2 and IFN-γ which act upon 
macrophages to enhance their killing ability and also encourage the 
proliferation of cytotoxic CD8+ T cells (Mosmann and sad, 2006). Th2 cells 
occur in the presence of IL-4 which can be released from B cells or DCs and 
they themselves can secrete IL-4, IL-5 and IL-10 and can act to enhance 
mast cell and eosinophil cell functions as well as promote B cell proliferation 
and antibody class switching (Constant and Bottomly, 1997). Th17 cells 
occur in the presence of TGF-β and IL-6 and are involved in the recruitment, 
activation and migration of neutrophils as well as the production of IL-21 and 
IL-22 (Bettelli et al, 2007).  
T lymphocytes have long been thought to be involved in both the 
initiation and resolution of disease and there has been much debate about 
the existence of T lymphocyte subpopulations which act as endogenous 
immunoregulators.  A number of different immune Treg cell populations have 
been identified and can be classified into either naturally occurring (nTreg) or 
inducible T regulatory types (Tr1, Th3) cells (Scumpia et al, 2006). As well as 
this, T cell subsets including CD8+ T cell suppressive cells, γδ T cells and 
natural killer T cells (NKT) all posess suppressive and regulatory functions 
(Boehmer, 2005; Miyara and Sakaguchi, 2007; Kabelitz, 1992) (Table 1.2). 
4 
 
 
Subset Function Development 
nTreg 
Immunosuppressive and tolerogenic responses 
(contact-dependent and independent 
mechanisms). 
Thymus 
Tr1 
IL-10 mediated suppression and involved in 
mucosal immunity. 
Periphery 
Th3 
TGF-β mediated suppression and involved in 
mucosal immunity. 
Periphery 
NKT cell 
Respond to atypical antigen presentation via 
CD1d molecule producing large amounts of 
cytokines (IL-4, IFN-γ, GM-CSF). 
Thymus 
CD8+ T cell IL-10 and TGF-β mediated suppression. Periphery 
δγ T cell pro- and anti-inflammatory functions  periphery 
 
Table 1.2 T regulatory cell subsets. 
T regulatory cell subsets found centrally and in the periphery in humans, their 
function and location of development are also shown. NKT= natural killer T, nTreg= 
natural T regulatory cell, Th= helper type, CD= cluster of differentiation, IL= 
interleukin, IFN-γ= interferon-gamma, GM-CSF= granulocyte-macrophage colony-
stimulating factor and TGF-β= transforming growth factor-beta. 
 
CD8+ suppressor T cells are found in the periphery and can produce 
several cytokines including IL-10 and TGF-β in order to suppress both CD4+ 
T cells and B cells (Filaci and Suciu-Foca, 2002). They can also recognise Ig 
molecules, inhibit Th cell proliferation and suppress autoimmune responses 
(Liu et al, 1998; Hahn et al, 2005). 
Tr1 cells are found in the gut and exert suppressive effects through 
contact-mediated independent mechanisms via the secretion of IL-10 and 
TGF-β. They are thought to be involved in tolerance towards antigens and 
can suppress memory and naïve T cell responses (Roncarolo et al, 2006; 
Groux et al, 1997). Tr1 cells have also been shown to have cytotoxic 
functions (via the production of perforin and granzyme B) when induced by 
CD3/CD46 leading to the apoptosis of target cells (Grossman et al, 2004).  
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Th3 cells are also found in the gut and are generated from gut 
associated lymphoid tissue (GALT) in response to TGF-β. These cells are 
primarily involved in the regulation of autoimmunity but have also been 
shown to aid IgA immune responses and can suppress Th1 and Th2 cell 
function and proliferation (Chen et al, 1994; Weiner, 2002).  
Another T regulatory cell subset, the γδ T cell, is involved in 
recognising whole proteins instead of peptides presented via MHC molecules 
on APCs. They are thought to have characteristics of both innate and 
adaptive immunity and can have pro- and anti-inflammatory properties 
depending on the TCR that they express (Born et al, 2005; Zheng et al, 
2013; Kuhl et al, 2009).  
NKT cells are thought to also be involved in innate and adaptive 
immune responses and can produce cytokines and release cytotoxic 
molecules. They recognise glycolipid antigens presented by the CD1d 
molecule and can produce several cytokines including IL-4 and IFN-γ 
(Godfrey et al, 2000). These cells also have the ability to indirectly sense 
infectious agents by responding to secreted cytokines from activated DCs 
(Tupin et al, 2007). 
Finally, the most widely investigated group of T regulatory cells are the 
nTreg cells, which are a subpopulation of CD4+ T cells that constitutively 
express high levels (+/bright/high) of the α-chain of the IL-2 receptor (CD25). 
Treg cells represent 1–3% of CD4+ T cells in normal humans and about 10% 
in rodents. The continuing controversy surrounding the presence of 
immunoregulatory T cells stems from the lack of reliable surface markers and 
inconclusive knowledge regarding their function and role within the immune 
response.  
Sakaguchi et al were the first to describe the critical involvement of 
CD4+CD25high Treg cells in the maintenance of peripheral tolerance to self 
antigens (Sakaguchi et al, 1995). Depleted CD4+ T cell suspensions were 
prepared from BALB/c nu/+ mice lymph nodes and spleens. These mice 
carry the recessive nude gene on one chromosome and so have a normal 
thymus and immune system. CD25+ T cells were depleted using a specific 
monoclonal antibody (mAb) from these cell preparations and these cells 
were then inoculated into BALB/c athymic nude (nu/nu) mice. All mice that 
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received the inoculation developed autoimmune diseases including thyroiditis 
and gastritis. This work demonstrated that a systemic autoimmune response 
occurs when CD4+CD25high Treg cells are removed within the first few days 
of birth and emphasised the importance of these cells in immunologic self-
tolerance and the negative control of immune responses (Sakaguchi, 2004). 
Cumulatively, these studies show that the loss or absence of what are now 
termed Treg cells renders animals and human susceptible to serious 
disease.  
Forkhead box protein 3 (Foxp3), a transcription factor that controls 
both CD4+CD25high Treg cell development and function, has been noted in 
mouse and human CD4+CD25high Treg cells (Hori et al, 2003). It has 
previously been demonstrated that Foxp3 is required for thymic development 
of Treg cells and that the expression of Foxp3 in naïve T cells provides a 
stimulus to convert them to Treg cells (Fontenot et al, 2003; Hori et al, 2003; 
Yagi et al, 2004). Foxp3 has also been shown to bind to DNA, localize to the 
nucleus and can act as a transcriptional repressor. It also antagonises 
nuclear factor of activated T-cells (NFAT) function by competing for DNA 
binding sites, inhibiting T cell development and proliferation (Schubert et al, 
2001). Foxp3 is now thought to be a reliable intracellular marker of 
CD4+CD25high Treg cells.  
 
1.2.1 Mechanisms of action of Treg cells 
 
There are several mechanisms by which Treg cells are thought to 
mediate a suppressive effect on other cells. Once activated, CD4+CD25high 
Treg cells suppress other T cells, NK cells and B cells, but can also affect the 
activation and function of monocytes, macrophages and dendritic cells (DCs) 
(Camara et al, 2003; Janssens et al, 2003; Taams et al, 2005; Ghiringhelli et 
al, 2006). CD4+CD25high Treg cells require T cell receptor stimulation to 
become activated and cytokines, including IL-2, to trigger their suppressive 
action (Thornton et al, 2004). In vitro studies into CD4+CD25high Treg 
suppressive activity using transwell experiments, have demonstrated that 
these cells can act on target cells in a cell-contact dependent manner (Wing 
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et al, 2006). CD4+CD25high Treg cells can also directly suppress effector T 
cells through molecules such as membrane transforming growth factor beta 
(TGF-β) or by killing effector cells via the release of the serine protease 
granzyme B (Grossman et al, 2004). They are also thought to act via the 
release of suppressive cytokines, such as IL-10, TGF-β and IL-35 (Chen et 
al, 2003). Finally, CD4+CD25high Treg cells can act as a “sink” to absorb 
surrounding IL-2 through their CD25 receptors (Thornton and Shevach, 
1998). CD4+CD25high Treg cells can therefore compete with effector cells for 
IL-2, which is an essential growth factor for T cells (Figure 1.1).  
Treg cells can be recruited into injured or inflamed tissue via their 
contact with endothelial derived intracellular adhesion molecule 1 (ICAM-1) 
and vascular cell adhesion molecule 1 (VCAM-1), which aid extravasation 
into the tissue from pulmonary vessels (Pribila et al, 2004). Endothelial 
contact with Treg cells is thought to not only activate Treg cells but initiate 
key anti-inflammatory and cardioprotective events to protect the endothelium 
from injury (Bedke et al, 2010). When activated by endothelial cells (ECs), 
Treg cells secrete IL-10 and TGF-β which can act as vasodilator by rescuing 
eNOS phosphorylation (Bhattacharyya et al, 2004). Treg secreted IL-10 can 
also reduce oxidative stress by inhibiting nicotinamide adenine dinucleotide 
phosphate-oxidase (NADPH) oxidase activity which produces reactive 
oxygen species under normal physiological conditions (Kassan et al, 2011). 
Treg cells can also interact with DCs (antigen-presenting cells), to cause 
tryptophan catabolism, leading to a reduction in T cell activation (Mellor and 
Munn, 1999; Terness et al, 2002; Fallarino et al, 2003). Hemeoxygenase-1, a 
stress-inducible protein, is produced by Treg cells, has anti-inflammatory 
properties and is mediated by inhibition of nuclear factor kappa B (NF-κB) 
activation (Gozzelino et al, 2010). This protein has also been shown to be 
protective in pulmonary arterial hypertension (PAH) (Christou et al, 2000). 
Treg cells have been shown to be protective in many cardiovascular 
diseases, including atherosclerosis and chronic heart failure, as they can 
modulate the effects of other immune cells (Mallat et al, 2005).  
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Figure 1.1 T regulatory cell mechanisms of action 
1) Cell to cell contact (contact mediated) suppression. Treg cells can change the 
function of antigen presenting cells (APCs) via contact mediated suppression which 
can inhibit the proliferation of effector T cells.  2) Soluble cytokines released by Treg 
cells (IL-10 and TGF- β) can be released to inhibit the effects of target cells. 3) Treg 
cells can sink the excess IL-2 in the vicinity of T effector cells, inhibiting their 
function and proliferation (Thornton and Shevach, 1998; Nakamura et al, 2001; 
Joetham et al, 2007). 
 
Defects in function or number of circulating Treg cells can upset the 
homeostastic balance of the immune system, and this is thought to 
propagate disease progression in many cardiovascular diseases (Mor et al, 
2006; Ulrich et al, 2008; Tang et al, 2010; Wigren et al, 2012). Increased 
numbers of Treg cells have been noted in both the peripheral blood and 
pulmonary vessels of idiopathic pulmonary arterial hypertension (IPAH) 
patients, whilst in animal models of PAH, it has been demonstrated that 
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immune reconstitution with Treg cells, prior to vascular injury, can protect 
against the development and progression of PAH (Tamosiuniene et al, 
2011). However, this work has only been undertaken in one subtype of PAH 
patients and few animal models of PAH, therefore, further work needs to be 
undertaken to address these issues.  
 
1.3   Pulmonary hypertension  
 
Pulmonary hypertension (PH) was first described in 1891 by Dr. Ernst 
von Romberg as an elevation in pulmonary blood pressure, leading to 
shortness of breath and dizziness (Romberg, 1891). PH is currently defined 
as a progressive increase in pulmonary vascular resistance (PVR), leading to 
right ventricular failure and death. Clinically, it is regarded as a mean 
pulmonary artery pressure (mPAP) ≥25 mmHg at rest as assessed by right 
heart catheterisation (Galie et al, 2009). This increase in pulmonary artery 
pressure can be caused by shunting of systemic blood, clots into the lung, 
vasoconstriction or vascular cell proliferation.  
PH can be subdivided into several forms of the disease which include 
PAH, PH due to left heart disease, PH due to lung diseases and/or hypoxia, 
chronic thromboembolic disease (CTEPH) and PH with unclear and / or 
multifactorial mechanisms (Humbert, 2012). Each of these five groups of PH 
diseases has different causes and pathological features (Table 1.3). 
Haemodynamically, PH can also be defined as pre-capillary or post-capillary 
PH. Pre-capillary PH, defined as a mPAP ≥25 mmHg and a pulmonary 
wedge pressure of <15 mmHg, includes clinical groups 1, 3, 4 and 5 of the 
clinical classification system (Table 1.3) whilst post-capillary PH is defined as 
a mPAP ≥25 mmHg and a pulmonary wedge pressure of >15 mmHg and 
includes clinical group 2. 
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1. Pulmonary arterial hypertension (PAH) 
  1.1 Idiopathic   
  1.2 Heritable   
                 1.2.1 BMPR2 
                 1.2.2 ALK1, endoglin (with or without hereditary  haemorrhagic telangiectasia) 
                 1.2.3 Unknown 
  1.3 Drugs and toxins induced   
  1.4 Associated with (APAH)   
                 1.4.1 Connective tissue diseases 
                 1.4.2 HIV infection 
                 1.4.3 Portal hypertension 
                 1.4.4. Congenital heart disease 
                 1.4.5 Schistosomiasis 
                 1.4.6 Chronic haemolytic anaemia 
  1.5 Persistent pulmonary hypertension of the newborn   
1' Pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatosis 
2 Pulmonary hypertension due to left heart disease 
  2.1 Systolic dysfunction   
  2.2 Diastolic dysfunction   
  2.3 Valvular disease   
3 Pulmonary hypertension due to lung diseases and/or hypoxia 
  3.1 Chronic obstructive pulmonary disease   
  3.2 Interstitial lung disease   
  3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern   
  3.4 Sleep-disordered breathing   
  3.5 Alveolar hypoventilation disorders   
  3.6 Chronic exposure to high altitude   
  3.7 Development abnormalities   
4 Chronic thromboembolic pulmonary hypertension 
5 PH with unclear and/or multifactoral mechanisms 
  5.1 Haematological disorders: myeloproliferative disorders, splenectomy   
  
5.2 Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis, 
lymphangioleiomyomatosis, neurofibromatosis, vasculitis   
  5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders   
  
5.4 Others: tumoural obstruction, fibrosing mediastinitis, chronic renal failure on 
dialysis   
 
Table 1.3 The most recent classification of pulmonary hypertension agreed 
upon at the WHO symposium in Dana Point, California. 
The five groups of pulmonary hypertension, including PAH, PH due to left heart 
disease, PH due to lung disease or hypoxia, chronic thromboembolic PH and PH 
with unclear and/or multifactorial origin. ALK-1 = activin receptor-like kinase 1 gene, 
APAH = associated pulmonary arterial hypertension, BMPR2 = bone morphogenetic 
protein receptor type 2, HIV = human immunodeficiency virus, PAH = pulmonary 
arterial hypertension. Subtypes focused on in this thesis are highlighted in red 
(Galie et al, 2009). Reproduced with the permission of Oxford University Press. 
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1.4  Pulmonary arterial hypertension 
 
Group 1 of the Dana Point Classification (PAH) can be further divided 
into five subgroups. The first group, IPAH, previously called primary PH, is 
PAH with an unknown etiology, and is described further in Chapter 1.3 (Table 
1.3, group 1.1). The second subgroup is hereditary PAH which including 
sporadic germline mutations in either bone morphogenetic protein receptor 
type 2 (BMPR2), activin-like kinase-1 (ALK-1), the glycoprotein endoglin and 
clinical familial cases with or without identified germline mutations (Table 1.3, 
group 1.2). The third subgroup of PAH consists of a group of patients 
diagnosed with PAH induced by drug and toxin use, such as amphetamines 
and the anorexigen (and serotonin reuptake inhibitor) dexfenfluramine (Table 
1.3, group 1.3). Subgroup 4 includes conditions associated with PAH such as 
connective tissue disease, human immunodeficiency virus (HIV) infection 
and portal hypertension (Table 1.3, group 1.4). These conditions usually pre 
date the onset of PAH and can have similar clinical presentations to 
subgroup 1 (IPAH). This group is thought to account for approximately half of 
all PAH patient cases (Humbert et al, 2006; http://www.ic.nhs.uk, 2011). The 
final subgroup, group 5, includes persistent pulmonary hypertension of the 
newborn, which occurs due to failure of the pulmonary vasculature to relax at 
birth, resulting in hypoxemia (Table 1.3, group 1.5). For the purposes of this 
thesis, two PAH patient groups will be discussed further (IPAH and SSc-
PAH).  
  
1.4.1 Idiopathic pulmonary arterial 
hypertension 
 
IPAH is thought to occur at an incidence rate of 2.1 cases per million 
per year in the general population in the UK, with 32% of all PAH patients in 
the UK having IPAH (http://www.ic.nhs.uk, 2011; Hurdman et al, 2012). IPAH 
patients have a three-year survival rate of 63% with the usual cause of death 
being right ventricular failure as a result of chronic vasoconstriction and 
12 
 
vascular remodelling (Hurdman et al, 2012). IPAH is a vasculopathy 
consisting of a progressive narrowing and occlusion of small pulmonary 
arterioles. IPAH is defined as a persistent elevation of mPAP without a 
demonstrable cause and occurs more frequently in females (Humbert et al, 
2006; Graham, 2011).  
A pathological characteristic of IPAH, which occurs in 15% of all PAH 
patients, is the development of plexiform lesions. These arise as a result of 
proliferating ECs, neoangiogenesis and the accumulation of inflammatory 
progenitor cells, myofibroblasts and connective tissue elements such as 
elastin and collagen (Tuder et al, 1994). Plexiform lesions, most commonly 
found in IPAH patients, can be found at branching points of pulmonary 
arteries of less than 300µm in diameter and are often associated with 
concentric intimal obliteration of pulmonary vessels  (Cool et al, 1997; Tuder, 
Lee, et al, 1998; Tuder, Radisavljevic, et al, 1998; Fishman, 2000). The 
plexiform lesion has been described by several groups as a dilated sac 
which has several channels that are separated by proliferating 
myofibroblasts and atypical ECs (Cool et al, 1999). Cool and colleagues  
used computerised 3D reconstructions of nine vessels in patient samples, as 
well as immunohistochemistry, to show that plexiform lesions are dynamic 
vascular structures that include ECs. Other groups have shown that ECs 
within plexiform lesions are highly proliferative and that altered survival of 
these cells contributes to the formation of these structures (Tuder et al, 1994; 
Lee et al, 1998; Sakao et al, 2005). 
 
1.4.2  Pulmonary arterial hypertension 
secondary to connective tissue 
disease 
 
PAH is a well-documented complication of connective tissue diseases 
(CTD) such as mixed CTD and scleroderma (SSc). Symptoms and clinical 
presentation in CTD associated PAH is similar to that of IPAH patients, 
however there is a shorter survival time associated with this condition 
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(Mukerjee et al, 2003; Dorfmuller et al, 2007). SSc, particularly of the limited 
disease type, is the main CTD associated with PAH (Mathai and Hassoun, 
2011; Hurdman et al, 2012). Patients with scleroderma associated PAH 
(SSc-PAH) have a three-year survival rate of 52% (Hurdman et al, 2012). 
SSc is a systemic autoimmune disease associated with deposition of 
connective tissue in inappropriate places. It is characterised by the 
deposition of collagen in the skin, but also in other organs such as the 
kidneys, heart, lungs and stomach. Females appear more susceptible to this 
disease (4:1 ratio) and the peak onset is between 30-50 years (Gu et al, 
2008). There are two main subgroups of SSc (limited and diffuse cutaneous), 
with the limited form being characterised by sclerotic plaques. Visceral 
involvement does not occur in this form of the disease and prognosis is 
better than in diffuse cutaneous-SSc (Simeon-Aznar et al, 2012). Raynaud’s 
phenomenon can also be associated secondary to SSc development and is 
classed as the diffuse form of the disease (Geroulakos, 2011). Raynaud’s 
phenomenon is a vasospasm of the arteries or arterioles causing a colour 
change after reperfusion. Raynaud’s phenomenon secondary to SSc is a 
very severe condition and causes pain and digital ulceration due to ischemia 
(Guiducci et al, 2007). Vascular involvement in SSc has been shown to 
precede fibrosis and involves small vessels in which vascular remodelling is 
dysregulated (Kahaleh, 2008). Studies conducted on the vessel walls in 
these small arterioles show large gaps between ECs and a loss of integrity of 
the endothelial lining.   
Immune dysregulation has long thought to be involved in the 
pathogenesis of SSc and several lines of research are currently being 
undertaken to assess whether this can be targeted with pharmacodynamic 
therapy. A randomised, double-blind, placebo-controlled, phase II multicentre 
clinical trial is currently being undertaken across America to determine the 
effect of Rituximab, a monoclonal antibody against CD20 (B cell marker) on 
the progression of SSc-PAH (http://www.clinicaltrials.gov, 2012).  
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1.5 Pathobiology of pulmonary arterial 
hypertension 
 
 
PAH is a panvasculopathy, predominantly affecting the small 
pulmonary arteries (resistance arteries) and arterioles which regulate blood 
flow in the lung. In PAH, obstructions in the small pulmonary arteries caused 
by medial hypertrophy and concentric laminar intimal fibrosis cause complex 
changes such as EC dysfunction, inflammation, growth factor dysregulation 
and chronic vasoconstriction (Rabinovitch, 2008). 
Studies in the 1960’s and 1970’s by Wagenvoort examined pulmonary 
arteries from patients with PH and described vasoconstriction and medial 
hypertrophy associated with intimal fibrosis and occasional plexiform lesions 
(Wagenvoort, 1960; Wagenvoort, 1970). Remodelling of the pulmonary 
arteries has subsequently been shown to result from the abnormal 
proliferation of vascular smooth muscle cells (SMC) as well as an increase in 
EC proliferation and dysfunction leading to medial hypertrophy, concentric 
intimal lesions and a thickened adventitia This has also been confirmed in 
patients with hereditary PAH and in patients with BMPR2 mutations where 
intimal lesions were found to consist of ECs and myofibroblast cells (Cool et 
al, 1999; Atkinson et al, 2002). Chazova et al examined the structure of lung 
samples from patients with PAH and showed that all three layers (intima, 
media and adventitia) are involved in arterial remodelling (Chazova et al, 
1995). Increased production of extracellular matrix, as well as elastin and 
collagen deposition lead to a gradual remodelling of the adventitial layer of 
the vessels (Hassoun, 2005). Fibrotic lesions in the intimal layer of the 
pulmonary arteries can also occur, leading to a thickening of the vessel wall 
which occurs due to the recruitment and proliferation of fibroblasts and 
myofibroblasts (Humbert, 2012). 
EC dysregulation and dysfunction is a prominent feature of PAH, and 
has a considerable effect on the pulmonary vasculature and remodelling 
process. Under normal physiological conditions, the pulmonary endothelium 
regulates production of vasoactive mediators that control physical and 
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biochemical properties of pulmonary vessels that affect ability of the vessel 
to contract as well as cellular growth and proliferation. The endothelium 
maintains a low pressure environment, vascular tone and controls leukocyte 
trafficking (Young, 2012). In PAH, the endothelium of pulmonary vessels 
becomes injured which leads to apoptosis of usually quiescent cells. This 
encourages disruption of the pulmonary vascular intima leading to 
uncontrolled proliferation of underlying SMCs (Budhiraja et al, 2004). A 
dysfunctional endothelium also has a chronically impaired production of 
vasodilators and antiproliferative agents such as nitric oxide (NO) and 
prostacyclin and overexpresses vasoconstrictor and proliferative agents such 
as thromboxane A2 (TXA2) and endothelin-1 (ET-1) (Ozaki et al, 2001). It 
still remains unclear whether the imbalance of vasocontrictive and 
vasodilatory substances is in response to vascular injury or a direct effect of 
EC dysfunction (Graham, 2011). 
Prostacyclin, a metabolite of arachidonic acid, is produced by the 
endothelium and can act on SMCs to cause vasodilatation. Prostacyclin also 
inhibits vascular SMC proliferation, via the increase of intracellular cyclic 
adenosine monophosphate (cAMP) (Newby et al, 1992). Prostacyclin 
receptor knockout mice develop severe PAH and levels of prostacyclin have 
been shown to be decreased in PAH patients (Tuder et al, 1999; Hoshikawa 
et al, 2001). A reduced expression of endothelial nitric oxide synthase 
(eNOS) in the lungs of PAH patients has been shown to lead to decreased 
levels of NO and therefore decreased levels of cyclic guanosine 
monophosphate (cGMP) and increased vasoconstriction (Giaid and Saleh, 
1995; Kim, 2011). PDE-5 within SMCs decreases levels of cGMP, having a 
similar effect to NO. PDE-5 activity has been shown to be increased in the 
lungs of hypoxic rats further suggesting a role for this molecule in PAH 
(Maclean et al, 1997). 
Vasoconstrictive mediators such as ET-1, serotonin and TXA2, can 
also cause platelet aggregation and have mitogenic effects on smooth 
muscle cells (Hanasaki et al, 1990; Pakala et al, 1994; Ikeda et al, 1997). 
Vascular EC ET-1 levels have been shown to be increased in PAH and 
correlate with disease severity (Christman et al, 1992; Giaid et al, 1993; 
Rubens et al, 2001). TXA2 levels and receptor density within the right 
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ventricle have also been shown to be increased in PAH patients (Christman 
et al, 1992; Katugampola and Davenport, 2001).  
Another important aspect of pulmonary vascular remodelling in PAH is 
SMC hyperplasia which leads to medial hypertrophy and luminal narrowing 
of distal vessels (Tajsic, 2011). Phenotypic changes occur within pulmonary 
artery SMCs in PAH, including a down regulation of functional voltage gated 
potassium channels that allow membrane depolarisation leading to 
vasoconstriction. This then leads to contraction and mitogenesis of these 
cells (Yuan et al, 1998). An increased serum IL-6 level, as noted in PAH 
patients, could also lead to increased migration of SMCs and the synthesis of 
IL-6 themselves (Humbert et al, 1995; Wang and Newman, 2003).  
 
1.6 Mechanisms of pulmonary arterial 
hypertension pathogenesis 
 
Several mechanisms have been shown to contribute to the 
development and progression of PAH, however none can completely explain 
all aspects of its development. Although it is unclear whether a common 
molecular mechanism underlies the cause of PAH, several key pathways 
and molecules (e.g. BMPR2, inflammation, hypoxia, cytokines, shear stress), 
acting alone or in combination, have been proposed to play an important role 
in PAH pathogenesis (Tuder et al, 1994; Shimoda and Semenza, 2011). 
1.6.1 Genetics  
 
 Several genetic mutations have been shown to predispose PAH, the 
most widely studied of these are mutations leading to dysfunctional TGF‐β 
signalling. These will now be discussed in further detail.  
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1.6.1.1 Bone morphogenetic receptor 2 mutations 
  
Several groups have reported mutations in the BMPR2 gene in 10-
30% of patients with IPAH and > 75% of patients with hereditable PAH, but 
only 20% of affected family members succumb to the disease due to low 
penetrance of these mutations (Deng et al, 2000; Thomson et al, 2000; 
Austin, Phillips, et al, 2009). BMPR2 is a type II serine / threonine kinase 
receptor, which is widely expressed in pulmonary vascular ECs and SMCs 
and is a crucial mediator in development and organogenesis, as noted by the 
fact that BMPR2 knockout mice die during gastrulation (Beppu et al, 2000). 
In disease-free individuals, BMPR2 is thought to be vascular protective as it 
regulates EC and SMC phenotypes (Majka et al, 2011). In ECs, BMPR2 
signalling promotes cell survival, whilst in SMCs it leads to inhibited 
proliferative responses and induces apoptosis (Zhang et al, 2003; Teichert-
Kuliszewska et al, 2006). 
Mutations in BMPR2 lead to an impairment of intracellular signalling 
responses and apoptosis in ECs and SMCs (Lane et al, 2000). Morrell et al 
used 3H-thymidine incorporation studies to demonstrate that pulmonary 
artery SMCs with BMPR2 mutations are resistant to the growth inhibitory 
effects of BMPs and TGF-β. They postulate that the disruption of TGF-β 
signalling is a consequence of BMPR2 mutations in IPAH patients (Morrell et 
al, 2001). This might help explain exuberant cellular proliferation and 
vascular obliteration seen in this disease.  
 
1.6.1.2 Activin-receptor-like kinase 1 mutations  
 
Genetic studies have also shown mutations in another membrane 
bound receptor member of the TGF–β receptor signalling superfamily 
protein, ALK-1. Mutations in the ALK-1 gene, which encodes the TGF–β 
receptor, have been reported in patients with hereditary hemorrhagic 
telangiectasia and PAH. Mutations of this type are less common than 
BMPR2 mutations in PAH patients and can be due to missense, deletion and 
nonsense mutations (Trembath et al, 2001). Under normal conditions, ALK-1 
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is expressed in a limited number of cells including ECs and interacts with 
TGF-β1 and activins. It transduces TGF-β1 signals by phosphorylating 
Smad1 or Smad 5 (Oh et al, 2000; Lamouille et al, 2002). 
 
1.6.1.3 Endoglin mutations  
 
Endoglin (also termed CD105) is a gene that encodes a TGF-β 
receptor complex accessory protein that is found on chromosome 9 
(Chaouat et al, 2004). It is permanently expressed on ECs and has been 
shown to interact with BMP-2 and BMP-7, which are involved in regulating 
TGF-β signalling (Barbara et al, 1999). Endoglin is also involved in 
angiogenesis as well as the maintenance of vascular integrity (Ray et al, 
2010). Mutations in endoglin can lead to hereditary haemorrhagic 
telangiectasia however an endoglin gene polymorphism has recently been 
found in SSc-PAH patients (McAllister et al, 1994; Wipff et al, 2007; Suzuki 
et al, 2012). 
 
1.6.2 Voltage-gated potassium channels 
 
Potassium channels (Kv) are transmembrane-spanning proteins that 
regulate cell membrane potentials and calcium movement in and out of cells. 
The intracellular calcium levels influence the contractile and proliferative 
status of SMCs, which in turn affect vasodilatation and contraction.  
Fawn hooded rats have an inherited platelet storage disorder and 
impairment of serotonin storage, making them susceptible to pulmonary 
hypertension (Bonnet et al, 2006). The Mitochondrial–Hypoxia Inducible 
Factor-1α–Kv Channel Pathway becomes abnormally regulated in fawn 
hooded rats, which disrupts oxygen sensing (reducing hypoxic pulmonary 
vasoconstriction) and triggers the development of PAH (Bonnet et al, 2006). 
Similar abnormalities occur in human IPAH.  
Mitochondrial abnormalities that disrupt the ROS-HIF-1α-Kv1.5 O2-
sensing pathway have recently been shown to be another contributing factor 
to the pathogenesis of PAH (Archer et al, 2008). This causes a reduction in 
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reactive oxygen species and an increase in hypoxia inducible factor 1 (HIF-1) 
α activation. It has also been shown that decreased expression of the O2-
sensitive K+ channel (Kv1.5) in rats treated with chronic hypoxia, can lead to 
the progression on PAH (Michelakis et al, 2002). Post et al also noted that 
hypoxic conditions could inhibit whole cell K+ currents in canine pulmonary 
artery SMCs which lead to vasoconstriction via membrane depolarisation 
and subsequent calcium entry (Post et al, 1992). Dichloroacetate, has been 
shown to increase oxidative phosphorylation within the mitochondria of 
SMCs, reversing both monocrotaline (MCT) and chronic hypoxia induced 
PAH in rats, providing evidence that this could be a potential therapeutic 
target in PAH patients (Michelakis et al, 2002; McMurtry et al, 2004).  
 
1.6.3 Serotonin dysregulation 
 
 Serotonin (5-HT) is a neurotransmitter that is synthesised in ECs 
through the action of tryptophan hydroxylase 1 (Tph1).  It can then act upon 
5-HT receptors to cause constriction and proliferation of pulmonary artery 
SMCs (Willers et al, 2006). 5-HT can also cause these effects in fibroblasts 
(Welsh et al, 2004).  
The first suggestion that 5-HT may be involved in the pathogenesis of 
PAH was when there was an epidemic of clinical symptoms of PAH in 
patients taking appetite suppressant drugs (Aminorex and Dexfenfluramine), 
which inhibit 5-HT uptake in platelets (Gurtner, 1985). Plasma 5-HT levels 
have been shown to be increased in IPAH patients and it is suggested that  
5-HT propagates the development of PAH both clinically and experimentally, 
via its ability to encourage vasoconstriction and remodelling of the pulmonary 
vasculature (Herve et al, 1990; Herve et al, 1995; Eddahibi et al, 1997; 
MacLean et al, 2000). ECs and SMCs from PAH patients also have an 
increased ability to produce 5-HT and proliferate in response to 5-HT than 
control cells (Eddahibi and Adnot, 2001; Willers et al, 2006). An increased 
expression of 5-HT receptors has also been confirmed in pulmonary arteries 
of PAH patients. Other studies suggest that PAH can be inhibited in mice 
deficient for 5-HT receptors, further emphasising their involvement in the 
pathogenesis of PAH (Launay et al, 2002).  
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An increased expression of the serotonin transporter (SERT) has also 
been reported in IPAH patients, whilst inhibition of this transporter in rats can 
prevent and even reverse PAH caused by MCT injection or hypoxia in mice 
(Eddahibi et al, 2001; Hironaka et al, 2003; Marcos et al, 2003; Guignabert et 
al, 2005).  
The Tph1 gene was found to be increased in the lungs and pulmonary 
ECs from patients with IPAH and interestingly, a genetic deletion of this gene 
in mice has been shown to protect against hypoxia-induced PAH (Morecroft 
et al, 2007). The sex hormone, 17β-oestradiol, produced by the ovaries, has 
been shown to attenuate both hypoxic PAH and MCT induced PAH, via its 
effect on the 5-HT pathway (Lahm et al, 2012). 17β-oestradiol has also been 
shown to increase expression of Tph1 in human pulmonary artery SMCs 
from controls (White, Dempsie, et al, 2011).  
There are several lines of evidence that converge to support the 
theory that serotonin dysregulation is involved in the pathogenesis of PAH. 
Firstly, the increased susceptibility of females for the disease and the fact 
that female mice overexpressing SERT exhibit PAH when induced by 
hypoxia, compared to males that remain unaffected (White, Dempsie, et al, 
2011; White, Loughlin, et al, 2011).  Only female SERT+ mice develop PAH 
whilst ovariectomy can completely abolish the development of PAH. Also, 
17β-oestradiol has been shown to play a critical role in this process as it’s 
reintroduction into ovariectomized SERT+ mice re-established the disease 
state, further confirming a strong link between the female gender and 
serotonin responses (White, Dempsie, et al, 2011). Secondly, normal 
physiological 17β-oestradiol levels can increase the expression of 
cytochrome P450 1B1 (an oestrogen metabolising enzyme) and cause 
pulmonary artery SMCs to proliferate. 17β-oestradiol can also increase the 
expression of 5HT1B receptor, SERT and Tph1, which have all been shown 
to be involved in the pathogenesis of PAH (White, Dempsie, et al, 2011). 
Cytochrome P450 1B1 expression is increased in clinical and experimental 
PAH and has also been shown to be expressed at lower levels in females. 
Levels of this enzyme have also been shown to modify PAH disease 
progression. In cytochrome P450 1B1 _/_ mice, hypoxia induced PAH is 
attenuated whilst the administration of a cytochrome P450 1B1 inhibitor 
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(2,3’,4,5’-tetramethoxystilbene) has been shown to limit hypoxia and hypoxia 
+ sugen 5416 PAH development in vivo (Austin, Cogan, et al, 2009; White et 
al, 2012).  
Finally, in the chronic hypoxic rat model of PAH, oral 
dehydroepiandrosterone treatment (an activator of calcium gated potassium 
channels) has been shown to prevent right ventricular hypertrophy (RVH) 
and pulmonary arterial vascular remodelling by opening large conductance 
calcium activated channels (Bonnet et al, 2003). Augmentation of these 
channels also leads to SMC repolarisation, leading to a protected PAH 
phenotype (Hampl et al, 2003). Taken together, these findings support the 
concept that the 5-HT pathway is involved in the pathogenesis of PAH.  
 
1.6.4 Plasma leptin and insulin resistance  
 
Leptin is an adipokine that regulates food intake and is released from 
adipose tissue enhancing metabolism. It acts on the hypothalamus to 
suppress appetite, but can also play a critical role in influencing innate and 
adaptive immune responses, as it has been shown to sustain low-grade 
inflammation which could lead to chronic disease. Leptin can induce T cell 
activation towards a Th1 response, including the production and release of 
IL-2 and other cytokines (Martin-Romero et al, 2000). Interestingly, a 
decrease in plasma leptin levels has also been shown to lead to an impaired 
immune response, and has been associated with increased incidences of 
coronary artery disease. In PAH, lower plasma leptin levels are associated 
with increased mortality (Lord et al, 1998; Ku et al, 2011; Tonelli et al, 2012).  
Recently, it was reported that IPAH and SSc-PAH patients have increased 
serum leptin levels, as well as an increased number and decreased function 
of circulating T cells expressing the leptin receptor. Huertas et al also 
confirmed that ECs from IPAH patients also synthesised more leptin and 
therefore suggested that this, in part, drives the pathogenesis of PAH 
(Huertas et al, 2012). 
Regulation of leptin has been shown to be partly due to insulin, and 
insulin resistance has been shown to be associated with elevated plasma 
leptin levels (Saladin et al, 1995; Zimmet et al, 1998). Insulin resistance is 
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thought to be common in PAH, especially in female patients, and has been 
shown to be a risk factor in other cardiovascular diseases (Zamanian et al, 
2009). Work undertaken by our laboratory confirms that ApoE deficient mice 
become insulin resistant on a high fat diet and are increasingly susceptible to 
PAH.  
 
1.6.5 Other mediators 
 
Several other mediators have been shown to increase in PAH, such 
as ET-1, which has vasoconstrictive effects in blood vessels (Cacoub et al, 
1997; Cacoub et al, 1997). Reduced bioavailability of endogenous NO has 
also been suggested to play a role in PAH (Giaid and Saleh, 1995).  
Ostoprotegerin, a member of the tumor necrosis factor receptor 
superfamily, is a secreted glycoprotein expressed in heart and lung tissue 
that regulates pulmonary artery SMC proliferation and migration. It is 
modulated by BMPs, 5-HT and IL-1 and it has been found to be increased in 
serum and within lesions found in the lung tissue of PAH patients (Lawrie et 
al, 2008; Condliffe et al, 2012).  
The cytokine, Tumor Necrosis Factor (TNF)-Related Apoptosis-
Inducing Ligand (TRAIL) is a receptor for osteoprotegerin and has been 
shown to induce SMC proliferation and EC apoptosis in vitro (Corallini et al, 
2008). TRAIL has also been found associated with pulmonary vascular 
lesions in both human and animal models of PAH further supporting the 
evidence that TRAIL has an important role in vascular biology. Recently, it 
has been reported that antibody blockade and genetic depletion of TRAIL in 
rodent models of PAH prevented the development of PAH (Hameed, Arnold, 
et al, 2011; Hameed, Chamberlain, et al, 2011). After recombinant TRAIL 
administration, PAH disease phenotype was restored, confirming that TRAIL 
is highly involved in the pathogenesis of PAH (Hameed et al, 2010; Hameed 
et al, In Press). 
 Osteopontin, also known as cytokine Eta-1, has also been suggested 
to play a role in PAH due to its ability to recruit macrophages and T cells to 
sites of inflammation and stimulate cytokine production within these cell 
types (Strom et al, 2004). It has also been suggested that this protein may 
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play a role in tissue repair and remodelling via its effects on vascular SMCs 
(Giachelli et al, 1998; Ashkar et al, 2000). Osteopontin levels are significantly 
elevated in the serum of IPAH patients and could be used as a biomarker in 
PAH (Lorenzen et al, 2011). 
 Iron deficiency is also frequently present in IPAH patients and is 
associated with disease severity and poor clinical outcome. Iron availability 
affects pulmonary haemodynamics by modifying mPAP and pulmonary 
vasoconstrictor responses to hypoxia (Ruiter et al, 2011). Oral iron therapy 
has been shown to be ineffective at restoring normal ferritin levels 
suggesting a problem with iron absorption in these patients. Interestingly, 
hepcidin, which regulates iron absorption and increases cellular iron storage, 
is raised in IPAH patients, impairing the body’s ability to absorb iron from the 
gut (Rhodes et al, 2011). 
Cytokine dysregulation is also a common feature in PAH, leading to 
an increase in pro-inflammatory cytokines, such as IL-1, IL-6 and fractalkine, 
within the serum of IPAH patients (Humbert et al, 1995; Balabanian et al, 
2002). These inflammatory cytokines can then have important downstream 
effects in the inflammatory response to vessel remodelling, as discussed 
later in Chapter 1.6.6.  
Taking all these mediators into consideration, it is highly likely that 
PAH has a multi-factoral pathobiology and it is unlikely that a single factor or 
gene mutation will explain all forms and cases of PAH. 
 
1.6.6  Inflammatory mediators in pulmonary 
arterial hypertension 
 
Inflammation is thought to play an important role in the pathogenesis 
of PAH. Inflammatory cells, including macrophages, T and B lymphocytes, 
and DCs have been found associated with plexiform lesions in lung samples 
from patients with IPAH (Tuder et al, 1994; Balabanian et al, 2002). 
Recently, emphasis has been put on natural killer (NK) cell involvement in 
the pathogenesis of PAH. These cells are functionally impaired in IPAH 
patients, expressing decreased activation markers (NKp46, 2DL1/s1 and 
3DL1) (Ormiston et al, 2012). NK cells bridge the gap between the innate 
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and adaptive immune system and their function is controlled by a balance 
between stimulatory and inhibitory signals that are delivered to the cell via 
receptor triggering (Smyth et al, 2005). A dysfunctional NK cell population 
could be a sign of an abnormal immune system and can lead to 
inappropriate immune processes (Sun et al, 2009). 
T cells, B cells and macrophages are thought to produce and react to 
pro-inflammatory cytokines, such as IL-6 and tumor necrosis factor alpha 
(TNF-α), that have been shown to be upregulated in the hypertensive 
pulmonary circulation and are thought to be linked to the structural 
remodelling which is seen in IPAH patients (Botney et al, 1994; Botney et al, 
1994; Humbert et al, 1995; Fujita et al, 2001; Zaiman et al, 2008). More 
recently, Steiner et al described how IL-6 over-expression in transgenic mice 
caused PAH (Steiner et al, 2009). IL-1 is also a potent pro-inflammatory 
cytokine involved in immune responses and has been shown to play a key 
role in acute and chronic inflammatory and autoimmune disorders. IL-1 is 
secreted from monocytes, macrophages, neutrophils, vascular ECs and 
SMCs (Goodman et al, 1982; Libby, Ordovas, Auger, et al, 1986; Libby, 
Ordovas, Birinyi, et al, 1986; Warner et al, 1987; Lindemann et al, 1988; 
Loppnow et al, 1994). Previously published work has shown the importance 
of IL-1 in the response to vascular injury (Bevilacqua et al, 1985). Serum IL-1 
levels have been found to be elevated in patients with PAH and it is 
proposed that this pro-inflammatory cytokine activates ECs, monocytes and 
T cells, and mediates SMC growth (Humbert et al, 1995). IL-1 receptor 
antagonist (IL-1RA) treatment can be used to reduce PAH in MCT treated 
rats and ApoE-/-/IL-1R1-/- mice, which further implicates IL-1 in the 
pathogenesis of PAH (Voelkel and Tuder, 1994; Lawrie et al, 2011). 
Increases in serum IL-2 have also been confirmed in IPAH, which correlate 
negatively with survival as IL-2 can promote T cell proliferation and activation 
augmenting inflammatory responses (Soon et al, 2010). 
Elevated levels of macrophage inflammatory protein-1α (MIP-1α) and 
increased P-selectin expression in patients with severe IPAH have also been 
reported (Humbert et al, 1995; Sakamaki et al, 2000). MCP-1, activates 
mononuclear cells and may play a role in the progression of PAH as anti-
MCP-1 gene therapy can be used to inhibit vascular remodelling and 
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therefore MCT-induced PAH in rats (Ikeda et al, 2002). The severity of 
remodelling in PAH has also been shown to correlate with levels of serum 
IgE and IgG1, as well as the cytokines IL-5 and IL-4, and Fractalkine (an 
inflammatory chemokine) is also upregulated in patients with PAH 
(Balabanian et al, 2002). The chemokine regulated and normal T cell 
expressed and secreted (RANTES) can encourage cell recruitment in the 
lungs of patients with PAH and it has been reported that ECs are a primary 
source of RANTES (Dorfmuller et al, 2002).  
As a key part of the immune system, it has been suggested that B 
cells may also be involved in the pathogenesis of PAH, as these cells have 
been found to be associated with other immune cells (macrophages and T 
cells) in plexiform lesions (Tuder et al, 1994). Ulrich et al also noted a 
change in the RNA expression profile of B cells in peripheral blood from 
IPAH patients, suggesting an increase in their activation when compared to 
healthy controls (Ulrich et al, 2008).  
Bellotto et al were the first to suggest a link between anti-inflammatory 
therapy and improvements in the prognosis of patients with PAH (Bellotto et 
al, 1999). Other studies have also shown that the clinical status of patients 
with severe PAH associated with systemic lupus erythematosus (SLE) and 
mixed CTD also improved with immunosuppressant therapy (Morelli et al, 
1993; Sanchez et al, 2006; Jais et al, 2008). Also, in MCT treated rats, 
dexamethasone, a corticosteroid and anti-inflammatory drug, has been 
shown to prevent and reverse PAH by improving haemodynamics and 
preventing pulmonary vascular remodelling. It is thought that this occurs via 
a reduction of inflammatory cells that express IL-6 and a reduction in the 
proliferative responses of SMCs (Price et al, 2011).  
There is also a link between PAH and autoimmune diseases such as 
autoimmune thyroid disease, in which an autoimmune injury and an altered 
immunoregulatory response lead to the progression of PAH (Chu et al, 
2002). Several studies have also noted auto-antibodies in the serum of PAH 
patients, including anti-phospholipid antibodies, anti-fibroblast antibodies, 
anti-centromere antibodies and anti-endothelial cell antibodies suggesting a 
dysfunctional immune phenotype (Luchi et al, 1992; Tamby et al, 2005; 
Tamby et al, 2006; Terrier et al, 2008). Anti-EC antibodies are thought to be 
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able to induce EC apoptosis and this is thought to initiate PAH disease 
progression.  
Inflammatory cells are also thought to modify the expression of growth 
factors such as vascular endothelial growth factor (VEGF) and TGFβ within 
vascular cells (Shen et al, 1993; Tuder et al, 1994). These growth factors can 
then act on inflammatory cells in a similar manner to cytokines (Botney et al, 
1994). Furthermore, inflammatory cells may provide the source of these 
growth factors, thereby providing a complex picture of how mediators and 
inflammatory cells interact within the disease setting of PAH.  
These studies, taken together with the evidence of inflammatory cells 
being present in plexiform lesions of patients with PAH, as well as their 
altered functions and behaviour, further emphasises the relevance of 
inflammation in pathogenesis of PAH and its progression. Most of what is 
known about inflammatory processes and their involvement in the 
pathogenesis of PAH, is a result of work performed on animal models of PAH 
as human tissues or in vivo systems are generally unavailable to study the 
disease before death. 
 
1.7 B and T cell involvement in the 
pathogenesis of pulmonary arterial 
hypertension 
 
Several lines of evidence suggest that lymphocytes are involved in the 
pathogenesis of PAH, with several research groups seeking to answer the 
question of whether specifically T cells contribute to the development of PAH 
or protect against it.   
B cells are antibody producing adaptive immune cells that have been 
shown to be present surrounding plexiform lesions within the lung tissue of 
IPAH patients, along with several other inflammatory cells (Voelkel and 
Tuder, 1994). Also, as previously mentioned, the presence of auto-antibodies 
against cellular components within the serum of PAH patients also suggests 
a strong connection between B cells and PAH disease pathogenesis, 
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however only a limited number of studies have determined the proportions of 
B cells within the peripheral blood of PAH patients.  
With regards to T cells, in several animal models of PAH, immune 
cells, specifically CD45+ and CD3+ T cells have been shown to be associated 
with vascular lesions within the lung of diseased animals. The localisation of 
these cells to the remodelled areas within the lung still does not explain 
whether they are there to either augment the progression of PAH or are 
increasing in number to protect the diseased vessels. 
The presence of T cells in lung tissue sections taken from PAH 
patients has been investigated by several research groups (Voelkel and 
Tuder, 1995; Dorfmuller et al, 2002; Dorfmuller et al, 2003). These T cells 
are also accompanied by an increased number of DCs, monocytes and 
macrophages, suggesting that there is a strong inflammatory component to 
this disease (Tuder et al, 1994). 
Other evidence to suggest that T cells are involved in PAH 
pathogenesis comes from studies in which athymic rats, lacking T 
lymphocytes, develop severe angioproliferative PAH after administration of 
the VEGFR2 inhibitor SU5416 given under normoxic conditions 
(Taraseviciene-Stewart et al, 2007). PAH also occurs in association with HIV 
infections, in which CD4+ T cells are diminished. T cells would normally 
regulate the inflammatory response to vascular injury, but in this situation an 
over exuberant inflammatory response occurs. In other experiments using 
the above model of PAH, splenocytes from euthymic animals were injected 
into athymic animals, which protected the animals from the development of 
vascular lesions (Taraseviciene-Stewart et al, 2007; Ulrich et al, 2008). The 
MCT rat model of PAH has also been used to assess the effect that absence 
of CD4+ T cells has on inflammatory response. However, Cuttica et al 
described how ablation of CD4+ T cells protected against rising right 
ventricular pressures and RVH. When CD4+ T cells were reintroduced into 
this model, it was noted that there was a markedly increased perivascular 
inflammation as well as vascular remodelling, increased right ventricular 
pressures and RVH after administration of MCT (Cuttica et al, 2011). It has 
also been shown that suppression of the adaptive immune system inhibits 
development of hypertension in experimental animal models. Systemic 
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hypertension was reduced to normal levels when an immunosuppressive 
treatment, mycophenolate mofetil, was given to genetically hypertensive rats 
(Rodriguez-Iturbe et al, 2001). 
There have also been several recent reports detailing abnormal 
proportions of T cells in PAH patients. Ulrich et al studied T cell subsets in 
IPAH patient peripheral blood samples using flow cytometry and reported a 
decrease in the proportion of CD8+ T cells and an increase in the proportion 
of CD4+CD25high Treg and  Foxp3+ Treg cells in peripheral blood (Ulrich et al, 
2008). Austin et al also noted a higher proportion of CD4+CD25high Treg cells 
in patients with IPAH and further characterised the CD8+ T cells within IPAH 
patients, revealing that there was a significant increase in effector-memory 
CD8+ T cells (CD45RA+ CCR7-). There was enhanced cytotoxic activity to 
peripheral antigens and a significant decrease in circulating naïve CD8+ T 
cells (CD45RA+ CCR7+) in patients with IPAH compared to controls (Austin 
et al, 2010). Lymphocyte profiles in PAH patients have also been studied by 
Soon et al, who reported elevated Treg cell subsets in patients with 
inheritable PAH with BMPR2 mutations, but not in CTEPH patients (Soon, 
2008). It has been suggested that the increase in Treg cells could be 
necessary to suppress self-reactive T cells and that a dysfunctional immune 
system could contribute to the pathology of this disease. It is possible that 
the differences in prevalence of certain T cell subsets could be an indicator 
of the pathogenic role of these cells in PAH.  
Austin et al also performed immunohistochemical analysis on IPAH 
patient lung tissue to identify T cell infiltration, and found increased numbers 
of CD3+ and CD8+ T cells in the peripheral lung of IPAH samples compared 
with controls (Austin et al, 2010). The functional ability of Treg cells from 
IPAH patients to suppress proliferation of T effector cells has also been 
assessed. Ulrich et al performed a co-culture assay to look at the functional 
status of CD4+CD25high Treg cells from IPAH patients, but found that it was 
the same in patients and controls. No other work has been performed on 
Treg suppressive capabilities in PAH patient peripheral blood samples to 
date. Other patient subgroups (SSc-PAH) have not been examined and only 
one assay has been used to determine the functional capacity of Treg cells 
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to inhibit T cell proliferation in IPAH patients (using a CyQuant proliferation 
kit) (Ulrich et al, 2008). 
The patients included in these studies were all on drug treatments 
specifically for PAH, which may have affected lymphocyte number and 
function. Ulrich et al included only steroid-naïve patients in their analysis, 
however many IPAH patients included in their study were taking drugs used 
to treat PAH such as prostanoids, E-RAs and PDE-5 inhibitors, which could 
have altered their lymphocyte profile (Ulrich et al, 2008). In 2010, Austin et al 
performed a similar study, including IPAH patients receiving prostanoid 
therapy at the time of the study of lymphocyte profile in blood (Austin et al, 
2010). 
Despite these limitations to the aforementioned studies, these findings 
suggest that it is possible that CD4+ T cell irregularities seen in patients may 
make patients susceptible to exaggerated vascular inflammation and 
vascular remodelling following vascular injury (Tamosiuniene and Nicolls, 
2011). 
 
1.7.1  T cells and their involvement in the 
pathogenesis of scleroderma 
 
The role of T cells in the pathogenesis of SSc is also relevant as these 
cells are thought to contribute to tissue damage due to production of soluble 
mediators such as IL-4, and IL-6 (Needleman et al, 1992). Studies on 
circulating T cell subsets in peripheral blood of patients with SSc are 
inconclusive, with studies reporting differing results. Inflammatory cell 
infiltration (including B cells, T cells and macrophages) can occur very early 
during the formation of lesions with skin lesions predominantly having CD4+ 
T cell driven responses (Mavalia et al, 1997). These cells appear activated, 
exhibit oligoclonal expansion and are predominantly Th2 cells. Th2 T cells 
infiltrated skin lesions and produced IL-4, and the fibrosis seen in lesions can 
be prevented by anti–IL-4 treatment (Ong et al, 1998). Serum from SSc 
patients also had increased levels of Th2 cytokines (such as IL-4) 
(Needleman et al, 1992). An increase in the numbers of inflammatory cells 
infiltrating the skin in patients with SSc has been shown to correlate with skin 
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thickening and disease progression (Roumm et al, 1984). Drug therapies 
directed against activated T cells (cyclosporin A and tacrolimus) and a 
deficiency of CD4+ T cells, have been shown to improve skin tightness in 
animal models (Wallace et al, 1994). This improvement has also been noted 
in SSc patients after they were treated with antilymphocyte globulin to 
remove T cells (Goronzy and Weyand, 1990).  
 Several groups have reported an increase in Treg cells (CD4+CD25+ 
and CD25highFoxp3highCD127neg T cells) with diminished suppressive function 
in peripheral blood of SSc patients (Radstake et al, 2009). However, Antiga 
et al reported a decreased number of CD4+CD25brightFoxp3+ Treg cells. 
Slobodin et al noted a correlation between CD4+CD25brightFoxp3+ Treg cell 
numbers and disease severity and activity, suggesting a role for Treg cells in 
the pathogenesis of SSc. It was also suggested that this expansion of Treg 
cells in SSc appeared secondary to the expansion of activated CD4+ T helper 
cells, as they were activated in the periphery to express Foxp3 and become 
active Treg cells (Slobodin et al, 2010). 
Several other research groups have reported an increased ratio of 
CD4:CD8 T cells, due to a reduction in CD8+ T cells in SSc patients (Barnett 
et al, 1989; Luzina et al, 2003; Antiga et al, 2010). Some researchers 
suggest that this reduction in CD8+ T cells may be due to lymphocytotoxic 
antibodies or anti-lymphocyte antibody-blocking determinants in blood 
(Kessel et al, 2004). The reduction in CD8+ T cells in peripheral blood of 
patients with SSc may also be due to tissue migration into the lungs, where 
they have been shown to increase in number and appear increasingly 
activated (Yurovsky et al, 1996).  
Activated T cells (CD4+ and CD8+) and elevated Th2 associated 
cytokines (IL-2, IL-4 and IL-6) have been found in peripheral blood of 
patients with SSc, further emphasising the involvement of abnormally 
activated T cells and immune responses in SSc (Freundlich and Jimenez, 
1987; Gustafsson et al, 1990; Sakkas and Platsoucas, 2004).  
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1.8 Involvement of heat shock protein 
70 in pulmonary arterial 
hypertension 
 
Ritossa et al were the first to describe heat shock proteins (Hsp) when 
they inadvertently subjected drosophila melanogaster larvae to an elevation 
in temperature and noticed that this induced the expression of new genes in 
the form of chromosomal puffs in salivary gland cells (Ritossa, 1962). 
Tissières et al later identified the products of these genes, to which the term 
‘heat shock proteins’ was attributed (Tissieres et al, 1974). 
Hsps are a group of highly conserved proteins that are present in the 
cells of all organisms. They can be extracellularly localized or plasma 
membrane-bound and have been shown to be released into the extracellular 
compartment from a number of different cell types under a range of 
conditions, in which they have been shown to exhibit a number of pro- and 
anti-inflammatory properties. Hsps range in size from 10-150 kDa and they 
are classified into families on the basis of the molecular size; namely 110, 
90, 70, 60 and 40 kDa. They are released from a variety of cells including 
vascular SMCs and tumour cells under stressful conditions (Ferrarini et al, 
1992; Xu et al, 1997; Liao et al, 2000). Hsps have been shown to have 
several roles including molecular chaperones or proteases and can regulate 
intracellular protein folding (McLean et al, 2002). Hsp activity is regulated by 
HIF-1, a transcription factor involved in controlling genes concerned with 
promoting cell survival in low-oxygen conditions (Date et al, 2005). Pockley 
et al have shown Hsp70 can be detected in the serum of normal individuals, 
however it is up-regulated in response to  stressful conditions such as heat, 
hypoxia or UV radiation, hence the name “stress protein” (Iwaki et al, 1993; 
Trautinger et al, 1996; Pockley et al, 1998). 
Despite being thought of as a “danger signal” inducing pro-
inflammatory immune responses, Hsp70 can also inhibit protein kinases and 
transcription factors, decreasing ICAM-1 expression on ECs and inhibiting 
leukocyte adhesion and cytokine production, acting in an anti-inflammatory 
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manner (House et al, 2001; Kohn et al, 2002; Nollen and Morimoto, 2002; 
Pratt and Toft, 2003). Recently, there has also been much interest in the 
cardioprotective role of Hsp70, as Hsp70 levels can be used to predict the 
development of atherosclerosis in subjects with established hypertension 
and it is proposed to modify the progression of disease (Pockley et al, 2003; 
Pockley et al, 2009). Pockley et al have demonstrated that elevated levels of 
circulating Hsp70 protect against the development of atherosclerosis in 
patients with established hypertension (Pockley et al, 2003). Vasopressin-
induced hypertension has also been shown to increase Hsp70 mRNA 
induction in rat aorta (Xu et al, 1995; Pockley et al, 2002; Pockley et al, 
2003). 
Hsp70 over-expression can also protect cardiac cells against 
stimulated ischaemia or thermal stress and therefore, it is possible that 
Hsp70 may maintain or induce an anti-adhesive phenotype in the vascular 
endothelium, which would lead to an anti-inflammatory state (Brar et al, 
1999; House et al, 2001).  
Although these findings emphasise the importance of Hsps in 
protecting stressed endothelial and cardiac cells in systemic disease, the 
effect on pulmonary circulation / right ventricular failure is yet to be defined. 
At present there is limited information available regarding the relationship 
between Hsp70 expression and disease severity / disease pathogenesis in 
PAH patients.  
In different disease states, Hsps can act in either a pro- or anti-
inflammatory manner with Hsp70 and Hsp60  both inducing and inhibiting T 
cell proliferation and function (van Roon et al, 1997; Zanin-Zhorov et al, 
2003; Zanin-Zhorov et al, 2006; Zanin-Zhorov et al, 2005).  HSP60 signaling 
can activate TLRs (TLR2 and TLR4) via CD14, a co-receptor molecule 
expressed on the membrane of immune cells such as macrophages and T 
cells. The activation of these TLRs can then inhibit the activation (in activated 
T cells) of T-bet and Nuclear factor of activated T-cells (NFAT) via the TLR2 
signaling pathway. This results in the depletion of TNF-α, IFN-γ and IL-2 
secretion, inhibiting Th1 cell differentiation.  
However the suggestion that Hsps can have anti-inflammatory effects 
via interactions with Treg cell populations suggests that Hsp70 might 
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modulate the pathogenesis of PAH possibly via interactions with Treg cells 
(Pockley et al, 2003; Zanin-Zhorov et al, 2006; Borges et al, 2012).  
 
1.9  Treatments of pulmonary arterial   
 hypertension 
 
Although current treatments for PAH cannot completely cure the 
disease, they can help to prevent disease progression, prevent pulmonary 
artery thrombosis and relieve the symptoms of PAH by limiting vascular 
remodelling within the pulmonary arteries and improving oxygen supply.  
Treatments for PAH include anticoagulants, oxygen and diuretics for right 
heart failure as well as vasodilators including calcium-channel antagonists, 
endothelin-receptor antagonists (E-RA), phosphodiesterase type 5 inhibitors 
(PDE-5) and prostanoids (Rich et al, 1992; Quinn et al, 1998; Zhao et al, 
2001). 
E-RAs, such as Bosentan and Ambrisentan, inhibit vasoconstriction 
and the mitogenic effects of ET-1, causing vasodilatation. PDE-5 inhibitors, 
such as Sildenafil, are relatively selective pulmonary vasodilators via their 
ability to increase cyclic guanosine monophosphate (cGMP). Sildenafil also 
has anti-mitogenic properties, making this drug highly appealing to patients 
that are non-responsive to calcium channel blocker therapy. Prostanoids 
such as Epoprostenol (a synthetic prostacyclin), cause vasodilatation, 
platelet aggregation and have anti-proliferative properties on cultured 
vascular SMCs, suggesting they may have an effect on vessel remodelling 
(Rubin, 2002).  
Combination therapy, using several combinations of the previously 
mentioned drugs, also shows promise, however the long term effects of this 
have not yet been confirmed (Hoeper et al, 2004). Oxygen therapy and anti-
coagulants such as warfarin are also used in combination with the previously 
mentioned drugs. New targets are emerging all the time regarding treatment 
of PAH, including rho kinase inhibitors, serotonin transporter inhibitors and 
regenerative therapy using bone marrow-derived endothelial-like progenitor 
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cells (Guignabert et al, 2005; Nagaoka et al, 2005; Zhao et al, 2005). These 
targets aim to have anti-proliferative and anti-remodelling effects as well as 
vasodilatory effects on SMCs (McLaughlin, 2011). 
 Despite advances in the understanding of PAH pathogenesis, at 
present there is still no cure for PAH except for a full lung transplantation, 
which only occurs in a few cases per year in the UK.  
 
1.10  Aims and hypotheses 
 
 The aim of this thesis was to determine the phenotypic profile of T cell 
populations in peripheral blood of patients with IPAH and SSc-PAH and 
compare these with controls. I aimed to use the fat fed ApoE-/-/IL1R1-/- 
mouse model of PAH to deduce the involvement of T cell subgroups in the 
progression of PAH disease and also aimed to determine the effect of T cell 
depletion had on the progression of PAH. I also aimed to determine Hsp70 
levels in serum and lung samples to relate them to disease progression. 
 I hypothesised that patients within different PAH subgroups would 
exhibit an altered T cell profile in peripheral blood compared to 
corresponding controls. I also hypothesised that changes in circulating T cell 
subsets would correlate with disease progression and vascular remodelling 
in an animal model of PAH and that a reduced CD4+ T cell subset may 
encourage the pathogenesis of PAH. I also hypothesised that changes in 
pulmonary vascular haemodynamics would cause EC stress and regulation 
of Hsp70. 
  
35 
 
Chapter 2  Characterising lymphocyte 
subpopulations in peripheral blood of 
patients with pulmonary arterial 
hypertension 
 
 
2.1  Introduction 
 
 As previously discussed in chapter 1.7, T cells are thought to be 
involved in the pathogenesis of PAH. Despite this, only a limited number of 
studies detailing changes in proportions of T cell subsets in PAH patients 
have been performed. Previous studies are limited by patient cohorts that 
were already on PAH treatment and therefore the aim of this chapter was to 
analyse T cell subsets in treatment naïve PAH patients. Additionally, 
published literature in this field only encompasses IPAH patients and so 
patients with PAH associated with CTD, specifically SSc where T cells play 
an active role in disease progression, will be examined (Wallace et al, 1994).   
 
2.2  Methods 
 
2.2.1 Ethics 
 
Ethical approval for this study was obtained from the Sheffield Local 
Research Ethics Committee (ref: 08 / H1308 / 193). Blood samples were 
taken after written informed consent was obtained from all participants in this 
study. Local Sheffield teaching hospital R and D approval for the 
Cardiovascular Biomedical Research Unit (CVBRU) tissue bank was also 
gained before the study was conducted (STH15222).   
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2.2.2 Patient Samples 
 
All experiments were performed in Department of Cardiovascular 
Science Laboratories at the University of Sheffield, in collaboration with the 
National Institute for Health Research Cardiovascular Biomedical Research 
Unit (CVBRU) and the Sheffield Pulmonary Vascular Disease Unit (SPVDU). 
Blood was collected from patients attending the SPVDU with suspected PAH 
following written informed consent. Diagnosis was later confirmed at a 
consultant led management, diagnosis and treatment meeting. Patients with 
no PAH at right heart catheterisation, and healthy age and sex matched 
patients, were used as controls along with patients diagnosed with SSc 
alone. All enrolled patients met diagnostic criteria for IPAH and SSc-PAH in 
accordance with accepted international standards (Galie et al, 2009). This 
included a mean pulmonary arterial pressure (mPAP) of ≥ 25 mmHg with a 
pulmonary capillary wedge pressure of ≤ 15 mmHg, and exclusion of left 
ventricular dysfunction.  
 A total of 65 patients were recruited throughout the duration of this 
project, however only 13 SSc-PAH patients and 15 IPAH patients were 
included in this study. Data was excluded from patients with 1) sub-optimal 
peripheral blood mononuclear cell isolation and 2) a diagnosis after initial 
blood draw as “not IPAH” or “not SSc-PAH”.  
A total of 16 healthy volunteers were recruited for this project with only 
one being excluded as it was later confirmed that they had taken anti-
inflammatory medication before blood draw. A total of 9 SSc controls were 
also recruited, with one being excluded due to insufficient CD3+ T cell events 
being recorded on analysis. SSc-no PAH patients were recruited from a 
rheumatology clinic as having no symptoms for PH or from the SPVDU as 
SSc patients referred with suspected PH who had a normal mean PAP at 
diagnostic right heart catheterisation These patients were taking a range of 
medications including vasodilators, anti-inflammatories proton pump 
inhibitors and pro-kinetic agents. Healthy control subjects were questioned 
about medical history and current drug therapies that they were undergoing 
prior to blood draw. To avoid changes in number and activation status of 
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circulating lymphocyte subsets due to drug therapies, healthy controls and 
SSc patients were included on the basis that they had not taken anti-
inflammatory agents, anti-histamines or immune-suppressive therapies prior 
to blood donation nor had they any co-morbidities such as autoimmune or 
cardiovascular disease.  
 
2.2.2.1 Lymphocyte subset staining in patient 
blood and controls 
 
Venepuncture was performed using a 21 G needle and 5 mL of blood 
was collected into lithium-heparin Vacutainer® (BD Biosciences, Oxford, UK). 
Isolation of peripheral blood mononuclear cells (PBMCs) was performed by 
density gradient centrifugation. Blood was diluted 1:1 with phosphate 
buffered saline (PBS) at room temperature and layered over an equal 
volume of density gradient medium LSM 1077 Lymphocyte. The preparation 
was centrifuged at 1200 x g for 20 minutes without a brake so as not to 
disrupt the layers generated during the centrifugation. Erythrocytes and 
dense granulocytes sedimented to leave a layer of PBMCs and platelets at 
the interface (Figure 2.1). 
After isolation, PBMCs were counted using a haemocytometer and 
1x106 PBMCs placed into each of 4 tubes. These tubes were an unstained 
tube, an isotype control tube, a T cell and B cell staining tube and a Treg cell 
staining tube. Antibodies were used according to the manufacturer’s 
instructions to stain the volume of blood or number of cells in each sample 
(see Appendix 1, section 3 for antibodies used). To each tube, 1 µL normal 
mouse serum was added to prevent non-specific monoclonal antibody (mAb) 
binding. The samples were incubated at room temperature for 15 minutes. 
The T and B cell tube contained markers against CD3, CD4, CD8, CD19, 
CD45, CD25 and CD69 whilst the Treg tube contained markers against CD3, 
CD4, CD25, CD127, CD69 and Foxp3. Isotype controls were added to a 
separate tube to allow removal of non-specific binding when analysing data. 
An amine reactive live / dead viability dye was added to both staining tubes 
to use as a dead cell exclusion marker. The samples were incubated for 30 
minutes at 4°C and washed in 1 mL PBS (300 x g, 5 minutes and 4°C).  
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Figure 2.1 Isolation of PBMCs from whole blood. 
An illustration of the different layers before and after density gradient centrifugation 
using LSM 1077 Lymphocyte. Before centrifugation, the whole blood was added to 
an equal volume of PBS and gently placed on top of an equal volume of LSM 1077 
Lymphocyte separation medium. After centrifugation, peripheral blood mononuclear 
cell (PBMC) collect at the interface between separated serum and LSM 1077 
lymphocyte solution. Erythrocytes and dense granulocytes collect at the bottom of 
the tube. PBMCs can then be removed, washed and fluorescently conjugated 
antibodies used to detect different lymphocyte subsets. 
 
Intracellular Foxp3 staining was undertaken after staining for 
extracellular markers. The Foxp3 Fixation/Permeabilization Concentrate and 
Diluent kit from eBioscience were used. In brief, cells were incubated for 60 
minutes at 4°C in the dark with freshly prepared fixation / permeabilization 
working solution. The cells were washed in 1 mL permeabilization buffer (300 
x g, 5 minutes and 4°C) and 20 µL of anti-Foxp3 antibody added for 30 
minutes, at 4°C in the dark. This was washed again before the cells were 
resuspended in 150 µL permeabilization buffer. Cells in all tubes were fixed 
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by adding 150 µL 1X CELLFix™ and stored in the dark at 4°C to allow 
analysis the next day. 
Lymphocytes were identified on the basis of their size and granularity, 
as represented by forward and side light scatter characteristics (FSC vs SSC 
respectively) and their expression of CD45. Multiparametric flow cytometry 
was performed on all samples using a BD LSRII flow cytometer (355 nm 
UV laser, 405 nm violet laser, 488 nm blue laser and a 633 nm red laser). All 
data were analysed using BD Biosciences FACSDIVATM acquisition and data 
analysis software using the gating hierarchy and scatter plots / histograms 
shown in Figure 2.2 and Figure 2.3. Data on a minimum of 10,000 CD3+ 
events (cells) in the lymphocyte gate were collected.  
CD45 (a protein tyrosine phosphatase located in all leukocytes except 
erythrocytes and platelets) was used to distinguish lymphocytes and also to 
determine the proportion of B and T cells. To assess the number of B cells 
within the peripheral blood sample, CD19 (a marker of B cells) was used to 
distinguish B cells from T cells.  T cell subsets were determined according to 
the expression of CD3 (part of the T cell receptor), CD4 (a glycoprotein 
expressed on the surface of T helper cells, monocytes, macrophages, and 
dendritic cells) or CD8 (a glycoprotein that serves as a co-receptor for the T 
cell receptor). Activated lymphocyte subsets were identified using the early 
activation marker, CD69.  
As previously mentioned in Chapter 1.2, T regulatory cells (Treg cells) 
are important in balancing Th1 and Th2 responses, maintaining self-
tolerance, and controlling autoimmunity.  
The relative frequency of Treg cells (CD4+CD25high, 
CD4+CD25highCD127low, CD4+CD25highFoxp3+ and 
CD4+CD25highCD127lowFoxp3+) were distinguished using markers against 
CD25 (the alpha chain of the IL-2 receptor), CD127 (interleukin-7 receptor-α 
chain) and Foxp3 (member of the forkhead box family of transcription 
factors). CD4 and CD25 are thought to identify Treg cells, however these 
cells could also include a subset of T cells that do not possess regulatory 
functions, as CD25 is also a T cell activation maker and can be expressed on 
T effector cells (Caruso et al, 1997). Therefore a combination of markers 
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including CD127 and Foxp3, as well as CD25, has been suggested to be a 
more robust method of identifying Treg cells (Banham et al, 2006; Su et al, 
2012; Yu et al, 2012). CD127 has been shown to inversely correlate with 
Foxp3 expression in Treg cells and Foxp3 is thought to be involved in Treg 
cell function (mentioned previously in Chapter 1.2) (Banham, 2006; Liu et al, 
2006; Hartigan-O'Connor et al, 2007). Current literature regarding markers 
used to identify and define Treg cells is conflicting; therefore, this study 
investigated the use of different combinations of mAbs for the identification of 
Treg cells.  
To ensure the integrity of the experimental data and to correctly 
interpret multicolour flow cytometry data, it was necessary to employ a 
mechanism called colour compensation to take into account the inherent 
overlap of emission spectra from different fluorescent fluorophores. Each 
fluorescently conjugated mAb was incubated with anti-mouse IgG-coated 
compensation beads and the UV live dead stain incubated with ArC™ 
reactive beads. These were used to establish the degree of spectral overlap 
and compensate for it in analysis. FACSDIVA™ software was used to 
automatically calculate compensation using the fluorescent emission of mAb 
stained beads. This removed the spectral overlap which is caused by 
fluorescent emission of one fluorochrome “leaking” into the detection channel 
of another fluorochrome.   
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Figure 2.2 Representative gating hierarchy template and acquisition plots 
used to define different lymphocyte subsets. 
A) Example dot plots and histograms depicting each gate in the gating hierarchy for T and B 
cells. B) The gating hierarchy used to distinguish T and B cell subsets as well as their 
activation status (CD69). Forward Scatter (FSC) and Side Scatter (SSC) were used to gate 
on the lymphocyte population before single cells and viable cells were selected for analysis. 
Laser detectors and marker are shown on χ axis and count or SSC are shown on the ƴ axis. 
Activation data are presented as a histogram whilst all other data are shown as scatter plots. 
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Figure 2.3 Representative gating hierarchy template and acquisition plots 
used to define Treg cells. 
A) Example dot plots and histograms depicting each gate in the gating hierarchy for Treg 
cells. B) The gating hierarchy used to distinguish Treg cells and activation status (CD69). 
Forward Scatter (FSC) and Side Scatter (SSC) were used to gate on the lymphocyte 
population before single cells and viable cells were selected for analysis. Laser detectors 
and marker are shown on χ axis and count or SSC are shown on the ƴ axis. Activation data 
are presented as a histogram whilst all other data are shown as scatter plots.  
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2.2.3 Treg functional studies 
 
A crucial component of our ability to resolve inflammatory responses 
involves the activation and activity of Treg cells. These cells have been 
shown to have a decreased suppressive function in inflammatory and 
autoimmune diseases such as multiple sclerosis and SSc, which explains 
how uncontrollable inflammatory processes dominate within these diseases 
(Venken et al, 2008; Radstake et al, 2009) Studies on suppressive 
capabilities of Treg cells from IPAH patients have revealed no differences 
between patients and controls, despite the increase in the proportion of Treg 
cells within the peripheral circulation (Ulrich et al, 2008). 
Therefore this work aimed to define the suppressive capabilities of 
Treg cells from treatment naïve IPAH and SSc-PAH patients with regards to 
their ability to suppress the proliferation of T effector cells (also known as T 
responder cells). I hypothesised that despite being increased in number, 
these cells would show a decreased ability to regulate T effector cell 
proliferation, based on previously published literature in similar disease 
states (Radstake et al, 2009).  
H3-thymidine (PerkinElmer, Buckinhamshire, UK) incorporation and 
CellTrace™ Violet (Invitrogen of Life Technologies Ltd, Paisley UK) 
incorporation were used to assess the capacity of Treg cells to suppress the 
proliferation of polyclonally activated T responder (Tresp) cells. Several 
commercial kits were available to isolate Treg cells (which also isolate T 
responder cells) and have been tested here to assess purity of isolated cells. 
As previously described, there are several cell surface markers which can be 
used to identify and isolate Treg cells, including CD127 and CD25 in 
immature Treg cells. Two commercially available Treg isolation kits were 
tested from STEMCELL technologies (STEMCELL Technologies, Grenoble, 
France) and Miltenyi Biotec (Miltenyi Biotec Ltd, Surrey, UK) to isolate Treg 
cells based on CD4+ and CD25high expression (EasySep® Mouse 
CD4+CD25+ Regulatory T Cell Isolation Kit and CD4+CD25+ Regulatory T 
Cell Isolation Kit respectively). CD4+CD25+CD127dim/– Treg cell isolation was 
also undertaken using the CD4+CD25+CD127dim/– Regulatory T Cells 
Isolation Kit II from Miltenyi Biotec and the Complete Kit for Human 
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CD4+CD127lowCD25+ Regulatory T Cells from STEMCELL Technologies. 
The protocols for these separation techniques are described below.  
 
2.2.3.1 EasySep® Mouse CD4
+
CD25
+
 Regulatory T 
Cell Isolation Kit  
 
After informed consent was provided, 50 mL of whole blood was taken 
from healthy volunteers into BD Vacutainer® Blood Collection Tube using a 
21 gauge needle. To isolate CD4+ T cells from whole blood, 2.5 mL of 
RosetteSep® Human CD4+ T cell Enrichment Cocktail (STEMCELL 
Technologies, Grenoble, France) was added to whole blood and incubated at 
room temperature for 20 minutes. The sample was diluted with an equal 
volume of PBS + 2% v/v foetal calf serum (FCS, 52.5 mL) and mixed gently. 
The diluted sample was layered over 15 mL density medium (RosetteSep® 
DM-L) and centrifuged at 1200 x g at room temperature for 20 minutes with 
the brake off. The enriched cells were removed from the density 
medium:plasma interface and washed twice in PBS + 2% v/v FCS. This 
involved adding 10 mL PBS + 2% FCS centrifuging at 1200 x g for 5 minutes 
at room temperature and aspirating the supernatant.  
After isolating CD4+ T cells, it was possible to isolate CD25+ T cells 
using the human CD25 positive selection kit. CD25 positive T cell isolation 
was undertaken by transferring 500 µL of the pre-enriched CD4+ T cells into 
a 5 mL polystyrene tube. 25 µL EasySep® positive selection cocktail was 
added to the cell suspension, mixed well and incubated at room temperature 
for 15 minutes. The EasySep® Magnetic Nanoparticles were resuspended 
and 25 µL added to the cells. This was mixed well and incubated at room 
temperature for 10 minutes. The cell suspension was brought to a total 
volume of 2.5 mL by adding Memorial Institute medium 1640 (RPMI) (Sigma 
Aldrich, Dorset, UK) with 2% v/v FCS and left to stand for 5 minutes. The 
cells were mixed thoroughly and the tube placed into "The Big Easy" 
EasySep® Magnet. The magnet was picked up and in one continuous 
movement, the tube and magnet inverted to pour off the supernatant fraction. 
The magnetically labelled cells remained inside the tube, held by the 
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magnetic field. The magnet and tube were returned to the upright position 
and the tube removed. 2.5 mL RPMI medium + 2% v/v FCS was added to 
the cells and mixed well. The tube was placed back into the magnet, left to 
rest for 5 minutes and the supernatant poured off again. This process was 
repeated twice more for a total of four 5-minute separations.  
The advantages of using the STEMCELL kits are that it is possible to 
save time by isolating cells directly from whole blood, rather than undertaking 
a PBMC preparation before isolating T cells. Also, the STEMCELL kits use 
magnets rather than columns to isolate the cells and there are also less 
wash steps involved, which decreases the amount of time it takes to isolate 
the Treg cells.  
 
2.2.3.2 CD4
+
CD25
+
 Regulatory T cell Isolation Kit  
 
After informed consent was provided, 50 mL of whole blood was taken 
from healthy volunteers into BD Vacutainer® Blood Collection Tubes using a 
21 gauge needle. To isolate CD4+CD25+ Treg cells from whole blood using 
the Miltenyi Biotec CD4+CD25+ Regulatory T Cell Isolation Kit, the PMBCs 
had to firstly be isolated (Chapter 2.2.2.1). The PBMCs were counted using a 
haemocytometer, centrifuged at 300 x g for 10 minutes and the supernatant 
removed. The cells were resuspended in RPMI medium + 2% v/v FCS to get 
a 2.5x107 / mL suspension. 10 µL of CD4+ T Cell Biotin-Antibody Cocktail 
was added per 1x107 total cells. This was mixed well and incubated at 4˚C 
for 10 minutes. 20 µL Anti-Biotin MicroBeads were added per 1x107 total 
cells. This was mixed well and incubated for 15 minutes at 4˚C. The cells 
were washed in 1.5 mL per 1x107 total cells by centrifugation for 10 minutes 
at 300 x g. The supernatant was then removed and the cells resuspended in 
500 µL buffer. 
To deplete the non-CD4+ cells, an LD column was prepared by rinsing 
with 2 mL PBS + 2% FCS and placed in the magnetic field of a MACS 
separator before the cell suspension was added. The unlabelled cells (CD4+ 
T cells) were passed through the column and the column was then washed 
again with 2 mL buffer and the unlabelled cells collected. The cell 
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suspension was centrifuged for 10 minutes at 300 x g, before the 
supernatant was removed and the cell pellet resuspended in 90 µL of PBS + 
2% v/v FCS. 10 µL CD25 Microbeads were then added to the cell 
suspension (scaled up accordingly if more than 1x107 total cells were used) 
and left to incubate for 15 minutes in the dark at 4˚C. 1.5 mL of PBS + 2% v/v 
FCS was added to the cells, before they were centrifuged at 300 x g for 10 
minutes to wash them. The CD4+CD25+ Treg cells were positively selected 
by applying the cell suspension to a pre-prepared MS column. The column 
was placed in the magnetic field of a MACS separator and was prepared by 
adding 500 µL PBS + 2% v/v FCS before the cell suspension was applied. 
The flow through was collected (CD4+ Tresp cells) and the column washed 3 
times with 500 µL PBS + 2% v/v FCS. The column was removed from the 
separator, and placed in a collection tube before 1 mL PBS + 2% v/v FCS 
was then pipetted onto the column and the column immediately flushed out 
using the plunger to collect the magnetically labelled cells (CD4+CD25+ Treg 
cells). This step was repeated twice more to increase the purity of the Treg 
population.  
 
2.2.3.3 CD4
+
CD25
+
CD127
dim/–
 Regulatory T Cells 
Isolation Kit II  
 
The isolation of CD4+CD25+CD127dim-/- Treg cells from whole blood 
using the Miltenyi Biotec CD4+CD25+ Regulatory T Cell Isolation Kit employs 
the same basic technique as previously described in the CD4+CD25+ 
Regulatory T Cell Isolation kit from Miltenyi Biotec, however for the depletion 
of non-CD4+ cells a different cocktail of biotin conjugated antibodies is used.  
The resultant Treg cell population is CD4+CD25+CD127dim-/- rather than 
CD4+CD25+. 
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2.2.3.4 Complete Kit for Human 
CD4
+
CD127
low
CD25
+
 Regulatory T Cells  
 
The isolation of CD4+CD25+CD127low Treg cells was undertaken in 
the same manner that CD4+CD25+ Treg cells were isolated using the 
EasySep® Mouse CD4+CD25+ Regulatory T Cell Isolation Kit from 
STEMCELL Technologies, however instead of using the RosetteSep® 
Human CD4+ T cell enrichment cocktail, the RosetteSep® Human 
CD4+CD127low Regulatory T Cell Pre-enrichment cocktail was added.  
 
2.2.3.5 Assessment of purity of T regulatory and T 
responder cell populations 
 
The purity of the Tresp and Treg cell populations isolated using the 
above approaches was measured using flow cytometry to determine which 
kit would be most reliable when setting up the Treg suppression assay. 
Purity of Treg cell populations (CD4+CD25high) was calculated as a 
percentage of the parent CD4+ T cell population. Purity of Tresp cells 
(CD4+CD25-) was also assessed as a percentage of the parent CD4+ T cell 
population. Purity of Tresp cells isolated in each kit was < 95% which meant 
that either kit could be used to isolate this T cell subset. However, Treg cell 
purity differed between the kits. The Miltenyi Biotec CD4+CD25+ Treg cell 
isolation kit provided a 64% pure Treg cell population, whereas the 
CD4+CD25+CD127- Treg cell isolation kit from Miltenyi Biotec produced a 
76.4% pure Treg cell population. The STEMCELL Technologies CD4+CD25+ 
Treg isolation kit gave a 77% pure Treg cell population, whilst the 
CD4+CD25+CD127- Treg cell isolation kit from STEMCELL Technologies 
provided a Treg cell population that was 90% pure. Therefore the 
STEMCELL kit was used to isolate Tresp and Treg cells for subsequent Treg 
suppression assays.  
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2.2.3.6 Treg cell suppression assays 
 
Treg cell function was assessed via the ability of this population to 
inhibit the proliferative responses of Tresp cells to a polyclonal stimulus (Treg 
suppression inspector beads). These beads (anti-biotin MACSiBead particles 
coated with biotinylated CD2, CD3, and CD28 antibodies) were added to co-
cultures of different ratios of Tresp and Treg cells to induce Tresp cell 
proliferation. In culture, Tregs alone are hypoproliferative (anergic) whereas 
Tresp cells alone show a proliferative response, which can be measured.  
 The Treg suppression assay was set up using 50 mL peripheral blood 
taken from healthy volunteers. The STEMCELL Technologies 
CD4+CD127lowCD25+ Treg isolation kit was used to isolate Treg cells and 
Tresp cells to perform this assay, as this proved to produce the purest 
populations of Tresp and Treg cells. Treg cells and Tresp cells were isolated, 
as previously described, under sterile conditions. The number of both Treg 
cells and Tresp cells was determined to ensure there were enough to run the 
assay (9x10⁵ Tresp cells and 6x10⁵ Treg cells needed to run assay in 
triplicate). Cell suspensions were washed and resuspended in RPMI with 2% 
v/v FCS at 5x10⁵ cells / mL. The appropriate volumes of both Tresp and Treg 
cells and Treg suppression inspector beads were transferred to a 96 well 
culture plate (Table 2.1).  
The wells were filled to a total volume of 210 µL with RPMI + 2% v/v 
FCS before incubating the plate at 37°C and 5–7% v/v CO₂ for 4 – 5 days. 
To measure proliferation using H3-thymidine, 1μCi of H3-thymidine was 
added to each well and incubated at the same conditions described 
previously, for a further 16 hours. The cells were washed and harvested 
using a cell harvester (Skatron instruments, Suffolk, UK). H3-thymidine 
incorporation was measured for 10 minutes using a scintillation counter 
(Beckman coulter, High Wycombe, UK). H3-thymidine is incorporated into 
new strands of DNA during mitotic cell division, and the radioactivity of the 
sample is measured using a scintillation counter. Only proliferating cells 
incorporate H3-thymidine, so this method measures DNA synthesis and can 
be used to quantify proliferation rates. 
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Ratio Tresp cells: 
Treg cells 
Tresp cells 
(5x105 
cells / mL) 
Treg cells 
(5x105 
cells / 
mL) 
Treg 
Suppression 
Inspector 
(1x107 
MACSiBead 
particles / mL) 
Culture 
medium 
(RPMI + 
2% v/v 
FCS) 
1:0 100 µL  - 5 µL  105 µL  
0:1 - 100 µL  5 µL  105 µL  
1:1 100 µL  100 µL  10 µL  - 
2:1 100 µL  50 µL  7.5 µL 53 µL 
4:1 100 µL  25 µL  6.5 µL 79 µL 
8:1 100 µL  12.5 µL  6.0 µL 92 µL 
Control 1:0 100 µL  - - 110 µL 
Control 0:1 - 100 µL  - 110 µL 
  
   
  
Total Volume 600 µL  387.5 µL  40 µL  654 µL  
Total volume for 
1 assay 
(triplicates) 
1800 µL  1200 µL  120 µL  2 mL 
 
Table 2.1 Pipetting scheme for Treg suppression assay 
Treg and Tresp cells were co-cultured in different ratios (column 1) with or without 
Treg suppression inspector beads to provide a polyclonal stimulus for Tresp cell 
proliferation (column 4). Culture medium was also added before incubation (column 
5). Total volumes for all components and for an assay in triplicate are shown in grey 
boxes. Data is kindly reproduced with permission of Miltenyi Biotec (Miltenyi Biotec 
Ltd, Surrey, UK).  
 
CellTrace™ Violet (Invitrogen of Life Technologies Ltd, Paisley, UK) 
was also used to detect Treg cell suppressive capabilities. CellTrace™ Violet 
diffuses into cells (in this case, T responder cells) and is cleaved by 
intracellular esterases creating a fluorescent compound which can bind to 
intracellular amines producing a fluorescent signal. Treg cell function can be 
determined by the ability of these cells to suppress the proliferation of Tresp 
cells, as measured on the basis of a decline in the fluorescence of 
proliferating cells. CellTrace™ Violet was prepared according to the 
manufacturer’s instructions (see Appendix 1, section 1) and incubated with 
Tresp cells for 20 minutes, at 37°C and protected from light. Unbound dye 
was then quenched, before the cells were added to the 96 well culture plate, 
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as previously described in the Treg suppression assay. Proliferation was 
assessed using flow cytometry (LSRII flow cytometer, violet 450 / 50 nm 
filter), with each violet peak representing a successive generation of Tresp 
cells proliferating in response to the Treg suppression inspector beads. Cells 
that were not proliferating remained to the right of the histogram at the 
brightest violet peak. With each cell division the intensity of the signal was 
reduced and the mean fluorescent index decreased.  
Numerous problems were encountered in performing this assay 
including an insufficient number of isolated Treg cells, proliferation of control 
populations and low purity of isolated Treg cell populations. Other groups 
have also noted problems in conducting Treg cell suppression assays due to 
small numbers of isolated Treg cells, suggesting that this is a major 
drawback of studying regulatory activity of Treg cells in vitro (Smolders et al, 
2009). If patient consent could be gained for a larger volume of blood to be 
donated (150 - 200 mL), a higher number of Treg cells could be isolated and 
the assay performed in triplicate to produce more reliable results. Purity of 
the isolated Treg cell population was also an issue as only a 90% pure 
population could be obtained. This meant that Tresp cells could be found 
within the Treg cell population, which could have affected the results of the 
assay. If a larger volume of blood can be used in future experiments, Treg 
and Tresp cells could be obtained via fluorescence activated cell sorting 
rather than via the methods used here. For cell sorting, several antibodies 
can be used to detect Treg cells (CD4, CD25 and CD127) and the resulting 
populations would be of a higher purity level. 
 The functionality of Treg cells could be assessed using other methods 
including measuring the release of mediators (IL-10 and TGF-β) and 
measuring activation of cells themselves, via the expression of activation 
markers such as CD69 (Lindsey et al, 2007). These methods, such as 
ELISPOT and flow cytometry, can provide an alternative way of quantifying 
Treg cell function. To measure proliferative responses of T responder cells to 
different ratios of Treg cell, other methods could be used such as flow 
cytometry to stain for T cell specific markers (CD4 and CD25) and the use of 
counting beads to determine exact cell numbers. However, this would require 
a larger volume of peripheral blood to isolate Tresp and Treg cells, a factor 
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which has limited some studies mentioned in this thesis. Other stimulatory 
methods could also be tested and used to conduct the proliferation assay, 
including concanavalin A (conA), or phytohaemagglutinin (PHA) stimulation 
(Trickett and Kwan, 2003).  
 
2.2.4 Statistical Analysis 
 
Proportional cell data were expressed as box and whisker plots 
showing minimum and maximum values. GraphPad Prism version 5.00 for 
Windows (GraphPad Software, San Diego, California USA, 
www.graphpad.com) was used for statistical analysis. To account for any 
non-normal data distributions, and for consistency of analysis, statistical 
significance was evaluated using nonparametric statistical techniques. 
Differences between two groups were compared using a two-tailed, Mann-
Whitney test whilst differences between multiple groups were compared 
using a Kruskal-Wallis test using Dunn’s post hoc test to compare all pairs of 
data. Both tests had 95% confidence intervals. A P value < 0.05 was 
considered statistically significant in all tests. 
 
2.3  Results 
 
2.3.1  Patient demographics 
 
A total of 28 PAH patients were recruited and included in these 
studies including 13 SSc-PAH and 15 IPAH patients. The mean age of SSc-
PAH patients was 66 years whilst for IPAH patients it was 58 years. This 
compared to a mean age of 60 in the healthy control group and 62 in the 
SSc-no PAH control group. Of the 13 SSc-PAH patients recruited, 8 were 
female whilst for the 15 IPAH patients, 9 were female. There was also a bias 
towards limited SSc-PAH patients compared to diffuse cutaneous SSc-PAH 
patients. Clinical parameters were assessed in patient groups at visit 1 to 
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confirm PAH diagnosis. The full patient demographics are described in Table 
2.2. 
There was a significantly higher mPAP in IPAH patients compared to 
SSc-PAH patients (55.86 ± 12.31 mmHg vs 37.40 ± 14.52 mmHg, n=13-15, 
P=0.007). There was also a higher pulmonary vascular resistance (PVR) in 
IPAH patients compared to SSc-PAH patients (847.60 ± 366.80 dynes/cm^5 
vs 492.00 ± 436.90 dynes/cm^5, n=13-15, P=0.02). There was no significant 
difference in Cardiac Output (CO) or Cardiac Index (CI) between the groups.   
The SSc-PAH patients showed a significantly lower forced expiratory 
volume compared to IPAH patients (1.10 ± 1.06 vs 2.12 ± 0.69, n=13-15, 
P=0.03), whilstFEV1 / FVC ratio did not significantly change between the two 
PAH patient groups. There was also no significant difference in shuttle walk 
test between groups. The shuttle walk test is a measure of the functional 
capacity of the patient and requires the patient to walk between two cones to 
a set of auditory beeps played on a CD with increasing speed. The patient 
walks for as long as possible until they become too breathless or can no 
longer keep up with the beeps, at which point their shuttle walk test score is 
calculated as the number of shuttles between cones (each shuttle represents 
10 metres). 
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 Healthy SSc-no PAH SSc-PAH IPAH 
Statistical 
Analysis 
n 15 8 13 15 N/A 
Age 60 ± 3 62 ± 8 66 ± 8 58 ± 16 N/S    
Sex 8F 6M 7F 1M 8F 5M 9F 6M N/A 
Phenotype N/A 7 ltd,1 diff 12 ltd, 1 diff N/A N/A 
mPAP (mmHg) N/A N/A 37.40 ± 14.52 55.86 ± 2.31 ** 
CO (L/min) N/A N/A 5.65 ± 1.79 4.55 ± 1.54 N/S    
PVR (dynes/cm^5) N/A N/A 492.00 ± 436.90 847.60 ± 366.80 * 
FEV1 actual (L) N/A N/A 1.10 ± 1.06 2.12 ± 0.69 * 
FEV1 / FVC actual 
 
N/A N/A 0.43 ± 0.39 0.68 ± 0.09 N/S    
Shuttle walk test 
(m) 
N/A N/A 238.00 ± 173.30 192.70 ± 156.10 N/S  
CI N/A N/A 2.85 ± 0.78 2.63 ± 0.78 N/S  
HR (bpm) N/A N/A 76.56 ± 13.57 79.67 ± 18.21 N/S  
 
Table 2.2 Pulmonary arterial hypertension patient demographics. 
n number (n), age, sex, phenotype of disease, mean pulmonary artery pressure 
(mPAP) measured in millimetre of mercury (mmHg), cardiac output (CO) measured 
in litres per minute (L/min), pulmonary vascular resistance (PVR) measured in 
dynes/cm^5, forced expiratory volume in one second (FEV1) measured in litres (L), 
forced vital capacity (FVC), shuttle walk test, cardiac index (CI) and heart rate (HR) 
measured in beats per minute (bpm) are shown for healthy, SSc-no PAH controls 
and IPAH and SSc-PAH patients. Male (M) and female (F) participants as well as 
the phenotype of their disease, limited (ltd) or diffuse cutaneous (diff) are shown. 
Data depicted as mean ± SD. Patient groups compared using a two tailed Mann 
Whitney test whilst patient and control groups were compared using a Kruskal 
Wallis Test with Dunn’s post hoc test. A 95% confidence interval was used where 
P< 0.05 is considered significant (*). Not applicable (N/A) applied where statistical 
analysis was not undertaken and N/S where statistical analyses were not significant. 
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2.3.2 T cell subsets in patient and control 
peripheral blood samples  
 
To determine lymphocyte subpopulations within the circulation, 
lymphocytes were isolated from peripheral blood, analysed using flow 
cytometry and T and B cell subgroups detected. Patients with IPAH and SSc-
PAH, as well as healthy controls and SSc alone without evidence of PAH, 
were enrolled on the study. Changes in proportions of different T cell subsets 
were determined in each study group after gating around the total 
lymphocyte population and collecting 10,000 CD3+ T cell events. Proportions 
of CD4+ T cells, CD8+ T cells and a CD4:CD8 T cell ratio, a numerical value 
used clinically, were calculated for each study group.  
 
2.3.2.1  CD4
+
 T cell subset 
 
There was no change in the proportion of circulating CD4+ T cells (as 
a percentage of total CD3+ T cells) in the peripheral blood of PAH patient 
groups when compared to both control groups (Figure 2.4, A). To determine 
if there was a change in the proportion of CD4+ T cells in the individual 
patient groups, the group was split into IPAH and SSc-PAH patients and 
compared to their relevant controls (Figure 2.4, B and C). There was 
however, still no difference in the proportion of CD4+ T cells between groups.  
There was also no change in total lymphocyte counts in whole blood, 
as noted from clinical data in either IPAH or SSc-PAH patients when 
compared to control samples. 
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Figure 2.4 Proportions of CD4+ helper T cells in peripheral blood of PAH 
patients and controls. 
A) CD4+ T cells in all PAH patients. B) CD4+ T cells in healthy controls and IPAH 
patients. C) CD4+ T cells in Scleroderma controls (SSc-no PAH) and SSc-PAH 
patients. Data are shown as a percentage of total CD3+ T cells. Data analysed by a 
Kruskal Wallis Test with Dunn’s post hoc test or by a two tailed Mann Whitney test. 
A 95% confidence interval was used where P< 0.05 is considered significant (*). All 
Box and whisker plots depict median with minimum to maximum values in each 
study group. IPAH patients n=15, SSc-PAH patients n=12, healthy controls n=15, 
SSc no-PAH controls n=8. 
 
2.3.2.2  CD8
+
 T cell subset 
 
Analysis of the proportion of CD8+ T cells showed a trend for a lower 
T cell population in the PAH patient population (Figure 2.5, A). To determine 
if this was common across both groups or specific to IPAH or SSc-PAH the 
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data were further broken down into these groups only and compared with 
corresponding controls (Figure 2.5, B and C). In IPAH patients, there was no 
difference in proportions of CD8+ T cells, when compared to healthy controls 
(Figure 2.5, B). However, the proportion of CD8+ T cells in SSc-PAH patients 
was significantly lower than in SSc-no PAH controls (18.10 ± 8.14% vs 30.40 
± 9.14%, n=7-12, P=0.009) (Figure 2.5 C).   
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Figure 2.5 Proportions of CD8+ cytotoxic T cells in peripheral blood of PAH 
patients and controls. 
A) CD8+ T cells in all PAH patients. B) CD8+ T cells in healthy controls and IPAH 
patients. C) CD8+ T cells in scleroderma controls (SSc-no PAH) and SSc-PAH 
patients. Data are shown as a percentage of total CD3+ T cells. Data analysed by a 
Kruskal Wallis Test with Dunn’s post hoc test or by a two tailed Mann Whitney test. 
A 95% confidence interval was used where P< 0.05 (*) and P<0.001 (**) are 
considered significant.  All Box and whisker plots depict median with minimum to 
maximum values in each study group. IPAH patients n=15, SSc-PAH patients n=12, 
healthy controls n=15, SSc no-PAH controls n=7. 
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2.3.2.3  CD4:CD8 T cell ratio 
 
There was no difference in the CD4:CD8 T cell ratio when all PAH 
patients were compared to both control groups (Figure 2.6, A). However, due 
to the decrease in the proportion of CD8+ T cells, there was a corresponding 
significantly higher CD4:CD8 ratio in SSc-PAH patients compared to SSc-no 
PAH controls (3.52 ± 2.28 vs 1.90 ± 1.46, n=7-11, P=0.018) (Figure 2.6, C). 
There was no difference in the CD4:CD8 T cell ratio in IPAH patients when 
compared to healthy controls noted in this study (Figure 2.6, B). 
 
Figure 2.6 CD4:CD8 T cell ratio in peripheral blood of PAH patients and 
controls. 
A) CD4:CD8 ratio in all PAH patients. B) CD4:CD8 ratio in healthy controls and 
IPAH patients. C) CD4:CD8 ratio in scleroderma controls and SSc-PAH patients. 
Data analysed by a Kruskal Wallis Test with Dunn’s post hoc test or by a two tailed 
Mann Whitney test. A 95% confidence interval was used where P< 0.05 is 
considered significant (*). All Box and whisker plots depict median with minimum to 
maximum values in each study group. IPAH patients n=13, SSc-PAH patients n=11, 
healthy controls n=15, SSc no-PAH controls n=7. 
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2.3.3 Activation status of T cell subsets in 
patient and control peripheral blood 
samples  
 
I next sought to determine if there were any changes in lymphocyte 
activation by examining the expression of CD69, an early activation marker of 
lymphocytes.  
 
2.3.3.1  Activation status of CD3
+
 T cells 
 
The proportion of activated (CD69+) CD3+ T cells was not significantly 
different across both control groups and both patient groups (Figure 2.7, A). 
This was also the case when IPAH patients were compared to healthy 
controls, and SSc-PAH patients were compared to SSc-no PAH controls 
(Figure 2.7, B and C). There was a greater degree of variation in the 
proportion of activated CD3+ T cells between patients within both the IPAH 
subgroup (0.004% to 2.5%) and SSc-PAH group (0% to 4.97%), which may 
have masked changes in these patient subsets. Previous studies have not 
identified the activation status of circulating T cells within SSc-PAH and IPAH 
patients, therefore further studies need to be undertaken to give a greater 
degree of confidence in this work.  
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Figure 2.7 Proportions of activated CD3+ T cells in peripheral blood of PAH 
patients and controls. 
A) CD3+CD69+ T cells in all PAH patients. B) CD3+CD69+ T cells in IPAH patients 
and healthy controls. C) CD3+CD69+ T cells in SSc-no PAH and SSc-PAH patients. 
All data presented as a proportion of total CD3+ T cell population. Data analysed by 
a Kruskal Wallis Test with Dunn’s post hoc test or by a two tailed Mann Whitney 
test. A 95% confidence interval was used where P< 0.05 is considered significant 
(*). All Box and whisker plots depict median with minimum to maximum values in 
each study group. IPAH patients n=15, SSc-PAH patients n=13, healthy controls 
n=14, SSc no-PAH controls n=7. 
 
2.3.3.2  Activation status of CD4
+
 T cells 
 
 In all PAH patients there was no difference in the proportion of 
activated CD4+ T cells in comparison to healthy controls or SSc-no PAH 
patient controls (Figure 2.8, A). To confirm that one patient group was not 
masking a change in another group, these data were further split into IPAH 
and SSc-PAH patient groups and compared to corresponding controls. Again, 
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there was no difference in the proportion of activated CD4+ T cells between 
IPAH patients and healthy controls, or between SSc-PAH patients and SSc-no 
PAH controls (Figure 2.8, B and C).  
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Figure 2.8 Proportions of activated CD4+ T cells in peripheral blood of PAH 
patients and controls. 
A) CD4+CD69+ T cells in all PAH patients. B) CD4+CD69+ T cells in IPAH patients 
and healthy controls. C) CD4+CD69+ T cells in SSc-no PAH and SSc-PAH patients. 
All data presented as a proportion of the total CD4+ T cell population. Data analysed 
by a Kruskal Wallis Test with Dunn’s post hoc test or by a two tailed Mann Whitney 
test. A 95% confidence interval was used where P< 0.05 is considered significant 
(*). All Box and whisker plots depict median with minimum to maximum values in 
each study group. IPAH patients n=15, SSc-PAH patients n=12, healthy controls 
n=15, SSc no-PAH controls n=7. 
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2.3.3.3  Activation status of CD8
+
 T cells 
 
There was no difference in the proportion of activated CD8+ T cells in 
PAH patients compared to controls (Figure 2.9, A) or after considering IPAH 
(Figure 2.9, B) and SSc-PAH groups separately (Figure 2.9, C). 
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Figure 2.9 Proportions of activated CD8+ T cells in peripheral blood of PAH 
patients and controls. 
A) CD8+CD69+ T cells in all PAH patients. B) CD8+CD69+ T cells in IPAH patients 
and healthy controls. C) CD8+CD69+ T cells in SSc-no PAH and SSc-PAH patients. 
Data are shown as a percentage of total CD8+ T cells. Data analysed by a Kruskal 
Wallis Test with Dunn’s post hoc test or by a two tailed Mann Whitney test. A 95% 
confidence interval was used where P< 0.05 is considered significant (*). All Box 
and whisker plots depict median with minimum to maximum values in each study 
group. IPAH patients n=13, SSc-PAH patients n=12, healthy controls n=15, SSc no-
PAH controls n=7. 
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2.3.4 T regulatory cells and their activation 
status in patient and control peripheral 
blood samples  
 
 Another T cell subset thought to be crucial in the resolution of an 
immune response is the Treg cell (Fehervari and Sakaguchi, 2004). 
Therefore, proportions and activation status of this cell type were analysed 
within patient and control groups. For this study, Treg cells were 
characterised based upon the expression of cell surface markers (CD3, CD4, 
CD25, and CD127) and intracellular expression of Foxp3. CD25 is the α-
chain of the IL-2 receptor and CD127 is the α-chain of the IL-7 receptor. 
CD4+CD25+CD127low/- Treg cells express Foxp3, with CD127 expression on 
Treg cells being inversely proportional to Foxp3 expression, therefore a 
combination of these markers was used (Liu et al, 2006; Shen et al, 2009).   
Data shown are CD4+CD25high and CD4+CD25highCD127low, as Foxp3 
event counts were too low. Therefore the analysis using the combination of 
CD25, CD127 and Foxp3 are not shown here (CD4+CD25high Foxp3+ and 
CD4+CD25highCD127low Foxp3+). From this point forward in this thesis only 
two combinations of markers will be used to define a Treg cell (CD4+CD25high 
and CD4+CD25highCD127low). 
When defined as CD4+CD25high, proportions of Treg cells in all PAH 
patients were no different in comparison to controls (Figure 2.10, A). When 
broken down into separate patient groups, this observation was also noted in 
IPAH patients, with no change in proportions of CD4+CD25high Treg cells 
compared to healthy controls and in SSc-PAH patients compared to SSc-no 
PAH controls (Figure 2.10, B and C).  
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Figure 2.10 Proportions of CD4+CD25high Treg cells in peripheral blood of PAH 
patients and controls. 
A) CD4+CD25high Treg cells in all PAH patients. B) CD4+CD25high Treg cells in 
healthy controls and IPAH patients. C) CD4+CD25high Treg cells in scleroderma 
controls (SSc-no PAH) and SSc-PAH patients. Data are shown as a percentage of 
total CD3+ T cells. Data analysed by a Kruskal Wallis Test with Dunn’s post hoc test 
or by a two tailed Mann Whitney test. A 95% confidence interval was used where 
P< 0.05 is considered significant (*). All Box and whisker plots depict median with 
minimum to maximum values in each study group. IPAH patients n=15, SSc-PAH 
patients n=12, healthy controls n=13, SSc no-PAH controls n=7. 
 
When defined as CD4+CD25highCD127low, proportions of Treg cells are 
not different between all PAH patients and controls (Figure 2.11, A). This is 
also true when IPAH patients are compared to healthy controls (Figure 2.11, 
B) and SSc-no PAH are compared to SSc-PAH patients (Figure 2.11, C). 
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Figure 2.11 Proportions of CD4+CD25highCD127low Treg cells in peripheral 
blood of PAH patients and controls. 
A) CD4+CD25highCD127low Treg cells in all PAH patients. B) CD4+CD25highCD127low 
Treg cells in healthy controls and IPAH patients. C) CD4+CD25highCD127low Treg 
cells in scleroderma controls and SSc-PAH patients. Data are shown as a 
percentage of total CD3+ T cells. Data analysed by a Kruskal Wallis Test with 
Dunn’s post hoc test or by a two tailed Mann Whitney test. A 95% confidence 
interval was used where P< 0.05 is considered significant (*). All Box and whisker 
plots depict median with minimum to maximum values in each study group. IPAH 
patients n=15, SSc-PAH patients n=10, healthy controls n=13, SSc no-PAH controls 
n=8. 
  
 As there was no difference in the proportion of Treg cells in either 
patient group, I next looked to determine whether there was any change in 
the activation status of Treg cells. Using CD4+CD25high as the first 
combination to describe Treg cells, there appears to be no change in the 
proportion of activated CD4+CD25high cells in PAH patients compared to 
controls (Figure 2.12, A). There was still no difference between patient and 
control groups when they were compared separately to their corresponding 
controls (Figure 2.12, B and C), however there was a greater spread of data 
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in the SSc-PAH patient group compared to SSc-no PAH controls (Figure 
2.12, C).  
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Figure 2.12 Proportions of activated CD4+CD25high Treg cells in peripheral 
blood of PAH patients and controls. 
A) Activated CD4+CD25high Treg cells in all PAH patients (CD69+). B) Activated 
CD4+CD25high Treg cells in healthy controls and IPAH patients. C) Activated 
CD4+CD25high Treg cells in scleroderma controls (SSc-no PAH) and SSc-PAH 
patients. Data are shown as a percentage of total Treg cell population 
(CD4+CD25high). Data analysed by a Kruskal Wallis Test with Dunn’s post hoc test or 
by a two tailed Mann Whitney test. A 95% confidence interval was used where P< 
0.05 is considered significant (*). All Box and whisker plots depict median with 
minimum to maximum values in each study group. IPAH patients n=12, SSc-PAH 
patients n=10, healthy controls n=13, SSc no-PAH controls n=5. 
 
 When Treg cells were defined as CD4+CD25highCD127low, there was 
no difference in the activation of CD4+CD25highCD127low Treg cells between 
patient and controls (Figure 2.13, A). The patient groups were also split into 
IPAH and SSc-PAH patients to compare with corresponding patient controls. 
This analysis revealed that in IPAH and SSc-PAH patients, there was no 
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change in activation of CD4+CD25highCD127low Treg cells between the patient 
groups compared to their corresponding controls (Figure 2.13, B and C).  
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Figure 2.13 Proportions of activated CD4+CD25highCD127low Treg cells in 
peripheral blood of PAH patients and controls. 
A) Activated CD4+CD25highCD127low Treg cells in all PAH patients. B) Activated 
CD4+CD25highCD127low Treg cells in healthy controls and IPAH patients. C) 
Activated CD4+CD25highCD127low Treg cells in scleroderma controls and SSc-PAH 
patients. Data are shown as a percentage of total Treg cell population 
(CD4+CD25highCD127low). Data analysed by a Kruskal Wallis Test with Dunn’s post 
hoc test or by a two tailed Mann Whitney test. A 95% confidence interval was used 
where P< 0.05 is considered significant (*). All Box and whisker plots depict median 
with minimum to maximum values in each study group. IPAH patients n=10, SSc-
PAH patients n=7, healthy controls n=12, SSc no-PAH controls n=5. 
 
2.3.5 B cells and their activation status in 
patient and control peripheral blood 
samples  
 
Another major lymphocyte subset was B cells, which are involved in 
producing antibodies within the humoral immune response. To gain a greater 
understanding of abnormalities in immune cell subsets within PAH patients, 
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the proportion of B cells and their activation status were considered next. 
The proportion of B cells (CD19+) as a percentage of total CD45+ leukocytes 
was measured in each patient and control sample, along with the activation 
status, as shown by expression of CD69.  
There was no difference in the proportions of B cells (CD45+CD19+) 
between patient and control groups (Figure 2.14, A). There was also no 
difference in either IPAH patients (Figure 2.14, B) or SSc-PAH patients 
(Figure 2.14, C) when compared to corresponding controls. There was, 
however, a trend for a higher proportion of B cells in SSc-no PAH patients 
compared to healthy controls (9.95 ± 3.06 vs 6.40 ± 2.43, n=4-10, P=0.07) 
(Figure 2.14, A).  
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Figure 2.14  Proportion of B cells in peripheral blood of PAH patients and 
controls. 
A) Proportion of B cells (CD19+) in all PAH patients. B) Proportion of B cells in IPAH 
patients. C) Proportion of B cells in SSc-PAH patients. Data expressed as a 
proportion of CD45+ cells. Data analysed by a Kruskal Wallis Test with Dunn’s post 
hoc test or by a two tailed Mann Whitney test. A 95% confidence interval was used 
where P< 0.05 is considered significant (*). All Box and whisker plots depict median 
with minimum to maximum values in each study group. IPAH patients n=11, SSc-
PAH patients n=9, healthy controls n=10, SSc no-PAH controls n=4. 
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CD69 expression was used to investigate changes in the activation 
status of B cells within patient and control samples. The proportion of 
activated B cells was similar in control groups and all PAH patients (Figure 
2.15, A). There was also no change in the proportion of B cells when all PAH 
patients were split into IPAH patients and SSc-PAH groups and compared to 
their corresponding controls (Figure 2.15, B and C). There was a large range 
of activated B cells in all SSc-PAH patients and healthy volunteers, as shown 
by the large minimum and maximum data bars. Further work to increase the 
sample population of these cohorts would allow for more accurate 
conclusions to be drawn about the changes in activation status of B cells 
within these subsets. 
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Figure 2.15  Proportions of activated B cells in peripheral blood of PAH 
patients and controls. 
A) Proportion of activated B cells (CD19+CD69+) in all PAH patients. B) Proportion 
of activated B cells in IPAH patients. C) Proportion of activated B cells in SSc-PAH 
patients. Activation status of B cells expressed as a CD69+ cells as a proportion of 
CD45+CD19+ cells. Data analysed by a Kruskal Wallis Test with Dunn’s post hoc 
test or by a two tailed Mann Whitney test. A 95% confidence interval was used 
where P< 0.05 is considered significant (*). All Box and whisker plots depict median 
with minimum to maximum values in each study group. IPAH patients n=10, SSc-
PAH patients n=9, healthy controls n=10, SSc no-PAH controls n=4. 
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2.3.6 Correlations between clinical data and 
T cell subsets 
  
 After initial analysis of proportional CD4+ T cell data in patients and 
controls, it was evident that although there was no overall change in the 
mean of each data set, there was an increase in the spread of data in the 
patient groups compared to their corresponding controls (Figure 2.16).  
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Figure 2.16 Scatter plot showing spread of CD4+ T cell data in PAH patients 
and controls.  
IPAH and SSc-PAH patient groups are shown along with SSc-no PAH and healthy 
control gourps. Data are shown as a percentage of total CD3+ T cells. Error bars 
depict mean ± SEM. n=8-15 per patient group. 
 
Therefore to determine whether or not this change in the range of data 
within the CD4+ T cell subset correlated with disease severity I compared 
clinical data from both SSc-PAH and IPAH patients against the proportion of 
CD4+ T cells in each patient blood sample. A correlation of the proportion of 
CD8+ T cells and CD4+CD25high Treg cells and clinical parameters was also 
made. Clinical phenotyping was undertaken at visit 1 before PAH specific 
treatment was administered.  An R and P value were calculated for each pair 
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of data using a two tailed, non-parametric (Spearman) correlation test with a 
95% confidence level. Pairs of data that had a P value < 0.05 were 
considered significant. 
There is a significant negative correlation between CD4+ T cells and 
the shuttle walk test (R=-0.54 and P=0.04) in IPAH patients, however no 
significant correlations were noted between CD8+ T cells, CD4+CD25high Treg 
cells and other clinical parameters (Table 2.3). I also noted a significant 
negative correlation between CD4+ T cells and cardiac index (CI) (R=-0.7 
and P=0.03) in SSc-PAH patients, however no significant correlations were 
seen between CD8+ T cells, CD4+ CD25high Treg cells and other clinical 
parameters (Table 2.4). These data suggest that proportions of CD4+ T cells  
are inversely proportional to clinical markers of disease progression such as 
CI and shuttle walk test in PAH patients and could be used in the future in 
diagnosis or prognosis in PAH patients.  
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Comparison R value P value 
eGFR 
vs CD4
+
 T cells 0.14 0.80 
vs CD8
+
 T cells 0.63 0.42 
vs CD4
+
CD25
high
 Treg cells 0.64 0.18 
CRP 
vs CD4
+
 T cells 0.14 0.64 
vs CD8
+
 T cells 0.06 0.86 
vs CD4
+
CD25
high
 Treg cells -0.03 0.93 
FEV1 
vs CD4
+
 T cells 0.00 0.99 
vs CD8
+
 T cells 0.22 0.50 
vs CD4
+
CD25
high
 Treg cells -0.02 -0.95 
FEV1/FVC ratio 
vs CD4
+
 T cells -0.14 0.64 
vs CD8
+
 T cells 0.26 0.42 
vs CD4
+
CD25
high
 Treg cells -0.47 0.09 
Shuttle 
vs CD4
+
 T cells -0.54 0.04 
vs CD8
+
 T cells 0.30 0.32 
vs CD4
+
CD25
high
 Treg cells 0.06 0.83 
HR 
vs CD4
+
 T cells 0.15 0.59 
vs CD8
+
 T cells -0.22 0.47 
vs CD4
+
CD25
high
 Treg cells -0.22 0.44 
mPAP      
vs CD4
+
 T cells 0.05 0.85 
vs CD8
+
 T cells -0.31 0.30 
vs CD4
+
CD25
high
 Treg cells -0.06 0.84 
CO  
vs CD4
+
 T cells 0.28 0.32 
vs CD8
+
 T cells -0.48 0.10 
vs CD4
+
CD25
high
 Treg cells 0.25 0.37 
PVR 
vs CD4
+
 T cells -0.26 0.34 
vs CD8
+
 T cells 0.30 0.32 
vs CD4
+
CD25
high
 Treg cells -0.23 0.42 
CI 
vs CD4
+
 T cells 0.03 0.92 
vs CD8
+
 T cells -0.28 0.35 
vs CD4
+
CD25
high
 Treg cells 0.26 0.34 
Table 2.3 Correlation data between CD4+ T cells, CD8+ T cells, CD4+CD25high 
Treg cells and clinical parameters in IPAH patients. 
R and P values are shown. Estimated glomerular filtration rate (eGFR), C reactive 
protein (CRP), Forced expiratory volume in one second (FEV1), forced vital capacity 
(FVC), shuttle walk test (shuttle), heart rate, (HR), mean pulmonary artery pressure 
(mPAP), cardiac output (CO), pulmonary vascular resistance (PVR) and cardiac 
index (CI) are shown. n=15 and significant data shown in bold (P< 0.05).   
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Comparison R value P value 
eGFR 
vs CD4
+
 T cells -0.10 0.95 
vs CD8
+
 T cells 0.30 0.63 
vs CD4
+
CD25
high
 Treg cells -0.40 0.52 
CRP 
vs CD4
+
 T cells -0.37 0.50 
vs CD8
+
 T cells 0.66 0.18 
vs CD4
+
CD25
high
 Treg cells -0.31 0.56 
FEV1 
vs CD4
+
 T cells 0.03 1.00 
vs CD8
+
 T cells -0.01 0.96 
vs CD4
+
CD25
high
 Treg cells 0.00 1.00 
FEV1/FVC 
ratio 
vs CD4
+
 T cells 0.15 0.80 
vs CD8
+
 T cells 0.13 0.78 
vs CD4
+
CD25
high
 Treg cells -0.23 0.65 
Shuttle 
vs CD4
+
 T cells 0.43 0.25 
vs CD8
+
 T cells -0.62 0.09 
vs CD4
+
CD25
high
 Treg cells 0.30 0.44 
HR 
vs CD4
+
 T cells -0.03 0.95 
vs CD8
+
 T cells -0.28 0.46 
vs CD4
+
CD25
high
 Treg cells -0.02 0.98 
mPAP      
vs CD4
+
 T cells 0.10 0.79 
vs CD8
+
 T cells 0.22 0.54 
vs CD4
+
CD25
high
 Treg cells -0.35 0.31 
CO  
vs CD4
+
 T cells -0.35 0.33 
vs CD8
+
 T cells -0.32 0.37 
vs CD4
+
CD25
high
 Treg cells 0.50 0.14 
PVR 
vs CD4
+
 T cells 0.22 0.54 
vs CD8
+
 T cells 0.20 0.58 
vs CD4
+
CD25
high
 Treg cells -0.55 0.10 
CI 
vs CD4
+
 T cells -0.70 0.03 
vs CD8
+
 T cells -0.04 0.92 
vs CD4
+
CD25
high
 Treg cells 0.21 0.44 
Table 2.4 Correlation data between CD4+ T cells, CD8+ T cells, CD4+CD25high 
Treg cells and clinical parameters in SSc-PAH patients. 
R and P values are shown. Estimated glomerular filtration rate (eGFR), C reactive 
protein (CRP), Forced expiratory volume in one second (FEV1), forced vital capacity 
(FVC), shuttle walk test (shuttle), heart rate, (HR), mean pulmonary artery pressure 
(mPAP), cardiac output (CO), pulmonary vascular resistance (PVR) and cardiac 
index (CI) are shown. n=12 and significant data shown in bold (P< 0.05).  
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2.3.7 Patient survival analysis  
  
As proportions of CD4+ T cells were shown to be inversely 
proportional to clinical markers of disease progression, I next sought to 
determine whether proportions of T cell subsets could be used to predict 
survival in PAH patients.  
Receiver-operating characteristics curves (ROC) and Kaplan-Meier 
survival analyses were performed using proportions of CD4+ T cells, CD8+ T 
cells or CD4+CD25high Treg cells. Firstly, ROC curves were constructed for 
IPAH, SSc-PAH, SSc-no PAH patients and healthy controls using 
proportional data on CD4+, CD8+ and Treg cell subsets.  
GraphPad Prism software was used to undertake ROC curve 
analyses in which proportions of each T cell subset from each patient 
subgroup (IPAH and SSc-PAH) were compared against their corresponding 
controls. A confidence interval of 95% was used and the results reported as 
a percentage. A combination of percentage sensitivity and percentage 
specificity that gave the highest likelihood ratio (the most confidence that a 
negative result is a true negative and that a positive result is a true positive) 
was selected. After performing a ROC analysis, a value of 83.33% sensitivity 
and 85.71% specificity for SSc-PAH patients and controls was chosen with a 
cut-off value of 22% for CD8+ T cells (P= 0.008) (Figure 2.17). I had intended 
to use these results to perform a Kaplan-Meier survival analysis; however 
there were insufficient clinical events in the SSc-PAH patient group to 
undertake this analysis. 
The analysis of CD4+ T cells and CD4+CD25high Treg cells in SSc-
PAH and all T cell subsets and IPAH patients revealed no significant 
differences. 
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Figure 2.17 Receiver operating characteristic curve to define optimum cut-off 
value for changes in the proportion of CD8+ T cells in the prediction of PAH. 
 Data shown are for SSc-PAH patients. 
 
2.3.8  Lymphocyte subset analysis in 
patients undergoing PAH treatment  
 
At the SPVDU patients return for follow-up visits after commencing a 
PAH specific therapy to be assessed for disease progression and the 
efficacy of the treatment plan. As these samples were available, I next 
sought to determine whether there was any change in the lymphocyte 
subsets previously discussed after commencing PAH specific treatment and 
whether they related to a marker of disease progression, the shuttle walk 
test, and the cut-off value from the ROC curve previously mentioned.  
 Of the 29 confirmed PAH patients from whom I had collected data 
regarding lymphocyte subsets (15 IPAH and 13 SSc-PAH), further data were 
collected from 5 of these patients (4 IPAH and 1 SSc-PAH) at follow-up over 
a period of 3 years. Data could not be collected from all patients for several 
reasons, including a lack of consent, death or due to the recent recruitment 
of the patient, as follow-up visits occurred on average every 6 months. 
Patients were diagnosed at visit 1 after which they were started on a 
course of PAH treatment applicable to their disease state and progression. 
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Blood samples were collected from these patients at subsequent follow-up 
visits and data compared to previous treatment-naïve data collected at visit 
1. Table 2.5 depicts PAH specific drug, time between visits and shuttle walk 
test results for all visit 1s and follow-ups (IPAH and SSc-PAH patients). 
Of the 5 follow-up patients recruited two were taking Bosentan or 
Ambrisentan (both E-RAs) throughout the duration of their treatment whilst 
two were taking Sildenafil (PDE-5 inhibitor). One patient was prescribed both 
Bosentan and Sildenafil. Of the 5 patients, 3 increased their shuttle walk test 
scores, 1 did not change from visit 1 to follow-up and the other had a 
decreased shuttle walk test score. 
 
Patient 
ID and 
PAH 
subtype  
Treatment 
At visit 1 
Treatment 
At follow-up 
visit 
Shuttle 
walk test 
at visit 1 
(m) 
Shuttle walk 
test (m) at 
follow-up 
visit (m) 
Time 
between 
visits 
(months) 
Δ shuttle 
walk test 
(m) 
276, 
SSc-PAH 
Bosentan Bosentan 80 180 10 +100 # 
90, 
IPAH 
Bosentan Ambrisentan 130 210 23 +80 # 
353, 
IPAH 
Bosentan 
Sildenafil 
Bosentan 
Sildenafil 
420 260 5 -160 
380. 
IPAH 
Sildenafil Sildenafil 30 30 8 0 
442, 
IPAH 
Sildenafil Sildenafil 360 370 7 +10 
 
Table 2.5 PAH specific drug therapy and shuttle walk test scores for all 
follow-up visits (IPAH and SSc-PAH patients). 
Patients 276, 90, 353, 380 and 442 were recruited upon return to the clinic for blood 
cell analysis using flow cytometry. The PAH-specific treatment taking at each visit 
and the time between visits (months) is shown. Shuttle walk test results at both visit 
1 and follow-up (metres) and the change between these (Δ shuttle walk test) in 
metres is also shown. A change in walking distance of more than 50 m is clinically 
significant (#) (Rasekaba et al, 2009). Ambrisentan and bosentan are both E-RAs 
whist sildenafil is a PDE-5 inhibitor. 
 
Analysis of how different treatment regimes affected T cell subsets at 
return visits was assessed by grouping patients according to which PAH-
specific drug treatment they were taking at visit 1, and not the disease 
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subtype (IPAH or SSc-PAH). As the sample population of each treatment 
group was so small, it is difficult to draw definitive conclusions from the data, 
however the data were still analysed.  
Proportions of CD4+ T cells did not appear to follow any trend in 
patients taking E-RAs (Figure 2.18, A). If these data are further divided into 
patient subtypes, the SSc-PAH patient taking an E-RA showed a decrease in 
the proportion of circulating CD4+ T cells at follow-up. The two patients taking 
PDE-5 inhibitors showed a decrease in their proportions of CD4+ T cells at 
follow-up (Figure 2.18, B). Patient 353, the only patient on both an E-RA and 
a PDE-5 inhibitor showed a trend for an increase in CD4+ T cells from visit 1 
to follow-up (plotted on both graphs, Figure 2.18, A and B).  
Interestingly, both patients only taking E-RAs had a significant 
improvement in their shuttle walk test results, whereas the proportion of 
circulating CD4+ T cells appeared to be returning to those that were present 
in healthy controls (62.20% as a proportion of total CD3+ T cells). Patients 
given PDE-5 inhibitors exhibited no improvement in their shuttle walk test 
scores. The patient given both drugs (patient 535) had a decreased shuttle 
walk test result at follow-up visit, but had an improved CD4+ T cell 
compartment.  
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Figure 2.18 Proportions of CD4+ T cells in PAH patients at follow-up. 
A) CD4+ T cells as a proportion of total CD3+ T cells in patients taking endothelin-1 
receptor antagonists B) CD4+ T cells as a proportion of total CD3+ T cells in patients 
taking PDE-5 inhibitors. Patient 353, taking an endothelin-1 receptor antagonist and 
a PDE-5 inhibitor, is shown on both treatment graphs. Data shown are from visits 1 
and follow-up. n=3.  
Proportions of CD8+ T cells in patients taking E-RAs showed a 
communal increase in the proportion of CD8+ T cells in response to these 
drugs in both IPAH and SSc-PAH patients (276, 90, 353) (Figure 2.19, A). 
Patient 276 (SSc-PAH) remained within the cut off value determined from the 
ROC curve in Chapter 2.3.7 (22%), despite a significant increase in the 
distance walked in the shuttle walk test (+100 m). An increase in distance 
walked was also noted in patient 90 at the follow-up visit as well as an 
increase in the proportion of CD8+ T cells in the blood. Patients taking PDE-5 
inhibitors exhibited a decrease in the proportion of CD8+ T cells at follow-up, 
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with one IPAH patient (442) showing a decreased proportion of CD8+ T cells 
below the 22% cut off value determined from the ROC curve (determined 
using data from SSc-PAH patients) (Figure 2.19, B). Patient 353, taking both 
medications showed an increase in the proportion of circulating CD8+ T cells 
in response to both medications, however their shuttle walk test score 
decreased significantly between visits (Figure 2.19, A and B).  
Taking these two sets of data together to create CD4:CD8 T cell ratio 
figures, there appears to be no communal trend in patients taking E-RAs, 
however, patient 276 had an improved shuttle walk test result at follow-up, 
matched by a reduced CD4:CD8 T cell ratio towards a healthy level (1.9). It 
would be interesting to note whether the walk distance continues to increase 
with further E-RA treatment at a future follow-up visit. Patients 442 and 353 
that were given PDE-5 inhibitors showed no change in the CD4:CD8 T cell 
ratio, however patient 380 showed an increased CD4:CD8 T cell ratio (Figure 
2.20 A and B). There were mixed changes in shuttle walk test results at 
follow-up visits within this treatment group.  
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Figure 2.19 Proportions of CD8+ T cells in PAH patients at follow-up. 
A) CD8+ T cells as a proportion of total CD3+ T cells in patients taking endothelin-1 
receptor antagonists B) 8+ T cells as a proportion of total CD3+ T cells in patients 
taking PDE-5 inhibitors. Patient 353, taking an endothelin-1 receptor antagonist and 
a PDE-5 inhibitor, is shown on both treatment graphs. Data shown are from visits 1, 
2 and 3. n=3.  
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Figure 2.20 CD4:CD8 ratio in PAH patients at follow-up.  
A) CD4+ T cells as a proportion of total CD3+ T cells in patients taking endothelin-1 
receptor antagonists B) CD4+ T cells as a proportion of total CD3+ T cells in patients 
taking PDE-5 inhibitors. Patient 353, taking an endothelin-1 receptor antagonist and 
a PDE-5 inhibitor, is shown on both treatment graphs. Data shown are from visits 1 
and follow-up. n=3.  
 
 A subgroup of T cells important in the resolution of immune response 
are Treg cells. These cells were defined here as CD4+CD25high, as 
differences in proportional data noted previously in section 2.3.4, 
demonstrated no change in results if either combination of markers is used to 
define them. In patients taking E-RAs, there was a decrease in proportions of 
Treg cells in all patients, whilst patients taking PDE-5 inhibitors exhibited no 
communal group change (one increased and the other decreased, Figure 
2.21, A and B). PDE-5 inhibitors had a mixed effect on proportions of Treg 
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cells in patient 442 and 380, with patient 442 showing no significant change 
in the proportions of Treg cells and patient 380 showing an increase in the 
proportions of Treg cells. However, the two patients with no change or a 
decrease in their shuttle walk test result at follow-up visit showed an increase 
in the proportion of circulating Treg cells, compared to patient 442 who had a 
modest increase in their shuttle walk test result (+10 m) and had no change 
in the proportion of circulating Treg cells (Figure 2.21, B). Patient 353, taking 
both medications showed an increase in the proportion of circulating 
CD4+CD25high Treg cells in response to both medications, closely resembling 
the response noted in patient 380 (Figure 2.21, A and B). 
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Figure 2.21 Proportions of CD4+CD25high Treg in PAH patients at follow-up.  
A) CD4+ T cells as a proportion of total CD3+ T cells in patients taking endothelin-1 
receptor antagonists B) CD4+ T cells as a proportion of total CD3+ T cells in patients 
taking PDE-5 inhibitors. Patient 353, taking an endothelin-1 receptor antagonist and 
a PDE-5 inhibitor, is shown on both treatment graphs. Data shown are from visits 1 
and follow-up. n=3.  
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As previously noted, the small number of patients recruited at follow-
up visits, makes it difficult to draw definitive conclusions from this preliminary 
data and further work needs to be undertaken to gain a greater 
understanding of the effect of different PAH treatment options on proportions 
of lymphocyte subsets, however these data may prove to be highly 
interesting. 
 
2.4  Discussion 
 
The main aim of the work presented in this chapter was to determine 
the phenotypic profile of T cell populations in peripheral blood of treatment-
naïve IPAH and SSc-PAH patients. Data regarding correlations between 
clinical parameters and T cell subsets were also collected and comparisons 
made between T cell subsets, treatment plans and changes in shuttle walk 
test compared at follow-up visits in patients that had begun PAH specific 
treatment. Treg cell functional assays were also undertaken in healthy 
volunteers with a view to determining abnormal functional responses of Treg 
cells in PAH patients at a later date. 
 
2.4 1  Clinical peripheral lymphocyte subset 
analysis 
 
Clinical studies performed to evaluate abnormalities in T cell subsets 
in PAH patients are limited and report conflicting results regarding the 
proportions of some subsets of T cell, therefore further work has been  
undertaken to determine definitive trends (Soon, 2008; Ulrich et al, 2008; 
Austin et al, 2010). Previous studies all had one major limitation in that 
consenting patients had already been diagnosed with PAH and had 
commenced PAH specific treatments, which could have affected proportions 
of T cell subsets within the peripheral circulation.  Therefore, it was important 
to establish a view of T cell subset abnormalities at baseline, in treatment-
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naïve PAH patients. My study is believed to be the first published analysis of 
T cell subsets in peripheral blood of treatment-naïve IPAH and SSc-PAH 
patients.  
Data published in this thesis suggest that treatment-naïve SSc-PAH 
patients have a significantly smaller proportion of CD8+ T cells than SSc-no 
PAH controls. One explanation as to why CD8+ T cell proportions are 
decreased in SSc-PAH patients (and noted in IPAH in previously published 
literature, but not in my results), could be that the Treg cell population could 
be acting as an “IL-2 sink” (previously described in Chapter 1.2.1). This 
reduction in pro-inflammatory cytokine could have a negative impact on Th1 
(CD8+ T cell) proliferation (McNally et al, 2011). Increased IL-6 serum levels 
have been noted in PAH patients, however the source of IL-6 increase is 
unclear. Dodge et al recently confirmed that IL-6 from DCs can inhibit Th1 
responses in the mucosal lung environment (Dodge et al, 2003). A similar 
response may be occurring in the pulmonary circulation in PAH, however 
further studies need to be undertaken to define the source of the increase in 
serum IL-6. It is also important to note that in previous studies in SSc-no 
PAH patients, proportions of CD8+ T cells were reduced in peripheral blood 
and showed an increased apoptotic phenotype (Kessel et al, 2004). 
Daley et al have suggested that PAH is a Th2 mediated disease 
(CD4+ T cells are the prominent cell type), as the deletion of CD4+ T cells 
from mice stimulated with aspergillus antigen challenge or depletion of IL-13 
prevented pulmonary arterial muscularisation (Daley et al, 2008). This is in 
contrast to Song et al, who propose that in BMPR2+/− mice treated with MCT 
and adenovirus expressing 5-lipoxygenase, showed an increased expression 
of MCP-1-α in lung tissue which could be driving a Th1 driven immune 
response (Song et al, 2008). The marked difference in T cell subset 
dominance (Th1 or Th2 driven) in both these models of PAH suggests that 
different initiating factors used to induce PAH produce different effects on T 
cell subsets. A Th2 dominant phenotype has previously been noted in SSc-
no PAH patients, further emphasising the importance of this subgroup of T 
cells in SSc-PAH patients (Boin et al, 2008).  
A decrease in CD8+ T cells has previously been noted in IPAH 
patients compared to healthy controls, however another study refutes this 
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finding and concurs with work undertaken in this thesis; confirming no 
change in CD8+ T cell populations in IPAH patients (Ulrich et al, 2008; Austin 
et al, 2010). One explanation for this disparity in findings could be that 
patients recruited onto these studies were undergoing treatment for PAH. 
Prostanoids are shown to inhibit T cell proliferation, while PDE-5 inhibitors 
have been shown to increase proliferation and activation of tumour infiltrating 
CD8+ T cells further demonstrating the mixed effects that PAH specific 
treatments have on T cell populations (Lee et al, 2005; Serafini et al, 2006). 
SSc-PAH patients recruited in this study were on average slightly older and 
with a wider age range compared to the IPAH patients studied by Austin et 
al, where no change in CD8+ T cell numbers in IPAH patient peripheral blood 
was noted. There have been published reports suggesting that T cell subsets 
(CD4+, CD8+ and Treg cells) decrease until the age of 30 and then remain 
constant until 70 years of age, after which point they decrease further 
(Utsuyama et al, 1992). Ulrich et al also noted a decreased proportion of 
CD8+ T cell in IPAH patient peripheral blood, and this was in patients with an 
average age of 51 years, which is similar to those enrolled in this study. 
Further investigation into whether age is a factor in these studies needs to be 
carried out, and if possible, younger SSc-PAH and IPAH patients need to be 
recruited and their results compared to those of older PAH patients to 
confirm that age does not affect T cell subsets in PAH patients.   
No change in activation status of T cells (CD4+ or CD8+) in either 
patient group compared to corresponding controls was noted in my study.  In 
IPAH patients there was an increased spread of data regarding CD4+ T cell 
activation compared to healthy controls; however this was not statistically 
significant. Further studies using an increased number of data sets will allow 
for more definitive conclusions to be drawn. The addition of other T cell 
activation markers such as CD30, HLA-DR and CD40L will allow for 
comparisons to be made between previously published literature and this 
work (Caruso et al, 1997). 
 In my study, a combination of markers was used to define Treg cells 
using flow cytometry. However, due to low event numbers, Foxp3 was not 
used as the data were unreliable. Therefore only CD4+CD25high and 
CD4+CD25highCD127low were used to define Treg cells. Proportions of Treg 
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cells (CD4+CD25high and CD4+CD25highCD127low) were no different between 
patients groups and corresponding controls in my study, however an 
increase in the proportion of circulating Treg cells has previously been 
described by both Austin et al and Ulrich et al in IPAH patients compared to 
healthy controls (Ulrich et al, 2008; Austin et al, 2010). As previously 
mentioned, these differences could be due to the age, sex and disease state 
of the patient, or their PAH specific therapy.  
There was also no change in activation status of Treg cells in either 
patient group, however there was a greater spread of data within the SSc-
PAH group compared to both control groups. This could reflect the severity 
of the disease in patients or possibly differences in age and sex as SSc-PAH 
is a relatively heterogeneous disease. Previous data gained from work 
performed on Treg cells from SSc-no PAH patients are conflicting. When 
limited and diffuse cutaneous patients are grouped together, it was noted 
that there was an increased proportion of Treg cells and a lower expression 
of the activation marker CD69 in peripheral blood of SSc-no PAH patients 
compared to healthy controls (Giovannetti et al, 2010; Slobodin et al, 2010; 
Mathian et al, 2012). However, in a study undertaken in diffuse cutaneous 
SSc-no PAH patients only, a decreased proportion of Treg cells was noted in 
peripheral blood (Papp et al, 2011). These studies further confirm the 
complexity of interpreting results from studies on patients with this disease 
and suggest that grouping of patients into different disease subtypes is 
important when analysing data.  
I found no significant change in the proportion of CD4+ T cells in 
peripheral blood of IPAH patients, which has previously been noted by other 
studies in IPAH patients undergoing PAH specific treatment (Ulrich et al, 
2008).  I also noted no change in the proportion of CD4+ T cells in peripheral 
blood of SSc-PAH patients compared to SSc-no PAH controls. There was, 
however, an increased range of data in SSc-PAH and IPAH patients, making 
me question the possibility of using CD4+ T cells to predict disease severity 
and patient survival. If proven, these clinical measurements could provide a 
quick and reliable test of disease progression.  
The proportion of circulating B cells in peripheral blood was also 
analysed, however there was no change between both patient groups and 
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their corresponding controls. The spread of data in both the IPAH patient 
group and the SSc-PAH patient group was larger than the control group and 
there was also a large spread of data regarding activation of B cells in all 
patient groups and healthy controls. This increase in the spread of data 
suggests that the proportion and activation of B cells is variable within 
patients and controls.  
The choice of control groups for PAH research is a controversial 
issue, as each subset of PAH patients requires a different control. For IPAH 
patient controls, healthy volunteers are used to compare against patient 
samples. However it has been suggested that a more accurate control group 
for immune system studies in PAH would be patients with heart failure 
without co-morbidities such as angina or stroke, as this would provide a 
relevant clinical group without an inflammatory component. For SSc-PAH, 
the relevant control group is SSc-no PAH. However this could be further 
divided into limited and diffuse cutaneous SSc to determine whether the 
response seen is a result of SSc disease progression. 
 
2.4.2 Correlation of clinical parameters with 
proportions of CD4
+
 T cells in 
pulmonary arterial hypertension 
patients  
 
Correlations between disease progression and clinical biochemical 
parameters such as CRP levels have been noted in CTEPH patients (Quarck 
et al, 2009), however correlations between changes in T cell subsets and 
clinical parameters measured at baseline have not been undertaken before 
in PAH patients. These data could prove highly useful in clinical diagnosis 
and monitoring of PAH progression as well as having potential to be used as 
a prognostic biomarker in clinical PAH. 
Work performed for this thesis confirmed that there was a significant 
negative correlation between the proportion of CD4+ T cells and Cardiac 
Index (CI) in treatment-naïve SSc-PAH patients. This suggests that as the 
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heart’s performance decreases, the CD4+ T cell population increases. In 
treatment-naïve IPAH patients there was a significant negative correlation 
between CD4+ T cells and the shuttle walk test. Both of these correlations 
could be used in future to predict the progression of PAH disease. 
Proportions of CD8+ T cells may also be used as a prognostic indicator in 
PAH. A Kaplan-Meier survival analysis could not be performed due to low 
death event numbers in SSc-PAH patients. Future analysis of CD8+ T cells 
proportions and survival data with increased patient numbers may provide 
evidence that CD8+ T cell proportions can predict survival.  
To exclude the possibility that these results are not a chance finding 
by looking for many associations, a second, completely separate cohort of 
patients could be studied and compared against the first cohort analysed in 
this thesis.  
 
2.4.3 Treatments of pulmonary arterial 
hypertension and their effect on T cell 
subsets proportions 
 
There is little evidence regarding the effects that PAH specific 
treatments, such as Bosentan and Sildenafil, have on healthy T cell 
populations and those in IPAH and SSc-PAH patients. This study area merits 
further investigation into how T cell subset changes can affect disease 
progression and whether manipulation of T cell subsets can be used as a 
viable treatment option. A low number of study participants and a varied time 
between visit 1 and follow-up visits made it hard to draw definitive statistical 
conclusions from preliminary work performed for this thesis. Neither 
treatment option has beneficial effects to modify proportions of CD8+ T cells 
or CD4+CD25high Treg cells to a “normal” level suggesting that, as 
proportions of CD8+ T cells are abnormally regulated in SSc-PAH patients, a 
more directed therapy to improve proportions of  CD8+ T cells is needed. 
E-RAs are an effective treatment option for PAH patients as they 
inhibit vasoconstriction within the pulmonary vessels. The effect that E-RAs 
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have on T cell subsets however, is under-investigated. Stimulation of ET-1 
receptors has been shown to provoke an increase in T cell number and their 
recruitment to inflammatory sites, whilst  E-RAs reduce T cell recruitment to 
sites of injury including the lungs (Fujitani et al, 1997; Sampaio et al, 2000; 
Zarpelon et al, 2012). ET-1 also acts through ET-1B receptors on ECs, to 
produce eNOS, which converts L-arginine into NO. NO production has been 
shown to inhibit IL-2 signalling in Th1 cells, leading to anergy of these cells 
(Bauer et al, 1997). In addition, SSc-PAH patients taking Bosentan for 12 
months have been shown to exhibit reduced serum levels of ICAM-1, VCAM-
1, P-selectin and platelet endothelial cell adhesion molecule 1 (PECAM-1), 
whilst T cells expressing lymphocyte function-associated antigen 1 (LFA-1) 
returned to normal levels from an increased level at baseline. These data 
suggest that Bosentan can regulate T cell / EC interactions and can inhibit T 
cell recruitment (Iannone et al, 2008). 
PDE-5 inhibitors such as Sildenafil are also a common choice in PAH 
treatment. Sildenafil has been shown to increase cGMP levels in T cells 
resulting in an increase in number and activation state of tumor-infiltrating 
CD8+ T cells. However, it has been shown not to have an effect on the 
proportion of CD4+ T cells, including Treg cells (CD4+Foxp3+) in cancer 
patients (Serafini et al, 2006). PDE inhibitors such as Rolipram have also 
been implicated in the resolution of inflammatory responses via their ability to 
inhibit IL-2 production in T cells (Robicsek et al, 1991; Gantner et al, 1998; 
Claveau et al, 2004). IL-4 and IL-5 production in Th2 cells has also been 
shown to be inhibited by PDE-4 inhibitors and non-selective PDE inhibitors 
such as Ibudilast can change the cytokine profile towards a Th2 phenotype 
(Crocker et al, 1996; Feng et al, 2004). These studies suggest that PDE 
inhibitors may have an effect on the number and function of T cell subsets in 
other disease settings, however, the effect that PDE-5 specifically has on T 
cell subsets in PAH remains unclear and further analyses need to be 
undertaken to determine their effects. 
Taken together, the results from my studies suggest that E-RAs may 
regulate production and activation of T cell subsets as a therapy for PAH. 
However, a more specific use of immunosuppressant therapies to regulate T 
cell subsets in conjunction with this treatment may be needed. Indeed, in 
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patients with SSc, Iloprost and low dose cyclosporine A have already been 
shown to improve patient skin fibrosis and reduce IL-6 levels, however side 
effects of cyclosporine A use are of concern and this drug combination does 
not address the rebalancing of T cell subsets that are abnormal in PAH 
patients (Filaci et al, 1999). In SSc patients, Bosentan has been shown to 
reduce levels of IL-2, IL-6, IL-8 and IFN-γ, whilst Sildenafil has been shown 
to reduce IL-1β, IL-2, IFN-γ and TNF-α serum levels in a mouse model of 
multiple sclerosis. These results suggest that PAH specific treatments are 
capable of influencing the cytokine milieu towards a Th2 phenotype (CD4+ T 
cell dominant), which could protect against disease and promote the 
resolution of inflammatory processes (Bellisai et al, 2011; Nunes et al, 2012).  
Data will continue to be collected by the pulmonary vascular research 
group at Sheffield University, as it is anticipated that an increase in 
information regarding T cell subsets and treatments will provide a greater 
understanding of how these specific drugs are affecting the T cell 
populations and how they could be manipulated to aid prevention of disease 
progression in PAH.   
 
2.4.4 Limitations leading to future work  
 
 Despite the novel findings presented in this thesis, this work has 
limitations mainly due to the low patient numbers. To gain a larger statistical 
population, more time is required to investigate a larger number of patients. 
 
2.4.4.1  Patient cohorts 
 
 Despite the large patient cohort recruited throughout the duration of 
the project, only around half could be used in this study. Sub-optimal PBMC 
isolation, diagnosis of “not PAH” after initial blood draw and a low CD3+ T cell 
event count for successful flow cytometric analysis were problems that 
limited numbers. Some patients that were initially thought to have IPAH or 
SSc-PAH were subsequently diagnosed as having another subset of PH 
(class 2-5 of Dana point classification) and were also not used in this study. 
Thus, recruitment of a sufficient number of patients to identify changes in T 
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cell subsets between patients and controls was challenging. However, as the 
study progressed, more accurate phenotyping of patients and analysis of T 
cell subsets by flow cytometric analysis occurred, leading to a more reliable 
set of results and a higher number of patients being recruited to the study.
 Patients returning to the SPVDU after visit 1 were also recruited for 
follow-up analysis of how PAH specific drug treatment was affecting 
proportions of T cell subsets within peripheral blood. Unfortunately these 
return visits were often irregular and variability made patient comparison 
difficult. Despite this, changes appeared to be occurring in T cell populations 
in PAH patients on PAH specific therapy, therefore this work needs further 
validation. A longer time period to collect samples will enable more analyses 
to be undertaken. This work is continuing within the pulmonary vascular 
disease group at Sheffield University.  
Unfortunately, end stage lung tissue was not available from IPAH or 
SSc-PAH patients following death, as post mortem tissue is currently 
unavailable in Sheffield. Lung tissue sections would allow analysis of 
infiltrating T cell subsets such as CD4+, CD8+ and Treg cells as well as their 
activation status. These data could then be compared with peripheral blood 
samples to further elucidate the reason for changes in circulating peripheral 
T cell subsets noted previously in this thesis. Even though studies into CD4+ 
and CD8+ T cell proportions within IPAH patient tissue have been carried out, 
this is not the case for SSc-PAH and analysis of infiltrating Treg cells has not 
been performed in either disease group.  
 
2.4.4.2 Foxp3 expression in T regulatory cells 
 
Levels of Foxp3 expression in CD4+CD25high Treg cells could not be 
detected in peripheral blood samples, as event numbers detected by flow 
cytometry were extremely low. A possible explanation could be that the 
levels of Foxp3 were too low to detect, and / or that the transient expression 
of Foxp3 was being overlooked at the time of analysis.  
 The validity of Foxp3 as a marker of Treg cells is still questionable. 
Some researchers believe that it is a highly valuable marker of functional 
Treg cells, whilst others have noted an upregulation of Foxp3 in human 
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activated non-regulatory CD4+ T cells and CD8+ regulatory T cells, thereby 
making it less reliable as a definitive marker of Treg cells (Banham et al, 
2006; Liu et al, 2006; Joosten et al, 2007; Wang et al, 2007). Previous 
studies have also shown that Foxp3 is not expressed on IL-10 secreting Treg 
cell populations and Treg cells can also downregulate their expression of 
Foxp3, losing their suppressor functions (Vieira et al, 2004).  
 
2.4.5  Concluding remarks 
 
The work undertaken in this thesis confirmed a significant  decrease in 
the proportion of circulating CD8+ T cells in SSc-PAH patients, but failed to 
show an increase in the proportion of circulating CD4+CD25highTreg cells, as 
previously described by Austin et al and Ulrich et al in IPAH patients 
undergoing PAH therapy (Ulrich et al, 2008; Austin et al, 2010). This work 
further confirms the importance of determining changes in lymphocyte 
subsets in treatment-naïve patients, to determine the effect that the disease, 
and not the treatments, have on circulating T cell populations.  
A negative correlation between proportions of circulating CD4+ T cells 
and clinical parameters, including CI and the shuttle walk test, was observed 
in PAH patients. This suggested that with further studies, the proportion of 
circulating CD4+ T cells has potential to be used as a valuable diagnostic or 
prognostic biomarker in both IPAH and SSc-PAH patients (Pendergrass et 
al, 2010).  
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Chapter 3  ApoE
-/-
/IL-1R1
-/-
 high fat diet 
model of pulmonary arterial 
hypertension 
 
3.1   Introduction 
 
Animal disease models offer a valuable insight into the progression of 
a disease rather than an end stage analysis of the disease state, which can 
be gained from patient samples at death. These models also allow for the 
detection of transient changes in factors affecting disease progression and 
biomarkers. Despite differences in onset of the disease, most models 
converge on the same endpoints of pulmonary vascular remodelling, an 
increase in mPAP and right ventricular failure. Although these models closely 
resemble human disease, no single model can completely recapitulate it.  
Determining whether alterations in T cell profiles occur at the same 
time, prior to, or after changes in pulmonary circulation requires the use of 
animal models of PAH. It is also uncertain whether inflammation itself causes 
PAH or if inflammation occurs as a result of PAH. It could be possible that 
both of these situations occur together (Tamosiuniene and Nicolls, 2011). 
Several models of PAH providing evidence for T cell involvement in 
the pathogenesis of PAH have been published. Studies have used 
immunohistochemistry to show CD3+ and CD45+ T cell localisation to lesions 
within the pulmonary vasculature in these models (Marsboom et al, 2008; 
Song et al, 2008; Steiner et al, 2009; Summer et al, 2009; Cuttica et al, 
2011). The presence of these cells could be either as a consequence of the 
disease (attempting to resolve inflammatory processes) or in a causative role 
(instigating an inflammatory response).  
Work undertaken by Taraserviciene-Stewart et al using an athymic 
nude rat model of PAH (in which the animals were given a vascular 
endothelial growth factor receptor blocker to induce PAH), has led to the 
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discovery that the absence of T cells enhances vascular remodelling, whilst 
replenishing this subset of lymphocytes prevents vascular remodelling 
(Taraseviciene-Stewart et al, 2007). In a more recent publication by this 
group, immune reconstitution using  CD4+ or CD4+CD25high T regulatory 
cells, was shown to lead to attenuated development of PAH (Tamosiuniene 
et al, 2011). These data, along with other reports, suggest a strong link 
between changes in T cell subset proportions and the progression of PAH, 
thereby providing an interesting area for further investigation.  
Apolipoprotein E (ApoE) is a plasma glycoprotein involved in 
cholesterol metabolism due to its ability to transport cholesterol and other 
lipids among various cells in the body. It is a constituent of all lipoproteins 
except low-density lipoproteins and is synthesised in the liver, brain, spleen 
and kidney, but has recently been shown to be produced by monocytes and 
macrophages in blood vessels (Meir and Leitersdorf, 2004). In SMCs, BMP-2 
signalling is peroxisome proliferator-activated receptor gamma (PPARƴ) and 
ApoE dependent and produces antiproliferative effects on SMCs. Mice with a 
deletion of PPARƴ in SMCs spontaneously develop PAH (Hansmann et al, 
2008). ApoE is also thought to have anti-inflammatory properties as it can 
suppress type 1, pro-inflammatory responses by inhibiting lymphocyte 
proliferation (Kelly et al, 1994; Ali et al, 2005). ApoE also protects against the 
development of atherosclerosis as ApoE-/- mice develop spontaneous 
hypercholesterolemia and atherosclerotic lesions (which can be exacerbated 
by an atherogenic diet), similar to those seen in the human condition 
(Bellosta et al, 1995; Thorngate et al, 2000).  
IL-1 has also been implicated in the pathogenesis of atherosclerosis 
via its ability to induce SMC proliferation and act as a co-stimulatory signal 
for T cell activation (Moyer et al, 1991; Hansson, 2001). IL-1 is a pro-
inflammatory cytokine released by a variety of cells including SMCs, ECs 
and mononuclear phagocytes and a link between increased serum levels of 
IL-1 and disease progression in PAH patients has been observed (Hogquist 
et al, 1991; Humbert et al, 1995; Imai et al, 2000; Clarke et al, 2009). Chronic 
treatment with human IL-1RA has been shown to reduce PAH and RVH in 
the MCT model of PAH and reduce PAH development in fat-fed ApoE-/- mice 
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further suggesting a role of IL-1 in the pathogenesis of PAH (Voelkel and 
Tuder, 1994; Lawrie et al, 2011). 
Because of a previous interest in atherosclerosis, our laboratory had 
access to mice deficient in IL-1R1 and ApoE. A cross was made between 
these two strains, which revealed the surprising finding that ApoE-/-/IL-1R1-/- 
mice acquired reduced atherosclerosis, but developed a severe form of PAH 
(RVSP average 75 mmHg) when fed on a high fat diet (paigen diet). A more 
severe form of distal pulmonary vascular remodelling was noted in these 
mice compared to ApoE-/- mice (Lawrie et al, 2011). In this model there is an 
exaggerated PAH phenotype despite reduced atherosclerosis and this is 
thought to be due to an alternatively primed IL-1R1 transcript expressed 
within the lungs, but not the aorta of these mice. This allows intact IL-1 
signalling within the lung and pulmonary vasculature. Increased serum 
cytokine levels (IL-6 and IL-1β) have also been noted in this model along 
with an increase in perivascular inflammatory cell infiltrates. Taken together, 
these findings make this model an interesting tool to study the involvement of 
inflammation in the pathogenesis of PAH. Immunohistochemical analysis 
revealed complex lesions and perivascular CD3+ T cells in the lungs of these 
mice. This model is therefore phenotypically relevant to studying the 
inflammatory processes involved in the development of these vascular 
lesions and the progression of PAH and provides a novel model of PAH 
development. 
Whilst work undertaken in the athymic rat treated with Sugen 5416 
has noted inflammatory cell infiltration of tissue surrounding pulmonary 
vessels preceding an increase in right ventricular pressure by several days 
(Tamosiuniene et al, 2011), a timecourse of the disease aimed at identifying 
the exact point at which this increase in T cells occurs within the peripheral 
circulation and lung tissue has not been undertaken. Therefore, work 
described in this chapter aimed to characterise T cell subsets in chow and 
fat-fed ApoE-/-/IL1R1-/- animals along a timecourse, as well as in CD4+ T cell 
depleted ApoE-/-/IL1R1-/- animals, and relate changes in T cell subsets to 
vessel remodelling within the pulmonary arteries. It also determined whether 
changes in proportions of T cell subsets occur as a cause or consequence of 
disease progression. I hypothesised that an increase in the proportion of 
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circulating T cells would occur as disease progressed. I also hypothesised 
that with the deletion of CD4+ T cells, disease phenotype would worsen due 
to the removal of protective Treg cells within the CD4+ T subset.  
 
3.2   Methods 
 
All experimental procedures were approved by the University of 
Sheffield Ethics Committee and conformed to Home Office regulations under 
the Animals Scientific Procedures Act (1986). Work was carried out under 
project licence PPL 40 / 3517. ApoE-/-/IL1R1-/- mice were generated at JAX 
labs by cross breeding ApoE -/- (JAX 2052) with IL-1R1-/- (JAX 3245) mice 
(Maine, USA) (Chamberlain et al, 2006; Chamberlain et al, 2009). All mice 
were on a C57 / BL6 background and housed in a controlled environment 
with a 12 hour light / dark cycle at 22˚C and a constant air pressure. 
Littermates were housed together with a maximum of 5 animals per cage, 
with all cages being provided with environmental enrichment. 
 
3.2.1 ApoE
-/-
/IL-1R1
-/-
 timecourse study  
 
Forty 10 week old male ApoE-/-/IL1R1-/- mice were fed on either 
paigen diet (18.5% fat, 0.9% cholesterol, 0.5% cholate, 0.259% sodium) or 
chow diet (4.3% fat, 0.02% cholesterol) ad libitum (n=5-6 per group) for 1, 2, 
4, 6 or 8 weeks. Paigen diet was supplied by Special Diet Services 
(Braintree, Essex, UK) and chow diet was supplied by Harlan Global Diets 
(Madison, USA) (Appendix 1, section 4). Time points of 1, 2, 4, 6 and 8 
weeks were selected for both chow and paigen-fed mice. At each time point, 
peripheral blood and lung tissue were collected and weight measurements 
(to the nearest 0.1g) were taken (week 0 and at each time point before 
sacrifice).  
Extensive phenotyping of this animal model was not carried out to 
maximise the opportunity to optimise a flow cytometry protocol to stain small 
amounts of blood from mice. Assessment of disease was assessed by 
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quantifying the degree of pulmonary vascular remodelling on processed lung 
sections. 
.  
3.2.1.1  Cardiac puncture  
 
Cardiac puncture was performed to collect peripheral blood samples, 
as this provided the largest volume of blood for flow cytometry analysis. 
Around 1 mL blood was collected via cardiac puncture for flow cytometry. 
Cardiac puncture was performed on anaesthetised animals after loss of the 
pedal reflex. The animal was placed on a pre-heated mat (37˚C) on its back. 
The heart was palpated before a 20 G needle, attached to a syringe, was 
inserted at a 25˚ angle, slightly left of and under the sternum. The needle 
was directed towards the animal’s head. Blood was drawn up into the syringe 
from the heart until between 600-1000 µL blood had been collected. The 
blood was then transferred into a BD Vacutainer® Blood Collection Tube and 
placed on ice to maintain cellular integrity. 
 
3.2.1.2  Lung and splenic tissue preparation  
 
To detect changes in proportions of T cells present in splenic tissue 
and the migration of these cells into the lung tissue, the right lung and spleen 
were also removed for immune cell analysis (at week 8 time point only). 
These were both passed through separate 100 µm cell strainers (BD 
Biosciences, Oxford, UK) into 500 µL of 0.15% w/v Collagenase A (Roche, 
Welwyn Garden City, UK) and PBS respectively. Collagenase A was used to 
dissociate lung tissue and liberate immune cells to be analysed using flow 
cytometry. Lung tissue was allowed to incubate with collagenase A for 1 hour 
at 37˚C in a water bath before being washed in PBS and processed for flow 
cytometric analysis. Lung tissue was also incubated with 500 µL of 1X 
GIBCO® Hank's Balanced Salt Solution which was used as a negative 
control, to rule out the possibility of non-tissue derived cells from the blood in 
the lung affecting the results. T cell proportions were compared using flow 
cytometry prior to the use of Collagenase A in these animal studies. 
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3.2.1.3  Flow cytometric analysis of T cell subsets in 
blood and tissue samples 
 
Detection of changes in T cell subsets in peripheral blood and 
liberated cell suspensions was performed using flow cytometric analysis. 
Blood and dissociated tissue samples were split into 3 equal amounts and 
placed in separately labelled epindorfs labelled “unstained”, “isotype 
controls” and “stained”. Cell suspensions were stained according to the 
manufacturer’s instructions using the panel of fluorescently conjugated 
antibodies and isotype controls shown in Appendix 1, section 3. In brief, cell 
suspensions were incubated with the required amount of fluorescently 
conjugated antibodies against CD3, CD4, CD8, CD25 and a UV live / dead 
marker, for 30 minutes at 4˚C in the dark, before the cells were washed at 
300 x g for 5 minutes at 4˚C in cell staining buffer (PBS + 10% v/v FCS).  
In studies of T cell subsets in mouse models of PAH, antibodies 
raised against CD4 and CD25 were used to define Treg cells. In mice, all 
CD4+ and CD25high cells are regulatory T cells, whilst in humans this is not 
the case, as CD25high cells are not all Treg cells (Taams et al, 2001; Su et al, 
2012). Therefore, additional Treg cell markers were used to define Treg cells 
in human studies. 
The cells were then resuspended in 100 µL cell staining buffer and 
incubated with 4 mL 1X red blood cell lysis solution (Miltenyi Biotec, Surrey, 
UK) for 20 minutes at room temperature in the dark. The cells were then 
washed in cell staining buffer as previously described and the cells 
resuspended in 20 µL cell staining buffer before 150 µL 1X CELLFix™ was 
added (BD Biosciences, Oxford, UK). Samples were stored at 4˚C to allow 
for analysis at a later date (within 4 days). 
Lymphocytes were identified on the basis of their size and granularity 
using a forward and side light scatter plot with dead cells excluded from the 
analysis using the UV live / dead dye. Data on a minimum of 10,000 CD3+ 
events was collected for each sample in the lymphocyte gate and 
FACSDIVA™ software was used for analysis. The gating strategy and 
example scatter plots used to analyse the samples are shown in Figure 3.1. 
Compensation was undertaken using anti-rat IgG-coated compensation 
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beads (BD Biosciences, Oxford) and ARC™ reactive beads (Invitrogen of 
Life Technologies Ltd, Paisley UK) as previously mentioned in Chapter 
2.2.2.1. FACSDIVA™ software was used to automatically set up and apply 
the compensation. 
 
 
 
Figure 3.1 Representative gating hierarchy and dot plots templates used to 
define T cell subsets in blood and tissue samples. 
A) Representative dot plots showing T cell populations. B) Representative gating 
hierarchy. Forward scatter (FSC) and side scatter (SSC) cells gated on, then 
doublet cells removed to leave single cells. Viable cells were then gated on and a 
gate placed around CD3+ T cells. T cell subsets including CD4+, CD8+ and 
CD4+CD25high were then gated on.  
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3.2.1.4 Tissue preparation for analysis by 
immunohistochemistry 
 
The abdominal aorta was exposed and cut to allow blood to drain. A 
transverse incision was made below the diaphragm from one side of the 
animal to the other, exposing the liver and stomach. A vertical abdominal 
incision was then made to expose the lower abdominal contents. Using small 
forceps, the zyphoid process was lifted and a hole was made in the 
diaphragm below the sternum. The right and left sides of the chest wall were 
then cut free and the chest wall removed. A saline-filled syringe was inserted 
into the right ventricle and saline injected slowly to flush the lung of blood. A 
mid-line incision was made in the neck to expose the trachea thereby 
enabling it to be cut. The heart and lungs were removed en bloc and the 
spleen removed from the abdominal cavity.  
Blood was flushed out of the body by dissection of the lower aorta and 
the left lung was inflated using a 10 mL syringe attached to a 20 G needle. 
This was then filled with 10 mL water and attached to a small length of tubing 
inserted into the trachea. To inflate the lung, a tie was made around the 
trachea and tube to ensure water retention. The water was then injected 
slowly into the lung to inflate it. The lung and heart were then placed in a 
falcon tube containing 10 mL formalin for 24 hours to fix the tissue. After 24 
hours, the left lung was removed and processed as below. 
 Lung and splenic tissue was embedded and cut according to sample 
size and type (lungs into 4 pieces, spleens embedded whole). Tissue was 
sandwiched between 2 sheets of Whatman Grade 1 filter paper then placed 
inside a plastic cassette. Cassettes were then placed in a large beaker filled 
with 50% v/v ethanol, covered and left to dehydrate for 1 hour. The 50% v/v 
ethanol was removed and replaced with 70% v/v ethanol for 1 hour before 
again being replaced by 90% v/v ethanol for 1 hour. Two 100% v/v ethanol 
dehydration steps were then performed for 1 hour each before the cassettes 
were put into a mix of 50:50 xylene:ethanol mix for 1 hour. The cassettes 
were removed, placed in xylene for two 1 hour periods and placed into pots 
of molten wax at 60˚C for 1 hour. 
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After 1 hour in molten wax, the cassettes were removed from the pots 
and the tissue block recovered. The flat side of the cut tissue was placed flat-
side down into clear plastic moulds before molten wax was used to fill the 
mould and the cassette lid placed on top. This was repeated for all samples 
and the moulds left to set overnight before sections were cut. 
For sectioning, wax blocks were pressed from the moulds and placed 
on ice for at least 1 hour, prior to cutting with a Leica RM2135 microtome 
(Leica Microsystems, Wetzlar, Germany). All vessels were cut to 5 µm 
thickness and floated out on a water bath, heated to 35˚C, to flatten the 
sections. Sections were mounted on Polysine™ glass slides. 
 
3.2.1.5 Immunohistochemical analysis 
 
Lung sections were stained with antibodies against CD8, CD4, CD25, 
smooth muscle actin (SMA) and vessel elastin to assess marker expression 
within the lungs taken from both chow and paigen fed ApoE-/-/IL1R1-/- mice. 
This involved de-waxing the slides in 100% v/v xylene for 10 minutes before 
re-hydrating them through graded ethanol to water (100% v/v ethanol; 100% 
v/v ethanol, 90% v/v ethanol, 70% v/v ethanol, 50% v/v ethanol  each for 2 
minutes). Endogenous peroxidases were then blocked with 3% hydrogen 
peroxide for 10 minutes before being rinsed in water. The slides were 
incubated in 1% w/v milk buffer (Marvel, available in supermarket stores) for 
30 minutes at room temperature to stop non-specific binding of the 
secondary antibody. Excess milk buffer was removed by tilting the slide and 
blotting the drained liquid before the primary antibody was added for 1 hour 
at room temperature in a humidity chamber (see Appendix 1, section 5 for all 
antibodies and clone numbers used in immunohistochemical analyses). The 
slides were washed 3 times in PBS before being incubated with the 
secondary antibody for 30 minutes at room temperature in the humidity 
chamber. The slides were washed a further 3 times in PBS and incubated for 
30 minutes with Vectastain Elite ABC kit working reagent (see Appendix 1, 
section 5), washed and then and incubated with DAB substrate for 5 minutes 
before being rinsed in water. The slides were counterstained using Carazzi’s 
Haematoxylin for 1 minute then washed in water. The slides were finally 
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dehydrated through graded alcohols 50% v/v ethanol, 70% v/v ethanol, 90% 
v/v ethanol, 100% v/v ethanol; 100% v/v ethanol each for 2 minutes) to 100% 
v/v xylene, before being mounted using DPX mountant (see Appendix 1, 
section 5).  
For some stains it was necessary to use an antigen retrieval step 
before incubating sections with the primary antibody. Antigen retrieval is a 
method that can be used to break up protein cross-links formed when tissues 
are processed by formalin fixation. This allows hidden antigenic sites to 
become available for antibodies to bind to. Several heat mediated antigen 
retrieval methods were used for a variety of different staining procedures 
(see Appendix 1, section 5). The antigen retrieval step was undertaken after 
incubation with hydrogen peroxide and before the milk buffer step. Citrate 
buffer, TRIS / EDTA or EDTA (see Appendix 1, section 5) were heated in a 
heat proof container in a water bath to 95˚C before slides were added for 20 
minutes (10 minutes for EDTA). After this time, the heat proof container was 
removed from the water bath and left to cool to room temperature for a 
further 20 minutes. The slides were then rinsed once in PBS. 
For Millers Elastin staining, slides were re-hydrated in 100% v/v 
xylene for 10 minutes before passing through 100%, 90% and 70% v/v 
ethanol for 2 minutes each, then in water for 2 minutes. The sections were 
oxidised with potassium permanganate for 3 minutes. The slides were rinsed 
in water then bleached with oxalic acid and rinsed in water again. The nuclei 
were stained with Carazzi’s haematoxylin for 2 minutes before the tissue was 
differentiated by incubating with acid alcohol for a few seconds (see 
Appendix 1, section 5). The slides were “blued” with hot running water before 
being stained with alcian blue pH 2.5 for 5 minutes. The slides were rinsed in 
water followed by 95% v/v industrial methylated spirits before Miller’s Elastin 
stain was added for 30 minutes. After rinsing in water, the slides were put in 
95% v/v IMS briefly before being rinsed in water. Curtis’ Modified van Gieson 
was added to the slides for 6 minutes before they were dehydrated back 
through 70%, 90% and 100% v/v ethanol then 100% v/v xylene. The slides 
were mounted using DPX mountant and left to dry for 24 hours. 
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Stained slides were analysed using a camera mounted to a light 
microscope utilising NIS-elements software version 3.0 (Nikon, 
Badhoevedorp, The Netherlands).    
   
3.2.1.6 Analysis of Vessel Remodelling 
 
To determine the effect that paigen diet had on the process of 
remodelling within pulmonary arteries, two techniques were used to assess 
and quantify the amount of remodelling. This included analysing the media 
and cross-sectional area of vessels to give a ratio of the number of affected 
vessels and also the degree to which they were affected, by classifying each 
vessel as fully occluded, partly occluded and not occluded. These analyses 
were performed on SMA and Millers Elastin stained sections using NIS-
elements software. For both analyses, the pulmonary arteries were 
categorised based on their external diameter and divided into 3 groups: small 
pulmonary arterioles with a diameter of <50 µm, medium pulmonary arteries 
with a range in diameter from 51 to 100 µm, and large pulmonary arteries 
with a diameter greater than 100 µm. For SMA analysis, the degree of 
muscularisation was calculated as the area of the media divided by the 
cross-sectional area of the whole artery (media / CSA). A well characterised 
method for analysing the percentage of muscularised vessels within tissue 
was used which included measuring alcian blue elastic van Gieson staining. 
6 views of lung sections and the pulmonary arteries were categorised as 
occluded (slit-like, or no lumen remaining), muscularised (crescent, or 
complete rings of muscle), or nonmuscular (no apparent muscle) and 
counted (Schermuly, 05; Lawrie et al, 2011). 
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3.2.2 CD4
+
 T cell depletion model  
 
To determine the effect that depletion of CD4+ T cells had on disease 
progression, an antibody against this cell subset was administered to fat-fed 
ApoE-/-/IL1R1-/- mice for 4 weeks and then the mice left to develop PAH on 
paigen diet. The haemodynamic assessment of disease progression was 
then compared to IgG treated control mice fed with paigen diet for 8 weeks. 
The protective effect that these cells had on the disease phenotype was also 
assessed, as the removal of this cell subset also removed Treg cells involved 
in inflammatory response resolution. This study also provided information 
regarding the question of whether CD4+ T cells were found in the lung as a 
cause or consequence of the disease. 
Twelve 10-13 week old male ApoE-/-/IL1R1-/- mice were fed paigen 
diet for 8 weeks. Mice were ear clipped to identify individual mice within a 
cage. Weight measurements (to the nearest 0.1g) were taken at week 0 and 
week 8. Intraperitoneal injections of either LEAF purified anti-mouse CD4 
antibody or purified rat IgG control (see Appendix 1, section 4) both at a dose 
of 0.5 mg / mouse, were given once weekly, for 4 weeks from the 
commencement of paigen diet. Six animals were assigned to each treatment 
group (Figure 3.2). Before mice were sacrificed (after 8 weeks of feeding on 
paigen diet), echocardiography and cardiac catheterisation were undertaken 
to assess the haemodynamic changes between the two groups. Data gained 
from this would later be used to compare changes in T cell profiles to 
corresponding changes within the pulmonary circulation. 
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Figure 3.2 Experimental design for the CD4+ T cell depletion study. 
An 8 week timecourse was set up to study the progression of PAH in IgG treated 
controls and CD4 antibody treated animals fed on paigen diet. 12 ApoE-/-/IL1R1-/- 
mice were split into two groups (6 in each group) and given 0.5 mg / mouse / week 
dose of GK1.5 CD4 depletion antibody or IgG control for 4 weeks. After this time the 
mice continued to be fed on paigen diet for a further 4 weeks before being 
sacrificed, echocardiography and cardiac catheterisation carried out and organs and 
tissues removed. 
 
3.2.2.1 Echocardiography 
 
To gain a greater understanding of the changes in size and shape of 
the heart, echocardiography was performed using the Vevo 770 system 
(Visual Sonics, Toronto, Canada) using an RMV707B scan head. Data 
collection was undertaken by Dr Abdul Hameed, Ms Nadine Arnold and Dr 
Alan Lawire and data analyses by myself. Anaesthetised animals were 
placed on a heated platform and covered to minimise heat loss and rectal 
temperature, heart rate, and respiratory rate recorded continuously 
throughout the study. Anaesthesia was induced and maintained using 
isoflurane through oxygen (5% v/v Isoflurane, 2 L / minute oxygen), 
maintaining heart rates at around 450 to 500 beats per minute, whenever 
possible. The mice were depilated and preheated ultrasound gel was applied 
(Aquasonics 100 Gel; Parker Labs, Inc., Fairfield, NJ). From the right 
parasternal long axis view, right ventricle free wall parameters were 
determined using M-mode.  
Standard parameters of the left ventricle were measured using 2-
dimensional, M-mode and Doppler pulse wave in the short axis view at the 
level of the papillary muscles. Analysis was performed offline using the 
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accompanying software (Vevo 770, V3.0; Visual Sonics). Measurements 
were taken during the relevant phase of the cardiac cycle that did not 
coincide with inspiration artefact.  
 
3.2.2.2 Cardiac catheterisation 
 
To measure the haemodynamic alterations that are a consequence of 
disease, left and right ventricular catheterisation were performed using a 
closed chest method. The right ventricle was assessed via the right external 
jugular vein and the left ventricle via the right internal carotid artery under 
isoflurane-induced anaesthesia.  
The Millar catheter was placed in a beaker of saline for 20 minutes 
prior to calibration. The pedal reflex was then checked before the neck fur 
was wetted with ethanol. Fine scissors were used to make an incision to the 
right of midline from the neck to the clavicle to expose the external jugular 
vein.  Fine curved forceps were used to dissect the tissue around the vein. 
The vein was then isolated and a 4.0 suture passed underneath it to ligate 
the vein distal to the heart. A second suture was placed around the vein and 
loosely tied proximally to the heart (ready to tie around the catheter once 
inserted). Tension was then placed on the distal suture with forceps so that 
the vein was stretched before a 25 G 5/8” needle (bent at a 90˚ angle) was 
inserted into the vein and the catheter inserted simultaneously.   
 After the catheter was inserted the suture was loosely tied off to 
prevent bleeding. The catheter was then advanced into the right ventricle. 
Systemic pressures were recorded by pulling the catheter back and using the 
proximal suture to tie off the vein. CO data was derived using a pressure 
volume catheter and the CI was normalised by body weight. 
Data were collected from the right ventricle using a Millar ultra-
miniature pressure-volume PVR-1030 1F catheter (Millar Instruments Inc, 
Houston, TX, USA) and from the left ventricle using a Millar ultra-miniature 
pressure-volume PVR-1045 1F catheter, coupled to a Millar MPVS 400 and 
a PowerLab Client data acquisition system version 7 (AD Instruments, 
Oxford, UK) and recorded using Lab chart Pro software (version 6.0, for 
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Microsoft windows, AD Instruments, Oxfordshire, UK). Pressure volume 
analysis was performed using PVANv2.3 (Millar Instruments Inc, Houston, 
USA). 
 
3.2.2.3  Blood and tissue sample collection, 
preparation and analysis 
 
As previously described, peripheral blood samples were collected via 
cardiac puncture, and lung and splenic tissue collected and prepared for flow 
cytometric analysis. Tissue sections were prepared for immunohistochemical 
and immunocytochemical analysis of vessel remodelling and T cell marker 
expression (see Chapter 3.2.1.1 - 3.2.1.6 for collection, preparation and 
analysis of samples). 
 
3.2.2.4 CD4
+
 T cell depletion confirmation 
 
To confirm that CD4+ T cells had been efficiently depleted, blood was 
taken from 6 randomly selected mice (3 on IgG control and 3 on CD4-
depletion antibody) and stained using fluorescently conjugated antibodies 
against CD3, CD4 and CD8 at week 5 (1 week after cessation of 
administering the anti-CD4 antibody). Before being analysed by flow 
cytometry, 100 µL of blood was taken via a 20G needle from the tail vein into 
a BD Vacutainer® Blood Collection Tube. Blood was stained for 30 minutes 
as previously described in Chapter 3.2.1.3 and then red blood cells lysed. 
Antibodies were used in accordance with manufacturer’s guidelines and a 
tube containing relevant isotype controls was also set up. 
 
3.2.3 Statistical analysis  
 
A non-Gaussian distribution was assumed for all data. A two-way 
ANOVA with Bonferroni post hoc test was performed to compare data from 
treatment groups along a timecourse. A two-tailed Mann-Whitney U test with 
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95% confidence intervals was used, where appropriate, to compare pairs of 
data. A P value of < 0.05 was considered significant. 
 
3.3  Results 
 
3.3.1 ApoE
-/-
/IL-1R1
-/-
 timecourse 
 
Analysis of T cell subsets in peripheral blood from PAH patients 
revealed changes in several subsets. To determine whether these changes 
occur before, during, or later in the progression of vessel remodelling, an 
animal model of PAH was used, as patient samples only refer to end stage 
disease states. The ApoE-/-/IL-1R1-/- mouse model of PAH is a highly 
inflammatory based model of PAH, providing a relevant tool for the analysis 
of T cell subsets within blood and tissues.  
 Changes in haemodynamics, vessel remodelling and T cell subsets in 
peripheral blood, were assessed in animals  after 1, 2, 4, 6 and 8 weeks on 
either chow or paigen diet.  
 
3.3.1.1 Haemodynamic and vessel remodelling 
analysis  
 
Disease progression was assessed using several parameters 
including body weight and measurements of vessel remodelling including the 
number of vessels affected and the degree of remodelling. Body weight was 
assessed at every time point (week 1 to 8) and no change in weight between 
animals fed on chow or paigen was noted at any time point.  
The degree of muscularisation was measured using the area of the 
media divided by the cross-sectional area (CSA) of the whole artery (media / 
CSA). The medial / CSA of small pulmonary arteries and arterioles (<50 µm) 
in paigen-fed animals was increased significantly at week 6 compared to 
chow-fed controls (0.11 ± 0.04 vs 0.40 ± 0.05, n=4-5, P=0.0001) and also at 
week 8 (0.11 ± 0.05 vs 0.37 ± 0.04, n=4, P=0.0001) (Figure 3.3, A). There 
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was also an increase in media / CSA from week 2 onwards in paigen-fed 
animals, however these differences were not significant until week 6.  
An increased media / CSA was also noted in medium sized vessels 
(50-100 µm) in paigen-fed animals at week 8 (0.06 ± 0.005 vs 0.17 ± 0.05, 
n=4-5, P=0.0001). Again, a gradual increase in the media / CSA of vessels 
was noted in paigen-fed animals from week 1, however when compared to 
chow fed controls, there was no significant difference until week 8 (Figure 
3.3, B). 
 An increase in media / CSA was also seen in large vessels (>100 
µm) at week 6 (0.04 ± 0.04 vs 0.19 ± 0.06, n=4-5, P< 0.01) and at week 8 
(0.06 ± 0.005 vs 0.17 ± 0.05, n=4-5, P< 0.001) in paigen-fed animals 
compared to chow fed controls (Figure 3.3, C).  
Taken together, these data suggest that an increased degree of 
muscularisation is occurring in pulmonary vessels of all sizes after 
commencement of the paigen diet in ApoE-/-/IL-1R1-/- mice. These data are 
comparable with previously published data regarding paigen feeding in the 
ApoE-/-/IL-1R1-/- mouse (Lawrie et al, 2011). 
The proportion of muscularised vessels as a percentage of total 
vessels was calculated based on the number of affected pulmonary arteries 
divided by the total number of arteries multiplied by 100 in elastin van Gieson 
stained lung tissue sections. There is a trend for an increase in the 
percentage of muscularisation in all vessel sizes from week 6 onwards in 
paigen-fed animals compared to chow-fed controls (Figure 3.4, A-C). At 
week 8, the percentage of muscularisation increased in large vessels (>100 
µm) in paigen-fed animals compared to chow fed controls (12.45 ± 5.71 vs 
50.00 ± 28.88, n=4-5, P< 0.05) (Figure 3.4, C).  
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Figure 3.3 Comparison of extent of muscularisation in paigen and chow fed 
animals from 1 week to 8 weeks after commencement of diets.  
Extent of muscularisation measured as media/cross sectional area (Media/CSA), 
was measured in chow fed (clear bars) and paigen-fed (black bars) mice at 1, 2, 4, 
6, and 8 weeks (W1-8) after staining for smooth muscle actin and vessel size 
quantified using immunohistochemistry A)<50 µm vessels, B) 51-100 µm vessels 
and C) >100 µm vessels. n=2-5. Error bars depict mean ± SEM. Data analysed 
using a two-way ANOVA with Bonferroni post hoc test. P< 0.05 was considered 
significant (*). 
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Figure 3.4 Assessment of the percentage of muscularisation of pulmonary 
vessels in chow and paigen-fed animals. 
Vessel analysis using alcian blue elastin van Gieson staining on tissue sections 
taken from animals fed paigen or chow diet for 8 weeks. A) <50 µm vessel analysis 
B) 51-100 µm vessel analysis C) >100 µm vessel analysis. In all graphs the clear 
bar represents chow fed animals and the black bar represents paigen-fed animals. 
Data show % musculurised vessels. Error bars represent mean ± SEM, n=3-5 per 
group. Data analysed using a two-way ANOVA with Bonferroni post hoc test. P< 
0.05 considered significant.  
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3.3.1.2 Circulating T cell subset analysis  
 
The aim of this chapter was not only to identify changes in 
haemodynamic parameters and vessel remodelling between chow and 
paigen fed animals, but also to relate these changes to alterations in T cell 
subsets throughout a timecourse of PAH progression. To do this, an analysis 
of circulating T cell subsets was conducted using peripheral blood samples 
taken via cardiac puncture at week 1 to 8.  
 
 
Figure 3.5  T cell subsets in peripheral blood of paigen and chow fed animals. 
Peripheral blood was stained for T cell subsets and data are shown as a proportion 
of CD3+ T cells. A) Proportion of CD4+ T cells B) Proportion of CD8+ T cells C) 
CD4:8 ratio D) Proportion of Treg (CD4+CD25high) cells. Time points of week 1, 2, 4, 
6 and 8 are shown along the X axis. n=2-4 and error bars depict mean ± SEM. 
White bars depict chow fed animals and black bars represent paigen-fed animals. 
Data analysed using a two-way ANOVA with Bonferroni post hoc test. No results 
were significant. 
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These data are non-conclusive for any obvious significant changes in 
any T cell subset at any time point in paigen fed mice compared to chow fed 
controls (Figure 3.5, A to D). Interestingly, there was a significant increase in 
Treg cells (CD4+CD25high) in chow fed controls at week 6 compared to 
paigen fed animals, however this is unexplainable (Figure 3.5, D). 
I also investigated whether there was a modified recruitment of T cell 
subsets into lung tissue, as well as changes in T cell proportions within the 
spleen. Proportions of CD4+ T cells, CD8+ T cells and CD4+CD25high Treg 
cells were assessed at week 8 in blood as well as spleen and lung tissue. 
Lung tissue was digested by incubating the tissue with collagenase A, as 
previously described in chapter 3.2.1.2, to dissociate the tissue and liberate 
immune cells. The tissue from both lung and spleen were then passed 
through cell strainers to remove cells for flow cytometric analysis.  
Although not significant, there was a trend for a decrease in CD4+ T 
cells (as a proportion of total CD3+ T cells) in blood of paigen-fed ApoE-/-/IL-
1R1-/- mice at week 8 (27.75 ± 12.30% vs 45.65 ± 3.94%, n=4/group, 
P=0.11). No significant changes in CD4+ T cell populations were noted in 
spleen or lung tissue (Figure 3.6).  
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Figure 3.6 Proportions of CD4+ T cells in blood, spleen and lung tissue at 8 
weeks in chow and paigen-fed ApoE-/-/IL-1R1-/- mice. 
Error bars show mean ± SD and n=4/group. A Mann-Whitney U test with 95% 
confidence intervals was carried out on all data with a P value of < 0.05 considered 
significant (*). 
 
There was a tendency for increased proportions of CD8+ T cells in the 
lung tissue in paigen-fed mice at week 8 compared to chow fed controls 
(36.35 ± 5.57% vs 22.35 ± 8.01%, n=4/group, P=0.057), however their 
proportions did not change in blood or splenic tissue (Figure 3.7).  
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Figure 3.7 Proportions of CD8+ T cells in blood, spleen and lung tissue at 8 
weeks in chow and paigen-fed ApoE-/-/IL-1R1-/- mice. 
Error bars show mean ± SD and n=4/group. A Mann-Whitney U test with 95% 
confidence intervals was carried out on all data with a P value of < 0.05 considered 
significant (*). 
 
There was a significant decrease in CD4:CD8 T cell ratio in the blood 
of paigen-fed animals compared to chow fed controls (0.52 ± 0.15% vs 0.93 
± 0.20%, n=4/group, P=0.02). There was also a tendency for a decrease in 
115 
 
CD4:CD8 T cell ratio in paigen-fed animals in lung and splenic tissue; 
however these results were not significant (Figure 3.8). 
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Figure 3.8 CD4:CD8 T cell ratio in blood, spleen and lung tissue at 8 weeks in 
chow and paigen-fed ApoE-/-/IL-1R1-/- mice. 
Error bars show mean ± SD and n=4/group. A Mann-Whitney U test with 95% 
confidence intervals was carried out on all data with a P value of < 0.05 considered 
significant (*). 
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There were no differences in the proportion of CD4+CD25high Treg 
cells in paigen-fed animals in the blood, spleen or lung tissue compared to 
chow fed controls (Figure, 3.9).   
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Figure 3.9 Proportions of CD4+CD25highTreg cells in blood, spleen and lung 
tissue at 8 weeks in chow and paigen-fed ApoE-/-/IL-1R1-/- mice. 
Error bars show mean ± SD and n=4/group. A Mann-Whitney U test with 95% 
confidence intervals was carried out on all data with a P value of < 0.05 considered 
significant (*). 
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Taken together these data suggest there is a tendency for a decrease 
in CD4+ T cells in peripheral blood of paigen-fed animals at week 8, however 
Treg cells appear to be protected from this effect and their proportions do not 
decrease. There is a tendency for an increase in the proportions of CD8+ T 
cells in the lung of paigen-fed animals, suggesting a recruitment of these 
cells to the tissue, however neither of these observations are statistically 
significant. 
 
3.3.1.3 Cell marker expression within lung tissue 
 
After noting a change in the proportions of T cell subsets within blood, 
spleen and lung tissue using flow cytometric analysis, a further analysis of T 
cell populations within lung tissue was undertaken using 
immunohistochemistry. To confirm the changes in proportions of T cell 
subsets, previously noted in lung tissue (Chapter 3.3.1.2), 
immunocytochemical analyses were performed on random formalin-fixed, 
paraffin embedded, 5 μm thick sections of lung tissue taken from chow and 
paigen-fed ApoE-/-/Il-1R1-/- animals at each time point. Antibodies against 
CD4, CD8 and CD25 T cells were incubated with tissue sections for 1 hour 
before being analysed (see Appendix 1, section 5 for antibody specifics and 
clone numbers).  
An increase in perivascular CD4+ T cells was noted in paigen-fed 
animals at week 8 compared to chow fed controls (Figure 3.10). Minimal 
staining for CD8+ T cells in paigen-fed animals was noted at 8 weeks 
compared to chow fed controls. An increased amount of CD4+ and CD8+ T 
cell staining was also noted throughout the lung tissue of paigen-fed animals 
at 8 weeks. CD25 staining could not be detected in either chow or paigen-fed 
animals at week 8.   
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Figure 3.10 Representative images of lung sections stained for CD4+ and CD8+ 
T cells from chow and paigen diet–fed mice at 8 weeks. 
Sections were immunostained for CD4 and CD8 markers in chow and paigen-fed 
animals. Images taken at X400 magnification. Arrows depict staining. Scale bar =50 
µm. 
 
 
As previously noted in chapter 4.3.1.2, there is a tendency for a 
decrease in proportions of CD4+ T cells in peripheral blood of paigen-fed 
animals at week 8, but there is no change in the proportion of CD4+ T cells in 
lung and splenic tissue, as confirmed by flow cytometric analysis. However, 
an increase in CD4+ T cells was noted in immunohistochemical analysis of 
lung tissue sections taken from paigen-fed mice at 8 weeks. CD8+ T cells 
appear to be recruited to the lung tissue of paigen-fed animals at week 8 (as 
noted in both flow cytometry and histochemical analysis).  
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3.3.2 Depletion model  
 
There was a tendency for a decreased proportion of CD4+ T cells in 
the blood of paigen fed animals, so I next sought to determine whether 
changes in the proportions of CD4+ T cells in blood and lungs were due to 
the disease itself or were an effect of the disease. I therefore depleted this 
subset within the same model, to confirm whether CD4+ T cells propagated 
or abrogated disease progression.  
 
3.3.2.1 Confirmation of CD4
+
 T cells depletion 
 
Confirmation of CD4+ T cells depletion was undertaken using flow 
cytometry on peripheral blood from 3 randomly selected IgG controls and 3 
CD4 depleted mice at 5 weeks after commencement of paigen diet (1 week 
after finishing the 4 week antibody treatment or IgG control).  
CD4+ T cells were sufficiently depleted in antibody treated animals 
when compared to IgG controls (Figure 3.11). Of note, was the difference in 
proportions of both CD4+ and CD8+ T cells between animals within the IgG 
treatment group. CD4+ T cells ranged from 6.8% to 27.1% and CD8+ T cells 
from 12.5% to 41.8% in this control group. Proportions of both CD4+ and 
CD8+ T cells were low in mouse AL642, which may have been due to an 
increase in CD4-CD8- cells.  
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Figure 3.11 Confirmation of CD4+ T cell depletion in peripheral blood of fat fed 
ApoE-/-/IL-1R1-/- mice  
Confirmation of depletion was undertaken at week 5 (1 week after ceasing either 
CD4 antibody or IgG control). 3 IgG control and 3 CD4 Ab treated mice were 
selected at random to check that the CD4 depletion antibody had taken effect. Anti-
CD3 AF700, Anti-CD4 PB and anti-CD8 APC antibodies were used to detect CD3+, 
CD4+ and CD8+ T cells. Data are expressed as CD4+ (grey) and CD8+ (black) 
populations as a proportion of the total number of CD3+ T cells. IgG treated controls 
are shown on the left and CD4 depletion antibody treated animals (CD4 Ab) are 
shown on the right of the graph. 
 
3.3.2.2 Haemodynamic and vessel remodelling 
analysis 
 
To detect changes in haemodynamics, echocardiography and cardiac 
catheterisation were undertaken at 8 weeks in both CD4 depleted animals 
and IgG treated controls. There was no difference in the weights of CD4 
depleted and IgG control animals at week 0 and week 8. 
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Figure 3.12 Haemodynamic assessment of paigen-fed ApoE-/-/IL1R1-/- mice 
given a CD4+ T cell depletion antibody or an IgG control.  
A) Right ventricular systolic pressure (mmHg). B) Pulmonary artery acceleration 
time (PAAT) (ms). C) Cardiac Index (L/min/m2). RVSP measurements were made 
using closed chest cardiac pressure volume catheterisation, whilst a pressure 
volume catheter was used to assess cardiac output which was then used to derive a 
value of CI. PAAT measurements were taken using Vevo 770 echocardiography 
equipment. Error bars represent mean ± SD and n=4/group. A Mann-Whitney U test 
with 95% confidence intervals was carried out on all data. P< 0.05 considered 
significant (*).  
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There was a trend for an increase in RVSP in CD4 depleted animals 
compared to IgG controls (57.47 mmHg vs 44.66 mmHg, n=4, P=0.3) (Figure 
3.12, A). There was no change in CI in CD4 depleted animals compared to 
IgG treated controls at week 8 (Figure 3.12, C). Doppler ultrasound 
assessment of pulmonary artery acceleration time (PAAT), showed a trend 
for a decrease in CD4 depleted mice compared to IgG treated animals 
(Figure 3.12, B). These data (RVSP, PAAT and CI) are comparable with 
previously published data concerning the fat-fed ApoE-/-/IL-1R1-/- mouse 
model of PAH (Lawrie et al, 2011). 
To determine the effect that CD4+ T cell depletion had on the 
remodelling process within the lungs of fat-fed ApoE-/-/IL-1R1-/- mice, two 
analyses were carried out on lung tissue sections taken from both IgG 
treated and CD4 depletion antibody treated animals. This included assessing 
the degree of muscularisation of the pulmonary arteries and arterioles and 
determining the percentage of total vessels that were muscularised.  
There was a trend for increased media / CSA, as explained in Chapter 
3.2.1.6, in CD4 depleted animals in all vessel sizes compared to IgG 
controls, however this was not significant (Figure 3.13, A). This suggests that 
there is an increased degree of muscularisation within the vessels of CD4 
depleted animals, however this effect is minimal. Elastin van Gieson staining 
was used to assess remodelling in pulmonary vessels, providing a 
measurement of the percentage of vessels that were muscularised. There 
was a trend for an increase in the percentage of muscularised vessels in 
lung sections from CD4 depletion antibody treated animals in small vessels 
(<50 µm) compared to IgG treated controls (Figure 4.13, B). The percentage 
of muscularised medium and large vessels (51-100 µm and >100 µm) were 
no different between groups. Taken together, these data suggest that there 
are a greater number of muscularised vessels that have a greater degree of 
muscularisation in CD4 depleted animals, illustrating a slightly more severe 
disease PAH phenotype in these animals. 
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Figure 3.13 Analysis of number of remodelled vessels and degree of 
remodelling in lung tissue sections in CD4 depleted and IgG treated animals.  
Vessels were split into three different sized groups (<50 µm, 50-100 µm and >100 
µm) as well as those animals treated with IgG control (clear bars) and CD4 
depletion antibody (black bars). A) Media / CSA (cross sectional area) ratio is 
shown for each vessel size. B) Analysis of degree of remodelling in each vessel 
size. Data shown are from musculurised vessels. Error bars represent mean ± SEM, 
n=5-6 per group. Data analysed using a two-way ANOVA with Bonferroni post hoc 
test. P< 0.05 was considered significant (*). 
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3.3.2.3 T cell subset analysis in blood and tissue 
samples 
 
Changes in T cell subsets in CD4 depleted animals were assessed by 
flow cytometry facilitating analyses regarding T cells and disease 
progression at 8 weeks after beginning paigen-fed diet. T cell subsets (CD4+, 
CD8+ and CD4+CD25high) in peripheral blood, spleen and lung tissue of CD4 
depleted and IgG control animals were analysed using flow cytometry after 8 
weeks on paigen diet. A comparison of T cell subsets within the circulation 
and within tissue was then determined.  
The proportion of CD4+ T cells in splenic and lung tissue was 
significantly lower in CD4 depleted animals compared to IgG controls (16.85 
± 7.89% vs 56.20 ± 10.41%, n=4, P=0.02 and 0.31 ± 0.48% vs 2.10 ± 0.64%, 
n=4, P=0.05). There was a trend for a decrease in the proportion of CD4+ T 
cells (as a percentage of total CD3+ T cells) within blood at week 8; however 
this was not significant (Figure 3.14). CD4+ T cell depletion had been 
confirmed at week 5 in CD4 Ab treated animals, however the CD4+ T cell 
subset appeared to be recovering from transient depletion in blood, spleen 
and lung at week 8, as the proportion of CD4+ T cells in the circulation and 
tissue was returning to normal levels. 
The CD4:CD8 T cell ratio was significantly lower in CD4 depleted 
animals in blood (0.27 ± 0.04 vs 0.73 ± 0.42, n=4, P=0.02) lung (2.10 ± 0.64 
vs 0.31 ± 0.48, n=4, P=0.05), and splenic tissue (0.25 ± 0.17 vs 2.15 ± 0.60, 
n=4, P=0.02) at week 8, which correlates with previously shown data 
regarding an increased proportion of CD8+ T cells (Figure 3.15) and 
decreased proportion of CD4+ T cells (Figure 3.14).  
Proportions of Treg (CD4+CD25high) cells remained at similar levels in 
IgG and CD4 depletion treated animals in blood, spleen and lung tissue at 
week 8 (Figure 3.17). There is a large spread of data within the IgG control 
group in both blood and lung tissue, and therefore a larger sample size is 
needed to note any definitive changes in proportions of Treg cells within 
these environments. 
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Figure 3.14 Proportions of CD4+ T cells in blood, spleen or lung tissue of CD4 
depleted animals and IgG treated controls. 
Data from IgG controls (IgG), clear bars, and CD4 Ab treated animals (CD4 Ab), 
black bars are shown. CD4+ T cells are expressed as a proportion of the total CD3+ 
T cell population. Error bars represent mean ± SD, n=4/group. A Mann-Whitney U 
test with 95% confidence intervals was carried out on all data with a P value of < 
0.05 considered significant (*). 
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Figure 3.15 Proportions of CD8+ T cells in blood, spleen or lung tissue of CD4 
depleted animals and IgG treated controls. 
Data from IgG controls (IgG), clear bars, and CD4 Ab treated animals (CD4 Ab), 
black bars are shown. CD8+ T cells are expressed as a proportion of the total CD3+ 
T cell population. Error bars represent mean ± SD, n=3-4/group. A Mann-Whitney U 
test with 95% confidence intervals was carried out on all data with a P value of < 
0.05 considered significant (*). 
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Figure 3.16 CD4:CD8 T cell ratio in blood, spleen or lung tissue of CD4 
depleted animals and IgG treated controls. 
Data from IgG controls (IgG), clear bars, and CD4 Ab treated animals (CD4 Ab), 
black bars are shown. Error bars represent mean ± SD, n=4/group. A Mann-Whitney 
U test with 95% confidence intervals was carried out on all data with a P value of < 
0.05 considered significant (*). 
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Figure 3.17 Proportions of CD4+CD25high Treg cells in blood, spleen or lung 
tissue of CD4 depleted animals and IgG treated controls. 
Data from IgG controls (IgG), clear bars, and CD4 Ab treated animals (CD4 Ab), 
black bars are shown. CD4+ CD25high Treg cells are expressed as a proportion of 
the total CD3+ T cell population. Error bars represent mean ± SD, n=4/group. A 
Mann-Whitney U test with 95% confidence intervals was carried out on all data with 
a P value of < 0.05 considered significant (*). 
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3.3.2.4 Cell marker expression within lung tissue 
 
To assess T cell infiltration into lung tissue, immunohistochemical 
analyses were performed on random formalin-fixed, paraffin embedded 5 μm 
thick sections of lung tissue taken from IgG and CD4 depletion antibody 
treated animals at 8 weeks after beginning paigen-fed diet. These images 
were then compared with data collected by flow cytometric analysis on lung 
tissue samples mentioned previously in Chapter 3.3.2.3. 
 
 
Figure 3.18 Representative images of CD4 and CD8 expression in the lung 
tissue of IgG treated and CD4 depletion antibody treated animals at 8 weeks 
after commencing paigen diet. 
IgG and CD4 depletion antibody (CD4 Ab) treated animals shown. Images taken at 
X400 magnification. Arrows depict staining. Scale bar =50 µm. 
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The number of CD4+ T cells decreased in CD4 depleted animals 
compared to IgG controls within lung tissue (Figure 3.18). Staining for CD4 
was still evident around vessels but was reduced compared to IgG controls 
where perivascular CD4+ T cells were evident. The number of CD8+ T cells 
increased in lung tissue of CD4 depleted animals compared to IgG controls 
and associated vessels. These images correlated with data collected via flow 
cytometric analysis of lung tissue regarding a decrease in CD4+ T cells and 
an increase in CD8+ T cells. There was no staining for CD25 present in either 
CD4 Ab treated animals or IgG treated controls. This was as expected, as 
previous work undertaken in Chapter 3.3.1.3 also revealed no CD25 staining 
at 8 weeks in paigen-fed animals.    
 
3.4  Discussion 
 
Human samples can only provide information regarding end stage 
disease states. Therefore animal models, such as the fat fed ApoE-/-/Il-1R1-/- 
mouse model of PAH, can be utilised to determine changes in T cell subsets 
and other biomarkers along a timecourse of the disease. This allows a 
comparison of T cell subsets at different stages of disease progression with 
vessel remodelling and changes in haemodynamics. Although changes in T 
cell subsets within the peripheral circulation and lung tissue of PAH patients 
has been noted in Chapter 2.3.2 and in previously published literature, it is 
unclear whether these changes occur as a cause or consequence of the 
disease (Tuder et al, 1994; Dorfmuller et al, 2002; Dorfmuller et al, 2003; 
Ulrich et al, 2008; Austin et al, 2010).  
 
3.4.1   ApoE
-/-
/IL-1R1
-/- 
Timecourse 
 
A timecourse of PAH was set up using the fat-fed ApoE-/-/IL1R1-/- 
mouse model of PAH to study changes in T cell subset proportions and 
relate these changes to disease progression (as assessed by 
haemodynamic parameters and vessel remodelling analysis). This was to 
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determine whether changes in T cell subsets were as a cause or 
consequence of the disease. 
In this study no significant changes were noted in any T cell subset 
(CD4+, CD8+ or CD4+CD25high) at any time point, between chow fed and 
paigen fed animals. Confirmation of disease progression was obtained via 
vessel remodelling analysis and was noted to be increased at week 6 and 8. 
This result was unexpected as an increased number of lung tissue infiltrating 
CD4+ T cells has been noted in a previously published study at 1 week after 
endothelial cell injury caused by MCT in Rag1-/- mice (Cuttica et al, 2011). 
Differences in results noted could be due to the way in which PAH was 
initiated and the fact that B cells were also not present in the animals 
included in the study undertaken by Cuttica et al. 
When the 8 week time point was analysed in more detail changes in T 
cell populations in the lung and splenic tissue as well as in the blood were 
noted. There was a tendency for a decreased proportion of CD4+ T cells in 
peripheral blood of paigen fed animals compared to chow fed controls, 
however this was not observed in splenic and lung tissue. A tendency for an 
increase in the proportion of CD8+ T cells was noted within lung tissue of 
paigen fed animals at 8 weeks compared to chow fed controls. An increased 
number of CD8+ T cells were also noted in immunohistological analysis of 
lung tissue sections from these animals, further confirming the increased 
infiltration of CD8+ T cells into the remodelling lung tissue. An increased 
number of tissue infiltrating CD8+ T cells has previously been observed in 
IPAH end-stage lung tissue and it is suspected that a decreased proportion 
of CD8+ T cells in peripheral blood could be due to their migration to lung 
tissue (Ulrich et al, 2008; Austin et al, 2010). Despite this observation in 
human IPAH samples in previous studies, a decrease in of CD8+ T cells was 
not noted in this model at 8 weeks. Proportions of Treg cells did not change 
between groups at week 8 in blood, lung tissue or splenic tissue.  
Unfortunately, no firm conclusions can be drawn from these data, but 
this study reminds us how difficult it is to compare clinical disease with 
animal models. The complexity of the disease and undertaking this work also 
makes studying disease progression and mechanisms of disease difficult. It 
was anticipated that T cell subsets may change in accordance with disease 
132 
 
progression, as infiltrating T cells have been found to precede EC injury and 
vascular remodelling in the rat MCT model of PAH, however this was not 
noted in this diet induced model of PAH (Cuttica et al, 2011). These 
differences may be due to in the induction of disease or could be due to the 
two different animals (rats vs mice) used to investigate the disease.   
 
3.4.2   CD4 depletion model 
 
As a tendency for a decreased proportion of circulating CD4+ T cells 
was noted in the blood of paigen fed animals at week 8, and considering 
previous studies in rat and mouse models of PAH suggested a protective 
effect of CD4+ T cells, a depletion model was set up to determine the effect 
that depletion of CD4+ T cells had on PAH disease progression.  
CD4 depleted animals exhibited a significant elevation in RVSP (57.47 
± 54.00 mmHg compared to 44.66 ± 27.50 mmHg in IgG treated controls) 
and a corresponding decrease in PAAT, confirming that CD4 depleted 
animals have a more severe disease phenotype. An increase in number of 
affected pulmonary vessels and the amount of muscularisation within them 
was also noted in CD4 depleted animals, further confirming increased vessel 
remodelling and disease progression. 
Proportions of CD4+ T cells was significantly reduced in the lungs and 
spleen of CD4 depleted animals compared to controls, but there was only a 
trend for a decrease in CD4+ T cells in the blood of these animals. This could 
be because, after 4 weeks of being on the diet alone without the antibody 
treatment, the CD4+ T cell compartment is being restored in the blood.  
Proportions of CD8+ T cells, as predicted in the CD4 depleted animals, were 
significantly increased in blood, lung and splenic tissue, due to the 
decreased proportion of CD4+ T cells. In future work, the addition of counting 
beads to determine actual cell number will allow for a more detailed view of 
whether the number of CD8+ T cells changes in these animals. Interestingly, 
there was no change in the proportion of Treg cells in the blood, lung or 
splenic tissue of CD4 depleted animals compared to IgG treated controls. 
This could be because the Treg cells are being protected from depletion. 
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However, the reason for this and the mechanism behind this response is 
currently unknown. 
Previous studies in animal models of PAH have suggested a role for T 
cells in both protecting against PAH and propagating its progression In 
athymic rat models of PAH, the induction of PAH using Sugen 5416 with and 
without hypoxia as well as in MCT treatment, has shown T cells to be 
protective. This was due to the fact that when CD4+ T cells were 
reconstituted after initial injury, perivascular injury associated with endothelial 
cell apoptosis and vascular remodelling was reduced. CD4+CD25high Treg 
cells also showed the same response (Miyata et al, 2000; Taraseviciene-
Stewart et al, 2005; Taraseviciene-Stewart et al, 2007; Tamosiuniene et al, 
2011). In euthymic animals, where T and B cell subsets are intact, a 
depletion of CD4+ T cells also increased the animals’ susceptibility to 
developing PAH.  
Despite these studies suggesting a protective role for T cells in the 
development of PAH, RAG-1−/− mice which are devoid of T and B cells, when 
given angiotensin II infusion, desoxycorticosterone acetate or MCT, showed 
a decreased hypertensive response and less vascular remodelling. Adoptive 
transfer of T cells restored the hypertensive phenotype (Guzik et al, 2007; 
Cuttica et al, 2011). These studies in RAG-1−/− mice suggest that in these 
models of PAH, T cells propagate disease progression rather than protect 
against vascular remodelling.  
The role that T cells play in each experimental model of PAH seems to 
be different and makes it difficult to choose an appropriate and reliable 
animal model to study inflammatory mechanisms in PAH. Despite this, T 
cells do appear to be important in PAH disease progression, whether it be in 
a positive or negative way, and therefore warrant further investigation.    
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3.4.3  Concluding remarks 
 
Collectively, these animal studies suggest that T cell subsets are not 
abnormally regulated over time during the progression of PAH disease in the 
fat-fed ApoE-/-/IL1R1-/- and that depletion of CD4+ T cells propagates disease 
progression. This has been noted in another experimental model of PAH in 
which athymic nude rats developed PAH under normoxic conditions due to 
the absence of T cells and MCT treatment (Miyata et al, 2000; 
Taraseviciene-Stewart et al, 2007). These data together with previously 
published data, support the theory that T cells, specifically CD4+ T cells, are 
involved in protecting against disease progression, and it is thought that this 
may be due to the Treg cell subset within this T cell compartment 
(Tamosiuniene et al, 2011).  
Following further investigation, the clinical relevance of this work might 
enable T cell targeted therapy to be undertaken to restore the T cell subset 
regulatory effect and allow for the control of disease progression. 
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Chapter 4  Heat shock protein 70 
expression in pulmonary arterial 
hypertension 
  
4.1   Introduction 
 
A major molecular mechanism underpinning the progression of PAH 
disease is the dysfunction of endothelial processes. This may occur as a 
result of several sources of injury: hypoxia, shear stress or inflammation. 
Dysfunction of the EC layer can upset the balance between vasoconstriction 
and vasodilation, which can then initiate other downstream processes such 
as increased endothelial permeability and indirectly, the generation of 
cytokines (Davignon and Ganz, 2004). In PAH, altered EC proliferation 
results in the formation of plexiform lesions, a common pathological feature 
in clinical PAH (Tuder et al, 1994; Cool et al, 1999). Decreased production of 
endothelial vasoactive mediators such as NO and prostacyclin also leads to 
exuberant SMC growth and eventually structural remodelling of the 
pulmonary arteries (McLaughlin and McGoon, 2006). The stress placed on 
these ECs may cause them to produce and secrete stress proteins in an 
attempt to protect the endothelium from necrosis and apoptosis (Wang et al, 
1995).  
Hsps are a group of extremely conserved proteins that are present in 
intracellular compartments of all organisms. They can also be present in the 
extracellular milieu or associated with the plasma membrane. Hsps have 
been shown to be released by a number of different cell types including renal 
tubular cells (due to oxidative stress), monocytes (due to heat shock), 
PBMCs (due to heat shock), vascular SMCs (due to mechanical force 
stress), T cells (due to glucocorticosteroid-induced stress) and ECs (due to 
heat shock and oxidative stress) (Jornot et al, 1991; Wang et al, 1995; 
Fukuda et al, 1996; Poccia et al, 1996; Bachelet et al, 1998; Xu et al, 2000; 
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Hunter-Lavin et al, 2004). This occurs under a range of conditions, in which 
they have been shown to exhibit a number of pro- and anti-inflammatory 
properties including inducing the production of IL-6 in ECs, SMCs and 
macrophages. Hsps have also been shown to enhance the function of 
regulatory T cell populations, inhibit acute allograft rejection and temper 
inflammatory responses and it has also been suggested that self-Hsp70 
itself, can induce Treg expansion and activation by increasing levels of IL-10 
(Stordeur and Goldman, 1998; Borges et al, 2012). 
As well as pro- and anti-inflammatory properties, Hsps also have been 
shown to have cardio-protective roles. Initially, this was shown in the cardiac 
cell line, H9c2 derived from rat heart, which were protected against thermal 
or ischaemic stress because they over-expressed Hsp70 (Mestril et al, 1994; 
Heads et al, 1995). This protective effect was also seen in primary rat 
cardiac myocyte cultures transfected to over-express Hsp70 and in coronary 
ECs over-expressing Hsp70 (Cumming et al, 1996; Suzuki et al, 1998). The 
expression of cardio-protective Hsps such as Hsp70 in response to inducers 
of stress, such as heavy metal ions or protease inhibitors, is thought to 
protect the stressed endothelium by modulating leukocyte–endothelial 
interactions, reducing the number of adherent leukocytes and their migration 
through the vessel wall (Chen et al, 1996; Lynes et al, 2007). In vitro assays 
have also been undertaken, confirming that Hsp60 can activate immune cells 
such as Treg cells via activation of Toll-like receptor 2, enhancing their 
suppressive capabilities (van Roon et al, 1997; Zanin-Zhorov et al, 2003; 
Zanin-Zhorov et al, 2006). In 1993, Johnson and Tytell noted that Hsp70 
protected the viability of stressed aortic SMCs in vitro via cell surface contact 
rather than internalisation (Johnson and Tytell, 1993). 
The cardioprotective and anti-inflammatory nature of Hsp70 also 
make it an interesting and suitable protein target to investigate within the field 
of hypertensive disease. Several studies have been undertaken in this field. 
The first showed elevated Hsp70 levels in patients with peripheral vascular 
and renal vascular disease whilst Pockley et al noted elevated anti-Hsp70 
and anti-Hsp65 antibody levels in patients with hypertension (Wright et al, 
2000; Pockley et al, 2002). Elevated Hsp70 levels have also been linked to a 
reduced incidence of cardiovascular disease in patients with established 
137 
 
hypertension, further suggesting a link between circulating Hsp70 levels and 
cardioprotection (Pockley et al, 2003). There is however, no data regarding 
circulating levels of Hsp70 in serum or expressed Hsp70 within ECs in 
patients with PAH (IPAH or SSc-PAH). This is also true for experimental 
models of PAH. This research would allow for the differentiation between 
expressed and secreted Hsp70 being involved in the pathogenesis of PAH 
and allow for analysis into whether disease progression alters circulating and 
expressed Hsp70 levels.   
Therefore, the aim of this work was to determine levels of circulating 
Hsp70 in clinical serum samples as well as the expression pattern of 
circulating and expressed Hsp70 in serum and lung tissue using a rat and 
mouse model of PAH. Depletion of CD4+ T cells was also undertaken to 
determine the role of these cells in the pathogenesis of PAH. I aimed to 
ascertain whether Hsp70 expression was driven by the disease, by 
determining the expression of Hsp70 within the lung tissue in IgG treated and 
CD4+ T cell depleted paigen fed animals. The influence that hypoxia (stress) 
has on Hsp70 expression in cultured pulmonary artery endothelial cells (PA-
ECs) was also studied in vitro. This work was undertaken to identify how 
Hsp70 levels relate to disease progression. Based on published literature, I 
hypothesised that changes in pulmonary haemodynamics would cause 
endothelial stress and regulation of Hsp70 which would cause an increase in 
the production and release of Hsp70 from ECs within the pulmonary vessels 
(Jornot et al, 1991; Suzuki et al, 1998; Pockley et al, 2003; Luo et al, 2007; 
Pockley et al, 2009).  
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4.2  Methods 
 
Several in vitro methods were used to determine expression levels 
and localisation of Hsp70 both in murine models of PAH and in clinical 
samples. These are detailed below along with a brief explanation as to why 
they were chosen. 
 
4.2.1 Serum Hsp70 levels in Pulmonary 
Arterial Hypertension  
 
As previously mentioned, elevated Hsp70 levels are associated with a 
reduced incidence of cardiovascular disease in patients with established 
hypertension, however to date, circulating Hsp70 levels in serum have not 
been analysed in IPAH or SSc-PAH patients (Pockley et al, 2003). This work 
therefore aimed to determine Hsp70 levels in the serum of IPAH, SSc-PAH 
patients and healthy controls using the Hsp70 high sensitivity EIA kit which 
has been validated for the measurement of Hsp70 in serum and plasma 
(ENZO Life Sciences, Exeter, UK).  
Serum samples were analysed according to the manufacturer’s 
instructions and the assay contents from the Hsp70 high sensitivity EIA kit 
(see Appendix 1, section 1). Before starting the assay, the wash buffer was 
prepared by adding 50 mL of the supplied wash buffer concentrate to 950 mL 
of deionised water. This was kept at room temperature during the assay. A 
standard curve ranging from 0.2 ng / mL to 125 ng / mL was set up using the 
Hsp70 intermediate standard and assay buffer supplied in the kit. The Hsp70 
intermediate standard was prepared by adding 395 µL assay buffer to 5 µL 
of the 10 μg / mL recombinant human Hsp70. A serial dilution was then 
made to produce standards of 12.5, 6.25, 3.13, 1.56, 0.78, 0.39 and 0.2 ng / 
mL. All samples and standards were kept on ice during the assay. The 
samples were diluted 1 in 2 with assay buffer to remove matrix interference 
in the assay. 100 µL of serum samples and standards were added to an 
ELISA microtiter plate pre-coated with a mouse monoclonal antibody specific 
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to Hsp70 (clone number LK1.1). Standards were run in duplicate while 
samples were run once due to the availability of a limited volume of sample 
from each patient. 100 µL of assay buffer was also added to the control well. 
The plate was sealed then incubated for 2 hours at room temperature. The 
plate was washed by adding 400 µL of assay wash buffer, emptying the 
contents of the wells and repeating these two steps twice more. All traces of 
wash buffer were removed after the third wash by firmly tapping the plate 
onto a paper towel. This left the bound Hsp70 on the plate. 100 µL of rabbit 
polyclonal antibody specific to Hsp70 was then added which bound to the 
captured Hsp70 on the plate. The plate was sealed and incubated for 1 hour 
at room temperature then washed as previously described. 100 µL of 
horseradish peroxidase (HRP) conjugate solution (goat anti-rabbit IgG 
conjugated to HRP) was added to each well except the control well, to bind 
to the previous antibody. The plate was covered and incubated for 1 hour at 
room temperature, then washed as before to remove excess HRP conjugate 
solution. 100 µL of 3,3’,5,5’-Tetramethylbenzidine (TMB) substrate was 
added to each well except the control to generate a detectable blue colour. 
The plate was then covered and incubated for 30 minutes at room 
temperature before 100 µL of stop solution was added to stop the substrate 
reaction. After zeroing the microplate reader against the substrate blank 
control well, the optical density (resultant yellow colour) was read at 450 nm. 
The amount of signal is directly proportional to the level of Hsp70 in each 
sample. The plate was also read at an irrelevant wavelength and the 
readings subtracted from this reading to remove cross-plate variation in 
optical properties. Data was analysed with a 4-parameter logistic curve fit 
using GraphPad Prism version 5.00 for Windows. Unknown sample values 
were quantified against this standard curve. The sensitivity was determined 
by interpolation at 2 standard deviations above the mean signal at 
background (0 ng / mL). The inter-assay coefficient of variation was 12.8% to 
19.1% and the intra-assay coefficient of variation was 3.9% to 11.4% for this 
kit.  
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4.2.2  Hsp70 levels in rat monocrotaline 
serum 
 
An animal model of PAH was also set up to identify changes in serum 
Hsp70 levels in relation to disease progression. The rat MCT model of PAH 
is a well characterised model of PAH. MCT, when given to rats causes tissue 
damage in the lung, including cellular infiltration into the interstitium, 
endothelial injury and thickening of the medial wall of small pulmonary 
arteries which gives rise to PAH (Ghodsi and Will, 1981; Reindel and Roth, 
1991; Roth and Reindel, 1991; Miyata et al, 2000). It is thought to be the 
most aggressive form of PAH in any animal model and works by directly 
damaging the vascular endothelium and eventually leads to lethal PAH 
(Dumitrascu et al, 2008; Stenmark et al, 2009). The samples used in this 
study were archived serum samples that had been generated in a previous 
study undertaken by Dr Abdul Hameed and stored at -80˚C for <6 months 
(Hameed et al, 2009). For the induction of PAH, male Sprague Dawley rats 
(Charles River, UK) were given a single subcutaneous injection of MCT 
(Sigma Aldrich, Dorset, UK) at a dose of 60mg / kg. Serum samples were 
collected on day 2,7,14, 21 and 28 post MCT injection and analysed for 
circulating Hsp70 levels.  
Based on previously published literature, I hypothesised that levels of 
serum Hsp70 would increase in MCT treated rats as vascular remodelling 
became evident (Pockley et al, 2003). The Hsp70 high sensitivity EIA kit was 
used to analyse serum samples from a time course (2, 7, 14, 21, 28 days 
after MCT administration, n=4 / group) of samples from a MCT model of 
PAH. Serum samples were diluted 1 in 4 using assay buffer supplied with the 
kit to remove matrix interference. This dilution was chosen after a pilot study 
was performed on several dilutions of the same rat serum sample to 
determine which dilution fell within the range of the kit. All reagents were 
supplied with the kit, which was used according to the manufacturer’s 
instructions, as previously mentioned in Chapter 4.2.1.  
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4.2.3 Hsp70 expression in lung tissue from 
animal models of pulmonary arterial 
hypertension 
 
Intracellular expressed Hsp70 levels were also analysed in lung tissue 
of MCT treated animals and compared against IgG control animals. This was 
to determine whether circulating Hsp70 levels (analysed in serum samples 
derived from clotted blood samples) correlated with tissue expressed Hsp70 
levels. There is little evidence to show that stressed ECs produce Hsp70 in 
response to heat shock or ischaemic stress, however their production of 
other Hsps is well documented (Jornot et al, 1991; Li et al, 1992; Xu et al, 
1994; Wang et al, 1995; Piotrowicz et al, 1997; Pfister et al, 2005). Despite 
this, it is possible that ECs express Hsp70 in response to stress and 
therefore this matter needed to be evaluated further.  
As increased intracellular levels of Hsp70 have also been noted in 
patients with end stage vascular disease, I hypothesised that Hsp70 levels in 
the lung tissue would be increased in MCT treated animals as the disease 
progressed (Wright et al, 2000).  
Immunohistochemistry using a mouse mAb against Hsp70 (clone 
number C92F3A-5), was used to assess Hsp70 expression within the lung 
tissue of MCT treated and saline treated animals at different time points after 
MCT injection. Paraffin embedded lung sections (kindly obtained from Dr 
Abdul Hameed) were analysed as previously described in Chapter 3.2.1.4 
and 3.2.1.5. A citrate buffer antigen retrieval step was used and a 
biotinylated goat anti-mouse IgG secondary antibody was used to detect the 
primary antibody (Appendix 1, section 5). Stained slides were analysed using 
a camera mounted on a light microscope utilising NIS-elements software 
version 3.0. 
A second experimental model of PAH, the fat fed ApoE-/-/IL1R1-/- 
mouse model (previously described in Chapter 3.2.1) was also used to 
further confirm that disease progression has an effect on Hsp70 expression 
within the lung tissue of diseased animals. Depletion of CD4+ T cells, thought 
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to propagate disease progression within fat fed ApoE-/-/IL1R1-/- mice was also 
thought to alter Hsp70 expression in tissues, as the disease was predicted to 
be more severe, and therefore there would be more remodelling 
(Taraseviciene-Stewart et al, 2007). It was considered that an increase in 
vascular remodelling would lead to an increase in Hsp70 tissue expression 
levels, as several cell types involved in this vascular remodelling process 
(SMCs and ECs) have been shown to express Hsp70 in response to stress 
(Jornot et al, 1991; Xu et al, 1997; Liao et al, 2000).   
The primary Hsp70 antibody used to detect Hsp70 using 
immunohistochemistry techniques had no manufacturer recommended 
dilution,  so several were tried to optimise staining within mouse lung tissue 
(1 in 50, 1 in 100, 1 in 200, and 1 in 500) including antigen retrieval with 
citrate buffer to strengthen the staining signal (see Appendix 1, section 5). A 
negative control of PBS with secondary antibody was used with all 
optimisation protocols. After optimisation of the staining procedure, Hsp70 
expression was assessed using a 1 in 500 dilution (diluted in PBS) of a 
monoclonal anti-mouse Hsp70 primary antibody (clone number C92F3A-5) 
and incubated for 1 hour at room temperature. A biotinylated monoclonal 
goat anti-mouse secondary antibody was used to detect the primary antibody 
at a 1 in 200 dilution in PBS. This was incubated for 30 minutes at room 
temperature.  An antigen retrieval step, using citrate buffer (see Appendix 1, 
section 5) was carried out for 20 minutes before blocking non-specific 
binding of the primary antibody with 1% w/v milk buffer. Vectastain Elite ABC 
working reagent was then added and DAB substrate (3, 3'-diaminobenzidine) 
used to detect colour formation and Carazzi’s Haematoxylin was used to 
stain the nuclei of cells. Sections were analysed and images captured using 
a camera mounted on a light microscope and NIS-elements software.    
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4.2.4 Influence of hypoxia on Hsp70 
expression by cultured pulmonary 
artery endothelial cells 
 
Hypoxia, the impaired oxygen supply to tissues, can affect ECs lining 
vessels in a variety of ways, including altering the transcription of certain 
genes and changing vascular tone (Mehta et al, 1988). This occurs via the 
upregulation and release of inflammatory mediators and growth factors in an 
effort to initiate processes such as angiogenesis (Faller, 1999; Michiels et al, 
2000). Under hypoxic conditions, ECs can change their metabolic states and 
produce reactive oxygen species in an attempt to undertake anaerobic 
glycolysis (Paternotte et al, 2008). The long term effects of a hypoxic 
environment on ECs can be irreversible remodelling of the vasculature and 
SMC proliferation (Faller, 1999). Chronic hypoxia is also thought to increase 
eNOS production of NO via glutathione oxidation, which can lead to an 
increase in Hsp production (Kim et al, 1997; Shipp et al, 2012).  
In PAH, the impact that hypoxia has on vessel remodelling is unclear, 
however it is thought that hypoxic conditions could lead to increased SMC 
proliferation and extracellular matrix deposition. The cellular changes that 
occur due to hypoxia are also noted in end-stage PAH patients, thereby 
further emphasising the importance of hypoxia in the development of PAH 
(Chan and Loscalzo, 2008). However, little is known about how EC Hsp70 
expression relates to disease progression, and whether as previously stated, 
Hsp70 is involved in cardioprotection (Pockley et al, 2003).  
Therefore, to determine the effect of hypoxia on the Hsp70 expression 
profile in ECs, an in vitro method using cultured PA-ECs was established 
and Hsp70 protein and RNA expression assessed. The aim of these 
experiments was to assess the expression of intracellular and secreted 
Hsp70 in cell lysate and supernatant samples taken from cultured PA-ECs 
under hypoxic and normoxic conditions. I therefore hypothesised that Hsp70 
expression and release would increase in hypoxic conditions on PA-ECs. 
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4.2.4.1  Pulmonary artery endothelial cell culture 
 
PA-ECs (Cascade Biologics of Life Technologies Ltd, Paisley, UK) 
were thawed from frozen stocks (stored at -150˚C) and resuspended in M200 
complete culture medium. Cells were grown in 75 cm2 culture flasks in a 
humidified 37°C incubator with 5% v/v CO2 and passaged as they reached 
80-90% confluence (approximately every 7 days) using Trypsin-EDTA 
(0.05% v/v trypsin and 0.5 mM EDTA). Cells were maintained in M200 
complete growth medium supplemented with 10% v/v FCS, 1% w/v penicillin 
and 1% w/v streptomycin.  
 
4.2.4.2  Hypoxic cell culture and sample collection 
 
For hypoxic studies, PA-ECs were cultured in M200 complete growth 
medium before being removed from the flask and transferred to M199 media 
(2% v/v FCS in complete growth medium) (see Appendix 1, section 2) to 
align all cells to the same point in the cell cycle before inducing Hsp70 
expression in hypoxic conditions. Hsp expression has been shown to be 
upregulated in S phase of the cell cycle in HeLa cells, and so to avoid 
inaccurate results due to cell-cycle specific expression of Hsp70, the cells 
were aligned to the same point  (Milarski and Morimoto, 1986). 
PA-ECs were cultured under normoxic (21% v/v O2 and 5% v/v CO2) 
and hypoxic (1% v/v O2 and 5% v/v CO2) conditions in M199 media  in order 
to mimic the physiological conditions of the pulmonary endothelium in PAH  
(hypoxic environment within the remodelling vessels). A range of different 
passage numbers (3-8) were used to ensure that the response seen was not 
due to the age of the cells. 
Two 6-well flat bottomed plates were coated with collagen before 
being rinsed in PBS three times for each time point. For collagen coating, 2 
mL collagen stock (see Appendix 1, section 2) was added to each well on the 
6-well plate. This was left to incubate for 1 hour at room temperature before 
being removed and the plate washed 3 times with sterile PBS. PA-ECs were 
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seeded onto the 6-well plate at 12x104 cells / mL with 2 mL of M199 media in 
each well. Plates were then placed in either a hypoxic (Ruskinn, Bridgend, 
UK) or normoxic incubator (Sanyo, Loughborough, UK) for 6, 12, 24, 48 or 
72 hours.   
At these time points, the plates were collected from the incubators and 
the supernatants removed and stored at -80˚C in cryovials. The plates were 
then washed with PBS on ice three times to remove any traces of 
supernatant. All traces of PBS were removed by firmly tapping the plates 
onto paper towels before 200 µL of boiling lysis buffer (see Appendix 1, 
section 2) was added to each well to form a layer across the whole surface 
for 5 minutes. A cell scraper was used to detach all the cells and the lysate 
was then transferred to a 1.5 mL microfuge tube, before being boiled for 
another 5 minutes at 100˚C. The lysate samples were each split into two, 
centrifuged at 12000 x g for 10 minutes at 4˚C, the supernatant removed and 
the cell pellets stored at -80˚C. One lysate sample was then used in a protein 
assay and Hsp70 singleplex multibead kit whilst the other was used to 
extract RNA and protein using an AllPrep RNA/Protein Kit.  
 
4.2.4.3 Quantification of Hsp70 in cell lysate and 
supernatant samples 
 
At a later date, a protein assay was undertaken to detect levels of total 
protein in 1 sample of each cell lysate (BioRad DC protein assay, 
Hertfordshire, UK). This protein assay was chosen as it could be used with 
the detergent in the lysis buffer without complications. This was performed 
according to the manufacturer’s instructions. Briefly, working reagent A was 
prepared by adding 20 µL of reagent S (surfactant solution) to 1 mL of 
reagent A (alkaline copper tartrate solution). Protein standards were 
prepared with a range of 0.2 mg / mL to 1.5 mg / mL using the Protein 
standard I provided (1.5 mg / mL). This was originally a lyophilised 
preparation, which was rehydrated in 20 mL dH20. Protein standards 
included 1.5, 0.75, 0.5 and 0.2 mg / mL. 5 µL of standards and samples were 
pipetted in duplicate onto a clean, dry microtitre plate. 25 µL of working 
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reagent A was added to each well. This binds protein to a coloured chelate 
complex with cupric ions (Cu2+) in an alkaline environment with tartrate 
solution. 200 µL reagent B (Folin reagent) was then added to each well. The 
plate was then left for 15 minutes at room temperature. In this part of the 
reaction, folin is reduced producing a blue colour which can be measured. 
The optical density was read at 750 nm. The plate was also read at an 
irrelevant wavelength and the readings subtracted from this reading to 
remove cross-plate variation in optical properties. Data were analysed with a 
4-parameter logistic curve fit using GraphPad Prism version 5.00 for 
Windows. Data gained from the protein assay were then used to normalise 
the protein samples which were diluted appropriately with PBS to a 
concentration of 300 µg / mL (as this was the lowest total protein amount 
previously determined). 
The supernatant samples were defrosted to room temperature and 
were concentrated using a centrifugal protocol using Amicon Ultra-2 3K 
devices (originally Millipore Corporation, Massachusetts, USA) according to 
the manufacturer’s instructions. A previous pilot study undertaken by myself 
had shown that Hsp70 levels in unconcentrated supernatant samples were 
below the detection limit of the Hsp70 singleplex multibead kit, and therefore 
they were concentrated for future assays.  Briefly, this involved inserting the 
Amicon Ultra-2 devices into filtrate collection tubes. The supernatant 
samples were then added to the devices and covered with collection tubes. 
These were pushed firmly onto the devices and the filter devices placed into 
a swinging bucket rotor centrifuge for 60 minutes at 3000 x g. The device 
was removed from the centrifuge, and the Amicon Ultra-2 devices separated 
from the filtrate collection tubes. The Amicon Ultra-2 filter devices were then 
inverted and placed back in the centrifuge to spin for 2 minutes 3000 x g to 
transfer the sample from the devices to the collection tubes. After 
concentration, the samples were stored at -80˚C.  
The stored lysate and supernatant samples were analysed using the 
Hsp70 singleplex multibead kit to assess Hsp70 expression. Samples were 
defrosted and kept on ice before use. They were run either neat (supernatant 
samples) or at a concentration of 300 µg / mL (lysate samples). All reagents 
were supplied with the kit and the assay was performed according to the 
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manufacturer’s instructions. For reagent preparation, working 
HSP/Chaperone Multibead Buffer (termed wash buffer from now onwards) 
was prepared by adding 2 mL HSP/Chaperone Multibead Buffer solution to 
18 mL water. Working Hsp70 capture beads were prepared to a working 1X 
stock by adding 60 µL of stock Hsp70 capture beads to 1440 µL of assay 
buffer. Working strep-PE conjugate was also made to a 1X stock by adding 
120 µL strep-PE conjugate stock to 2880 µL assay buffer. Working Hsp 
antibody was made to a 1X stock by adding 120 µL Hsp antibody stock to 
2880 µL assay buffer. Standards were prepared by adding 1250 µL assay 
buffer to the defrosted standard cocktail vial, before vortexing briefly and 
being left at room temperature for 5 minutes. The vial was then vortexed 
briefly again and was ready for use. Standards ranging from 1.37 to 1000 ng 
/ mL were prepared including 1000 ng / mL, 333.3 ng / mL, 111.1 ng / mL, 
37.04 ng / mL, 12.35 ng / mL, 4.17 ng / mL and 1.37 ng / mL. 25 µL of each 
sample and standard were pipetted into labelled 17 x 100 mm polypropylene 
test tubes. Standards were run in duplicate whilst samples were run once as 
sample volume was limited.  
25 µL of chaperone buffer was added to two additional tubes labelled 
“standard 0” and “setup tube”. 25 µL of working Hsp70 capture beads was 
added to each tube including all standards and the setup tube. The tubes 
were covered with foil and incubated for 1 hour at room temperature. The 
tubes were then washed 3 times by adding 500 µL working wash buffer per 
tube, centrifuging at 200 x g for 5 minutes and aspirating the supernatant. 
This was repeated another 2 times to give a total of 3 washes. 50 µL working 
Hsp70 antibody reagent was then added to every tube. The tubes were 
covered with foil and incubated at room temperature for an hour before being 
washed 3 times with working wash buffer as previously mentioned. 50 µL 
working step-PE conjugate was added to every tube and covered with foil 
before incubating at room temperature for 30 minutes. The tubes were all 
washed 3 times as previously described and 250 µL working wash buffer 
added to each tube before the samples were analysed on an LSRII flow 
cytometer (BD Biosciences, Oxford, UK). The setup tube was used to detect 
the Hsp70 capture beads which were gated around in a forward and side 
scatter plot. A stopping gate of 1000 events was set up and a threshold of 
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5000 was used to remove cell debris. Data obtained were collected as 
median fluorescent intensity and analysed with a 4-parameter logistic curve 
fit using GraphPad Prism version 5.00 for Windows, so that sample 
concentrations of Hsp70 could be read as ng / mL. Unknown samples were 
quantified against this standard curve. The sensitivity was determined by 
interpolation at 2 standard deviations above the mean signal at background 
(0 ng / mL). The inter-assay coefficient of variation was 5.9% to 16.6% and 
the intra-assay coefficient of variation was 3.1% to 6.2% for this kit. 
 
4.2.4.4 Quantification of Hsp70 in isolated RNA 
samples 
 
A second set of cell lysate samples were used to purify and remove 
total protein and RNA. Levels of Hsp70 within RNA samples were measured 
whilst the protein samples were used by myself in another study measuring 
Hsp60 levels; however this work is not included in this thesis. RNA and 
protein were collected using the AllPrep RNA/Protein Kit according to the 
manufacturer’s instructions.  
The Protein Cleanup spin columns were vortexed gently to resuspend 
the resin before the caps were loosened a quarter turn. The bottom closures 
were then snapped off and the columns placed in 2 mL collection tubes that 
had been supplied. These were then centrifuged for 3 minutes at 750 x g. 
The Protein Cleanup spin columns were then equilibrated by adding 500 µL 
PBS, vortexing gently and centrifuging for 3 minutes at 750 x g. The Protein 
spin columns were then transferred to clean microcentrifuge tubes. Cell 
lysate samples collected previously in Chapter 4.2.4.2 were defrosted and 
kept on ice. They were then homogenised by pipetting up and down several 
times before being pipetted into AllPrep spin columns in 2 mL collection 
tubes. These were then centrifuged for 1 min at 7000 x g. At that point, the 
AllPrep spin columns contained the bound RNA and the flow through 
contained the total protein. The flow through (containing total protein) was 
then added dropwise onto the centre of the slanted gel bed in Protein 
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Cleanup spin columns. These were centrifuged for 3 minutes at 240 x g. The 
Protein Cleanup spin columns were then removed from the microcentrifuge 
tubes. The flow through solution contained purified total protein which was 
stored at -80˚C. 
AllPrep spin columns were then placed in new 2 mL collection tubes 
and 350 µL Buffer RLT added to each. The columns were centrifuged for 1 
minute at 7000 x g. 350 µL of 70% v/v ethanol was added to the flow 
throughs and mixed. 700 µL of each sample was then added to separate 
RNeasy spin columns which had been placed in 2 mL collection tubes. The 
lids were closed and the columns spun for 1 minute at 7000 x g.  The flow 
throughs were discarded and 700 µL Buffer RW1 was added to each 
RNeasy spin column. The lids were closed and the columns spun for 30 
seconds at 7000 x g. The flow throughs were discarded and 500 µL Buffer 
RPE was added to each RNeasy spin column. The lids were closed again 
and the columns spun for 30 seconds at 7000 x g to wash the spin column 
membranes. The flow throughs were discarded and this step was repeated. 
The RNeasy spin columns were then centrifuged for 1 minute at full speed to 
remove residual wash buffer, then placed in new 1.5 mL collection tubes and 
40 µL of RNase-free water was added directly to each spin column 
membrane. The lids were closed and the columns centrifuged for 1 minute at 
7000 x g to elute the RNA. The RNA samples were used immediately to 
transcribe cDNA for use in a real-time PCR reaction.  
For reverse transcription of RNA to cDNA, 1 µL of all RNA samples 
was analysed on the Thermo Scientific NanoDrop™ 1000 
Spectrophotometer (Thermo Fisher Scientific, Hemel Hempstead, UK) to 
calculate RNA concentration. Briefly this involved adding 1 µL of RNA onto 
the lower measurement pedestal, closing the sampling arm to initiate a 
spectral measurement and the operating software on the computer collecting 
measurements.  Results were used to calculate the volume of each sample 
needed to run 2 µg RNA in a RT-PCR reaction.  
The high capacity cDNA reverse transcription kit (Applied Biosystems 
of Life Technologies Ltd, Paisley, UK) was used to convert 2 μg RNA into 
cDNA. This involved adding 10 µL 2X RT master mix to each tube of a PCR 
microtube and cap strip (Sigma-Aldrich, Dorset, UK). To make the master 
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mix, 2 µL 10X RT buffer was added to 0.8 µL 25X dNTPs, 2 µL 10X reverse 
transcriptase random primers, 1 µL MultiScribe™ reverse transcriptase, 1 µL 
RNase inhibitor and 3.2 µL nuclease free water. The volume of RNA sample 
required was made up to 10 μL with sterile H2O and the samples were added 
to each tube of the PCR microtube and cap strip. The master mix was 
incubated for 1 hour at 37°C and then 95°C for 5 minutes in a PCR machine 
(G-storm, East Sussex, UK) as these parameters had been used previously 
within the laboratory. 
 The resulting cDNA samples were used for real-time PCR 
amplification of Hsp70. For this, 15 µL cDNA was added to 52.5 µL RNase 
free water. An RT negative sample was also added to 52.5 µL RNase free 
water. The cDNA negative control contained just 67.5 µL RNase free water. 
For the primer control, 25 µL of each primer was added in separate tubes to 
250 µL of the TaqMan Gene Expression Master Mix (master mix). The 
master mix contains AmpliTaq Gold® DNA Polymerase, UP (Ultra Pure), 
Uracil-DNA glycosylase, dNTPs with dUTP, ROX™ Passive Reference and 
Optimised buffer components. The primers for Hsp70 and ATP3 (as a 
control) (both from Applied Biosystems Biosystems of Life Technologies Ltd, 
Paisley, UK) were used in this assay. A total of 5.5 µL of each primer was 
then added to 4.5 µL of diluted cDNA in duplicate on the microplate. The 
plate was covered with a MicroAmp™ Optical Adhesive Film and analysed 
on a 7900HT Real-Time PCR system (Applied Biosystems of Life 
Technologies Ltd, Paisley, UK). For the reaction the thermal cycling 
conditions were set to a UDG Incubation step of 2 minutes at 50°C, followed 
by a step for enzyme activation for 10 minutes at 95°C finally followed by a 
PCR step for 40 cycles in which a denaturing step (15 seconds at 95°C) and 
an annealing and elongation step (1 minute at 60°C) occur. Sequence 
Detection System (SDS) version 2.3 software was used to automatically 
calculate the baseline and threshold for the amplification curves and Relative 
quantification (delta, delta CT) for the Hsp70 gene was determined using 
GraphPad Prism. ΔCT was calculated as the difference in CT values 
between Hsp70 and ATP5B and Hsp70 was normalised against ATP5B. 
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4.3  Results  
 
4.3.1  Circulating Hsp70 levels in pulmonary 
arterial hypertension 
 
Analysis of Hsp70 levels in serum samples taken from IPAH and SSc-
PAH patients and healthy controls was undertaken using the Hsp70 high 
sensitivity EIA kit; however Hsp70 serum levels in patients and controls were 
below the detection limit (0.2 ng / mL). The standard curve for this 
experiment is shown below (Figure 4.1). In future tests, concentrating the 
human serum samples before running the Hsp70 high sensitivity EIA kit 
would provide more reliable results, as the resulting data points would fall 
within the linear range of the standard curve. 
 
 S ta n d a rd  c o n c e n tra t io n s
(n g  /  m L )
H s p 7 0  c o n c e n tra t io n
(n g /m L )
0 5 1 0 1 5
0 .0
0 .1
0 .2
0 .3
 
Figure 4.1 Standard curve for Hsp70 levels in human serum samples. 
Standard curve produced using the Hsp70 high sensitivity EIA kit. Standards of 
12.5, 6.25, 3.13, 1.56, 0.78, 0.39 and 0.2 ng / mL were setup. 
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4.3.2  Hsp70 levels in rat serum  
 
As Hsp70 serum levels in patient samples could not be detected using 
the available kit, circulating Hsp70 levels in serum from the rat MCT model of 
PAH were assessed to determine whether Hsp70 levels changed with 
disease progression. 
There was a failure of an increase in levels of circulating Hsp70 in 
MCT treated animals at day 14 compared to saline controls (3703 ± 2596.0 
pg / mL vs 2007 ±  475.6 pg / mL respectively, n=4/group, P=0.01) (Figure 
4.2). 
Unfortunately serum samples from the fat fed ApoE-/-/IL1R1-/- mouse 
model of PAH were not available due to a limited blood sample size 
collected, however tissue was available for both the MCT rat model and the 
fat fed ApoE-/-/IL1R1-/- mouse model of PAH, and these were used to 
investigate the expression and localisation of Hsp70 within the lung tissue. 
 
 
Figure 4.2 Serum Hsp70 levels in the MCT rat and saline-treated controls.  
Saline (white bars) and MCT treated (black bars) animals at time points of 2, 7, 14, 
21 and 28 days. n=4 per group and data as ± SEM is shown. Detection limit set to 
lowest standard ± 2 SD (640 pg / mL). Data at each time point were analysed using 
a two-way ANOVA with a Bonferroni post hoc test where P< 0.05 is considered 
statistically significant (*). 
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4.3.3  Hsp70 expression in the lungs of rat 
and mouse models of pulmonary 
arterial hypertension 
 
After identifying a decrease in circulating Hsp70 within the serum of 
MCT treated rats at 14 days post injection, I next examined the localisation 
and distribution of Hsp70 within the lung tissue in the MCT rat model of PAH 
and the fat fed ApoE-/-/IL1R1-/- mouse model of PAH. This was to determine 
whether circulating levels of Hsp70 correlated with tissue expressed Hsp70 
within the lung, as this is the main site of vascular remodelling in PAH. The 
process of vascular remodelling is thought to induce stress protein 
expression due to the stressful nature of the environment (hypoxia, sheer 
stress and inflammation). I hypothesised that Hsp70 expression would 
correlate with disease severity. Immunohistochemistry to detect Hsp70 
protein expression was performed on paraffin embedded lung sections taken 
from both MCT and saline-treated animals at 2, 7, 14, 21 and 28 days post 
injection as well as fat fed ApoE-/-/IL1R1-/- mice at weeks 1 to 8. No Hsp70 
expression was noted in either MCT or saline treated animals. 
A second animal model of PAH (fat fed ApoE-/-/IL1R1-/- mouse) was 
therefore studied for changes in Hsp70 expression within diseased tissue, as 
the disease developed. Hsp70 was detected in a much larger number of 
perivascular inflammatory cells at all time points in fat fed ApoE-/-/IL1R1-/- 
mice compared to chow fed controls (Figure 4.3). Inflammatory cell infiltration 
into the lung tissue is more markedly apparent in this model which 
corresponds to the areas of high Hsp70 expression, suggesting that 
perivascular inflammatory cells are the source of the Hsp70, not the 
endothelium itself. In future work, it would be of interest to determine the 
exact identity of these cells that are expressing Hsp70 using a dual staining 
immunohistochemistry protocol. 
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Figure 4.3 Hsp70 expression in lung tissue of fat fed ApoE-/-/IL1R1-/- mice and 
chow fed controls. 
Representative images of Hsp70 expression at weeks 1 to 8 after commencing paigen or 
chow fed diet in ApoE
-/-
/IL1R1
-/-
 mice. All images taken at 400X magnification. 
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CD4+ T cells are thought to be involved in the pathogenesis of PAH 
and have been found associated with plexiform lesions within the lung tissue 
of IPAH patients (Tuder et al, 1994). However, it is still unknown whether 
they are functioning to regulate the disease or propagate its progression. 
Therefore, to study the role of these cells within PAH, CD4+ T cells were 
depleted in the paigen fed ApoE-/-/IL1R1-/- mouse of PAH and disease 
progression assessed.  
I aimed to determine whether Hsp70 expression was driven by the 
disease, by determining the expression of Hsp70 within the lung tissue in IgG 
treated and CD4 depleted paigen fed animals. I hypothesised that due to the 
infiltration of Hsp70-expressing inflammatory cells into the lung tissue of 
remodelling vessels noted previously in the paigen fed ApoE-/-/IL1R1-/- mouse 
of PAH, that removal of CD4+ T cells may affect Hsp70 expression in lung 
tissue of CD4 depleted animals.  
 
 
Figure 4.4 Hsp70 expression in lung tissue from paigen fed ApoE-/-/IL1R1-/- 
mice after CD4+ T cell depletion. 
Green arrows show location of Hsp70 staining specific to inflammatory cells. Images 
taken at X400 magnification.  
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Depleting CD4+ T cells rendered these animals more susceptible to 
PAH, as proven by an increase in RVSP and an increased number of 
remodelled vessels (Chapter 3.3.2.2). Hsp70 expression in CD4 depleted 
animals was markedly reduced, suggesting that as there were inflammatory 
cells expressing Hsp70 in IgG treated controls, that CD4+ T cells may be the 
source of the Hsp70 in these animals (Figure 4.4). Depleting CD4+ T cells 
had no effect on the expression of Hsp70 on ECs as Hsp70 was again not 
noted in ECs.  
 
4.3.4  Effect of hypoxia on cultured 
pulmonary artery endothelial cell 
Hsp70 expression 
 
Hypoxia is thought to be involved in the development of PAH via its 
effects on SMC proliferation and vessel remodelling, however little is known 
about its effects on EC expression of Hsps. Therefore, to determine the 
effect of hypoxia on Hsp70 expression in ECs, an in vitro method using PA-
ECs was established and Hsp70 protein and RNA expression assessed.  
In cell lysate samples, levels of Hsp70 protein did not significantly 
change when compared to normoxic samples. Hsp70 levels in lysates from 
normoxic and hypoxic cells increased throughout the time course, but were 
comparable in each condition (Figure 4.5, A). 
Quantitative real time-PCR was also used to quantify levels of Hsp70 
gene expression in cell lysate samples taken from PA-ECs cultured in either 
hypoxic or normoxic conditions at several time points. Data were normalised 
to ATP5B gene content and are shown in Figure 4.5, B.  
There is a significant decrease in the relative expression of Hsp70 in 
hypoxic lysates compared to normoxic lysates at 6 hours (2.26 ± 0.36 vs 
13.78 ± 3.58, n=2-3, P=0.02), however, relative expression levels of Hsp70 
remain low in both normoxic and hypoxic conditions at 24 and 48 hour time 
points.  
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Figure 4.5 Levels of Hsp70 protein and RNA expression in hypoxic and 
normoxic cell lysates. 
Normoxic groups are shown as clear bars and hypoxic groups as black bars. Data 
as ± SEM are shown. A) Hsp70 levels in cell lysates from cultured PA-ECs in 
normoxic and hypoxic conditions for 6 - 72 hours, n=3-10. B) Relative expression of 
Hsp70 RNA at 6 - 48 hours in normoxic and hypoxic cell lysates, n=2-3. Data at 
each time point were analysed using a two-way ANOVA with a Bonferroni post hoc 
test where P< 0.05 is considered statistically significant (*). 
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4.4  Discussion 
 
Previous studies undertaken by Pockley et al have demonstrated that 
elevated Hsp70 levels correlate with a reduced incidence of cardiovascular 
disease in patients with established hypertension, however little is known 
about the cardioprotective effects of Hsp70, especially within the setting of 
PAH (Pockley et al, 2003). Little evidence also exists on whether ECs 
express Hsp70 in response to heat shock or ischaemic stress and to what 
extent this expression protects the stressed endothelium from necrosis and 
apoptosis (Wang et al, 1995; Zhu et al, 1996; Amrani et al, 1998; Luo et al, 
2007).  
Therefore, the aim of this work was to determine levels of circulating 
Hsp70 in clinical end stage disease serum samples as well as the expression 
pattern of circulating and expressed Hsp70 in serum and lung tissue in 
animal models of PAH. The effect that altered disease progression had on 
expression of Hsp70 in endothelial and inflammatory cells was also 
assessed in a CD4 depletion model to determine whether Hsp70 expression 
was driven by the disease. The influence of hypoxia on EC Hsp70 
expression was also assessed in vitro to determine how Hsp70 levels relate 
to disease progression. Immunohistochemistry was also undertaken on 
mouse and rat lung tissue from animal models of PAH to determine cellular 
location of Hsp70 expression along a time course of the disease. This work 
aimed to address these gaps in knowledge surrounding Hsp70 and its 
expression in PAH patients and experimental models. 
Circulating levels of Hsp70 were below the detection limit of the kit 
used in serum samples from healthy controls and PAH patients. In future, 
either the serum needs to be concentrated before use, a Western blot used 
to quantify Hsp70 protein levels or a more sensitive ELISA may need to be 
used in order to quantify Hsp70 in serum from PAH patients. This is the only 
commercial kit available to detect Hsp70 in human plasma and serum 
samples, and has been used by several groups to detect circulating Hsp70 
levels in a variety of conditions. In one study undertaken in healthy 
volunteers and patients with chronic fatigue syndrome, levels of circulating 
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Hsp70 between 0.9 and 1.5 ng / mL were recorded (Jammes et al, 2009). 
Similar levels have also been reported in patients with hepatic stenosis, after 
coronary bypass and in resting healthy individuals (Dybdahl et al, 2002; 
Fortes and Whitham, 2009; Tarantino et al, 2012). The detection limit of the 
kit is 0.09 ng / mL as stated by the supplier, and the first points on the 
standard curve fall within the range of the results noted in the studies 
mentioned above, suggesting that a more sensitive means of Hsp70 
detection is needed in these samples.   
After inconclusive studies using serum samples from human end-
stage disease, an experimental time course of disease was undertaken to 
detect changes in serum Hsp70 levels and Hsp70 expression in lung tissue 
and relate this to human disease progression. In experimental PAH models, 
serum Hsp70 levels decreased in MCT treated rats from day 14. This is 
interesting as previous work undertaken in this model describes vascular 
remodelling and right ventricular hypertrophy as being evident at day 21 post 
MCT injection (Roth et al, 1981; Le Pavec et al, 2009). Levels of circulating 
Hsp70 remain lower in serum from MCT treated animals compared to saline-
treated controls from day 14 to 28 post MCT injection.  
Work undertaken in patients with cardiovascular diseases such as 
coronary artery disease and carotid atherosclerosis also correlate with data 
gained from my study, in that low circulating Hsp70 levels are more common 
in patients compared to controls (Zhu et al, 2003; Martin-Ventura et al, 
2007). This is also the case in patients with atherosclerosis associated with 
essential hypertension, where an increased intima-media thickness was less 
prevalent in patients with a high serum level of Hsp70 (Pockley et al, 2003). 
Taken together, data from the MCT model of PAH and from previous human 
studies, suggest that Hsp70 may protect against or modify the progression of 
cardiovascular disease, and that a dysregulation or reduced level of 
circulating Hsp70 could be prognostic of a poor response to prevent disease 
progression (Pockley and Frostegard, 2005). 
Hsp70 expression was not noted in the lung tissue of either MCT or 
saline treated rats. Hsp70 expression detection using this clone (C92F3A-5) 
has been undertaken before in other tissues and cell lines, however there is 
little evidence to suggest that it has been used to determine Hsp70 
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expression levels in paraffin-embedded rat lung sections (Mestril et al, 1994). 
Further investigations using alternative antibodies and clones could help to 
identify Hsp70 expression in rat lung tissue in the MCT timecourse in the 
future. 
An increased expression of Hsp70 was noted across the whole of the 
timecourse undertaken in paigen ApoE-/-/IL1R1-/- mice compared to chow fed 
controls. Disease progression can be noted at week 6 and 8 in paigen fed 
animals, as noted by an increase in vessel remodelling. In these animals, 
Hsp70 expression is noted after 1 week of beginning the diet suggesting that 
the diet may be causing the increased expression of Hsp70, not the 
remodelling process. However this has not been confirmed and literature 
regarding this subject is sparse. 
After depletion of CD4+ T cells, PAH disease progression worsened, 
as defined by increased RVSP and vessel remodelling. In these animals, 
levels of Hsp70 seen within the lung tissue decreased, suggesting that CD4+ 
T cells may be the source of Hsp70 expression within the lung, further 
supporting a role for T cells in PAH. Further investigations need to take place 
to determine the identity of the Hsp70 expressing cells. 
The original hypothesis of this element of the study was that changes 
in pulmonary haemodynamics would cause endothelial stress, which in turn 
would cause an increased production and release of Hsp70 from ECs within 
the pulmonary vessels. Interestingly, no EC specific staining for Hsp70 was 
noted at any point in experimental animal models. Limited evidence exists 
confirming the ability of ECs to express Hsp70 in response to stress, 
however Hsp70 EC expression has been noted in in vitro hypoxic studies 
(Chapter 4.3.4) (Jornot et al, 1991; Wang et al, 1995; Suzuki et al, 1998).  
There could be several explanations as to why Hsp70 expression was 
noted in EC in vitro hypoxic studies, but not in immunohistochemistry from in 
vivo MCT or the fat fed ApoE-/-/IL1R1-/- mouse model lung samples of PAH. 
Firstly, in vitro hypoxia is a very different environment to MCT and diet 
induced PAH in vivo. Therefore differences could have occurred due to the 
way in which the PAH phenotype was induced or the fact that in vivo and in 
vitro conditions are not always similar. Both MCT and paigen diet have been 
shown to have an effect on EC function, and therefore possibly Hsp 
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production; however, the mechanisms by which they exert these effects 
remain unclear (Wilson et al, 1992; Thomas et al, 1998; Reilly et al, 2006). 
Another difference between these studies was the time in which the assays 
were undertaken. The hypoxic experiments were short exposures to hypoxic 
stress (6 to 72 hours) whereas MCT and diet induced PAH are chronic 
stressors, lasting 1-2 months. This could mean that EC expression of Hsp70 
could have been missed in immunohistochemical staining as transient Hsp70 
expression has been noted in other cells (Jaattela et al, 1992; Sanz et al, 
1997; Ammon-Treiber et al, 2004).  
To determine the effect of hypoxia, a known contributing factor in 
PAH, on EC production of Hsp70, an in vitro culture model using PA-ECs 
was set up to determine levels of PA-EC-expressed and secreted protein 
and RNA expression in PA-EC cells of Hsp70 at different time points of 
hypoxic exposure. Unfortunately, the release of Hsp70 could not be analysed 
in supernatant samples, as levels of Hsp70 released by PA-ECs during a 6 - 
72 hour incubation in hypoxic conditions was below the detection limit of the 
kit available at the time. Using a higher number of seeded PA-ECs in the 
incubation stage of this assay could overcome this issue in the future.  
Hsp70 levels in normoxic and hypoxic cell lysates increased 
throughout the timecourse, but were comparable in each condition. Hsp70 
levels have been shown to increase in HeLa cells at the S phase of the cell 
cycle (RNA replication stage) (Milarski and Morimoto, 1986). As there are 
more cells present at 72 hours (due to proliferation) compared to 6 hours in 
culture (in both normoxic and hypoxic conditions) it is possible that the rise in 
Hsp70 noted is due to an increased number of proliferating cells. There was 
however, no difference between normoxic and hypoxic cell Hsp70 protein 
expression in cell lysate samples at any time point. This is interesting, as 
previous studies have noted that human microvascular ECs (HMEC-1 cell 
line) and bovine ECs can adapt to hypoxic conditions by producing ATP 
independently of oxygen. They have been shown to convert glucose to 
lactate via anaerobic glycolysis and Hsp70 expression levels mimic those 
seen under normal physiological conditions (Graven et al, 1993; Oehler et al, 
2000). Although the precise reason why this adaptation occurs is unclea,r it 
is thought that ECs are well adapted to low levels of oxygen in the 
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vasculature compared to other cell types, and can cope better with hypoxic 
conditions. 
An unexpected and unexplainable increase in Hsp70 RNA expression 
was noted in normoxic cell lysates at 6 hours compared to hypoxia treated 
PA-ECs.  After this time point relative expression of Hsp70 remained low in 
both normoxic and hypoxic conditions at 24 and 48 hour time points. As 
previously mentioned this could be due to an adaptive response of ECs to 
the hypoxic environment.  
In conclusion, these studies showed a decrease in serum Hsp70 
levels in the MCT rat model of PAH from week 14 as PAH progression was 
noted to occur. Hsp70 expression in perivascular inflammatory cells within 
lung tissue sections from fat fed ApoE-/-/IL1R1-/- mice was increased 
compared to chow fed controls, however it is unclear whether this is an effect 
of the method in which PAH was induced (paigen diet) or a consequence of 
PAH itself. Further investigations into Hsp70 expression in lung tissue 
sections from other disease models of PAH may help to answer this 
question. In cultured PA-ECs subjected to hypoxia there was no change in 
RNA or PA-EC expression levels of Hsp70 protein at any time point from 6 - 
72 hours compared to normoxic controls. These data confirm that cultured 
PA-ECs can express Hsp70 in both normoxic and hypoxic conditions, 
however hypoxic insult does not increase Hsp70 levels in these cells 
compared to normoxic controls. Despite seeing a decrease in Hsp70 serum 
levels in MCT treated rats, further work needs to be undertaken to 1) 
determine Hsp70 serum levels in PAH patients and 2) determine whether 
this protein can be used as a biomarker of PAH in the future.  
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Chapter 5  General Discussion  
 
PAH is a life threatening condition which is caused by the gradual 
occlusion of pulmonary vessels due to vasoconstriction, vessel remodelling, 
in situ thrombosis and inflammation. This restricts blood flow and increases 
pressures within these vessels, leading to increased strain on the heart, 
RVH, right ventricular failure and death. Many factors are thought to be 
involved in the pathogenesis of PAH, including inflammatory processes.  
Several sources suggest that T cells of the adaptive immune system 
are particularly involved in this process. Firstly, T cells have been found 
associated with vascular lesions in IPAH patient lung tissue (Tuder et al, 
1994). Secondly, several experimental models have shown that T cells 
protect against the progression of experimental PAH disease  (Miyata et al, 
2000; Taraseviciene-Stewart et al, 2005; Taraseviciene-Stewart et al, 2007), 
whilst immunosuppressive therapy has been shown to prevent experimental 
PAH and limit clinical PAH disease progression (Morelli et al, 1993; Bellotto 
et al, 1999; Rodriguez-Iturbe et al, 2001; Sanchez et al, 2006; Jais et al, 
2008; Price et al, 2011). In human studies, alterations in T cell subsets have 
been noted in the peripheral blood and lung tissue of IPAH patients 
undergoing PAH specific treatment, further suggesting that a dysfunctional T 
cell compartment may be involved in PAH pathogenesis (Ulrich et al, 2008; 
Austin et al, 2010). However, it is still unknown whether these changes in T 
cell populations are a cause or an effect of the disease. In experimental 
models of PAH, inflammation has been shown to precede vascular 
remodelling, however, literature on this subject is limited and so further work 
needs to be undertaken to clarify this issue (Cuttica et al, 2011). 
Hsp expression has been shown to be protective against stresses 
such as hypoxia and shear stress in several cell types, including SMCs and 
monocytes (Guzik et al, 1999; Xu et al, 2000). Hsp70  is a member of the 
stress protein family and its expression can be upregulated on all cells under 
stressful conditions such as heat shock or hypoxia. There is little evidence 
however, that ECs produce Hsp70 in response to hypoxia or oxidative 
stresses and Hsp70 serum levels have not been determined in IPAH and 
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SSc-PAH to date. Decreased levels of serum Hsp70 have been shown to 
correlate with increased risk of carotid atherosclerosis in patients with 
established hypertension, suggesting a cardioprotective role of Hsp70 in 
patients with hypertensive disease (Pockley et al, 2003).  
Therefore work undertaken in this thesis aimed to elucidate the role of 
T cells in the pathogenesis of PAH in patients with PAH and animal models, 
as well as determine expression levels of Hsp70 and Hsp70 serum levels in 
PAH patients and animal models. How changes in proportions of T cell 
subsets, changes in Hsp70 expression and serum levels correlate with 
disease progression, were also assessed. 
Previous studies have attempted to determine proportions of 
circulating lymphocytes in IPAH patients, but were limited by patient cohorts 
that were already on PAH treatment. Work was therefore undertaken to 
analyse T and B cell subsets in treatment-naïve PAH patients (SSc-PAH and 
IPAH). It was hypothesised that patients in different PAH subgroups would 
exhibit an altered T cell profile in peripheral blood. Multicolour flow cytometry 
was used to determine T cell (CD4 / 8 / 25 / 127) and B cell (CD19) subset 
profiles in peripheral blood of incident cases of IPAH and SSc-PAH, whilst 
CD69 (an early activation marker found on lymphocytes) was used to detect 
T and B cell activation. 
The main finding of this work was that the relative frequency of CD8+ 
cytotoxic T cells in treatment-naïve patients with SSc-PAH was significantly 
decreased compared to their corresponding controls. No change in the 
relative frequency of CD8+ T cells was noted in IPAH patients, which conflicts 
with  previously published data from Ulrich et al, who noted a diminished 
proportion of CD8+ T cells in the peripheral blood of IPAH patients 
undergoing PAH treatment (Ulrich et al, 2008). Differences noted between 
studies may be due to the cohort of patients analysed or the PAH specific 
treatments they were taking (discussed previously in Chapter 2.4.1). Further 
work could assess the function of this decreased subset of T cells, as this 
could provide information regarding their decreased proportions in PAH 
patients and their role within disease pathogenesis. No significant changes in 
other T or B cell lymphocyte subsets or their activation status were noted in 
either patient group in this study. 
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Correlation analyses between clinical parameters and proportions of T 
cell subsets highlighted a negative correlation between CD4+ T cells and CI 
in SSc-PAH patients and CD4+ T cells and the shuttle walk test in IPAH 
patients. Further analysis of proportions of CD4+ T cells within the circulation 
of PAH patients could predict disease progression, or even diagnosis, in the 
future.  
Follow-up blood sample analysis in returning patients after 
administration of PAH specific treatment, suggested that E-RA could return 
the proportion of circulating CD4+ T cells to “normal” levels and improve a 
patient’s exercise capacity compared to PDE-5 inhibitors. It was noted that 
neither treatment had beneficial effects on the modification of proportions of 
CD8+ T cells or CD4+CD25high Treg cells to a “healthier” level. Further work 
needs to be undertaken in order to increase the study number and the 
validity of these statements. Studies have shown that PAH specific therapies 
including Sildenafil and Prostaglandin I2 analogs, can modify T cell 
responses in other disease settings such as asthma, by suppressing DC 
activation and T cell stimulatory function and reducing their recruitment into 
the airways (Jaffar et al, 2007; Zhou et al, 2007; Wang et al, 2009). These 
studies suggest that T cell activation and migration can be modulated by 
these therapies, however literature regarding this topic is scarce and further 
work needs to be done to identify the exact effects that each therapy has on 
the proportion of circulating T cell subsets and their activation status. In 
future, it may be beneficial to prescribe therapies to PAH patients to restore 
the balance between Th1 and Th2 cells.  
Human samples only provide information regarding end stage disease 
states, therefore animal models, such as the fat fed ApoE-/-/Il-1R1-/- mouse 
model of PAH, are utilised to determine factors involved in the pathogenesis 
of PAH. Although changes in T cell subsets within peripheral circulation and 
lung tissue of PAH patients has been noted in Chapter 2.3.1 and in 
previously published literature, it is unclear whether these changes occur as 
a cause or consequence of the disease (Tuder et al, 1994; Dorfmuller et al, 
2002; Dorfmuller et al, 2003; Ulrich et al, 2008; Austin et al, 2010). It was 
hypothesised that these changes in T cell subsets would correlate with 
disease progression and vessel remodelling. To elucidate cause or effect of 
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changes in T cell frequency, I examined a time course of the paigen diet-fed 
ApoE-/-/IL-1R1-/- mouse model of PAH. In this model there was no difference 
in circulating T cell subsets whilst disease progression was confirmed by 
analysis of vessel remodelling. This was unexpected as a decreased 
proportion of circulating CD8+ T cells had been noted in the blood of SSc-
PAH patients previously in Chapter 2.3.1. This further emphasises the 
difficulties faced when using animal models to mimic human disease and the 
complexity of these experiments.  
The effect of CD4+ T cell depletion was also assessed in the paigen 
diet-fed ApoE-/-/IL-1R1-/- mice as these cells were thought to propagate 
disease progression. It was noted that CD4+ T cells are protective as their 
removal using a depletion antibody increased RVSP and vessel remodelling 
in CD4 depleted animals. This could be due to the lack of Treg cells, found 
within the CD4+ T cell compartment, as previous studies in other models 
have noted Treg cells can protect against Sugen 5416 initiated PAH in rats 
(Tamosiuniene et al, 2011). Therefore, a depletion of CD4+ T cells 
propagates disease progression in the fat-fed ApoE-/-/IL-1R1-/- mouse model 
of PAH, as shown by an increase in RVSP and increased vascular 
remodelling.  
To determine the effect that disease progression has on Hsp70 levels 
in clinical and experimental serum samples, Hsp70 expression within lung 
tissue and in vitro EC Hsp70 expression in animal models of disease, several 
techniques were used. These included, ELISA, immunohistochemistry, 
qPCR and Hsp70 Singleplex Multibead™ kit. Hsp70 was undetectable in 
clinical serum samples in IPAH and SSc-PAH patients, however in 
experimental models, a decreased serum level of Hsp70 was noted in 
monocrotaline treated rats, which coincided with vascular remodelling. 
Hsp70 expression in perivascular inflammatory cells within lung tissue of fat-
fed ApoE-/-/IL-1R1-/- mice also increased along a timecourse of disease 
progression. There was also no difference noted in Hsp70 RNA and protein 
expression in cultured ECs exposed to hypoxic and normoxic conditions. 
These data suggest a protected phenotype ECs which may be adapting to 
hypoxic conditions (Oehler et al, 2000). Limitations regarding the detection 
limit of currently available Hsp70 serum and plasma detection kits currently 
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hinders research in this area. Further work needs to be undertaken to 
quantify Hsp70 serum levels in PAH patients, possibly via the use of Western 
blots, whilst serum Hsp70 analysis could be undertaken in the fat-fed ApoE-/-
/IL-1R1-/- mouse model of PAH to relate changes of Hsp70 within lung tissue 
in inflammatory cells to circulating serum Hsp70 levels.  
Taken together, these findings suggest that subtypes of PAH are 
associated with distinct T cell profiles, perhaps reflecting the different 
aetiologies. Alterations in circulating CD8+ T cells suggest a dysfunctional 
immune system which could contribute to disease pathogenesis. In 
experimental models, the depletion of CD4+ cells was found to propagate 
disease progression, whereas Hsp70 levels were found to decrease in the 
serum of MCT treated rats but increase within inflammatory cells infiltrating 
the remodelled lung tissue in paigen diet-fed ApoE-/-/IL-1R1-/- mice. Further 
work to elucidate the exact role that T cells play in the pathogenesis of PAH 
needs to be undertaken, however these data suggest that circulating levels 
of CD4+ and CD8+ T cells could be used in the diagnosis of PAH and as a 
prognostic marker in PAH patients in the future (Pendergrass et al, 2010). 
In the future, further work could be undertaken to increase the sample 
population of patients being studied. Along with this, ethical approval to 
obtain a greater volume of blood could also be sought to continue the work 
regarding Treg cell function. Further work to analyse a greater number of 
subpopulations of T and B cells within the peripheral blood of PAH patients 
and controls could also be undertaken. A second cohort of patients could 
also be used to compare with the first set to confirm previous findings. Other 
models of PAH could also be used to assess T cell responses in vitro along a 
timecourse of the disease as well as assessing the involvement of Hsp70 in 
the pathogenesis of the disease. 
There is growing evidence of the importance of lymphocytes (B and T 
cells) in the resolution of disease pathogenesis in PAH. Firstly, immune 
reconstituted Treg cells have been shown to prevent early inflammation and 
attenuate PAH development in athymic rats treated with Sugen 5416 
(Tamosiuniene et al, 2011). This suggests that Treg cells are highly 
important in modifying the immune response in PAH. Secondly, pre-clinical 
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studies have resulted in funding to perform a clinical trial examining the effect 
of rituximab on disease progression in SSc-PAH patients. This is due to 
compelling pre-clinical data suggesting that rituximab improves lung function 
and skin thickening in SSc patients and in SLE associated PAH patients 
(Hennigan et al, 2008; Daoussis et al, 2010). This trial is currently being 
undertaken as modulation of the immune system may be an effective 
strategy for treating SSc-PAH (http://www.clinicaltrials.gov, 2012). Previous 
work determining the involvement of Treg cells and leptin in PAH has also 
provided evidence to suggest a dysfunctional T cell compartment in IPAH 
and SSc-PAH patients (Huertas et al, 2012). Taken together, these findings 
emphasise the importance of research in this area. There are however, 
several limitations to this work, which highlight the challenges faced in 
determining the role that lymphocytes play in the pathogenesis of PAH.  
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Appendix 1 
 
1. General reagents 
 
AllPrep RNA/Protein Kit  
(80404, Qiagen, Crawley, West Sussex, UK)  
The kit contained 50 AllPrep Mini Spin Columns, 50 RNeasy® Mini Spin 
Columns, 50 Protein Cleanup Mini Spin Columns, 50 1.5 mL Collection 
Tubes, 100 2 mL Collection Tubes, 12 mL Buffer APL, 45 mL Buffer RLT, 45 
mL of Buffer RW1, 11 mL of Buffer RPE (prepared by adding 4X 100% 
ethanol) and 10 mL of RNase-Free Water. All reagents were stored at room 
temperature. 
 
Amicon Ultra-2 (3K device)   
(UFC200324, Millipore Corporation, Massachusetts, USA) 
The kit contained 24 filtrate collection tubes, 24 filter devices and 24 
concentrate collection tubes. Kit contents were all stored at room 
temperature.  
 
Cell trace Violet Proliferation Kit  
(C34557, Invitrogen of Life technologies Ltd, Paisley, UK).  
5 µL Cell trace violet stock solution (5 mM) made up by dissolving 1 vial cell 
trace violet stock in 20 µL of DMSO. Stock solution was added at 1 µL / 1 
million cells and was stored at –20˚C protected from light. 
 
DC Protein Assay                               
(500-0112, BioRad DC protein assay, Hertfordshire, UK) 
The kit included 250 mL of REAGENT A (an alkaline copper tartrate 
solution), 2000 mL of REAGENT B (a dilute Folin Reagent), 5 mL of 
REAGENT S (surfactant solution) and a bovine serum albumin standard (1.5 
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mg / mL). All components were stored at room temperature away from direct 
sunlight. A bovine serum albumin standard (23209, Thermo Fisher Scientific, 
Epsom, UK) was used (2 mg / mL) along with the DC protein assay kit which 
was stored at room temperature. 
 
Gene-specific primers  
(Applied Biosystems of Life Technologies Ltd, Paisley, UK) 
Both primers were stored at -20˚C. 
ATB5B   25 µL 20X mix   HS0096959-ml 
HSPA1A (hsp70)   250 µL 20X mix   HS00359163-sl 
  
Hsp70 high sensitivity EIA kit  
(ADI-EKS-715, ENZO Life Sciences, Exeter, UK). 
The kit contained a Hsp70 Clear Microtiter Plate, 50 mL of assay buffer 28, a 
standard, 100 mL of wash buffer concentrate, 25 μL of Hsp70 High 
Sensitivity Standard, 10 mL of Hsp70 High Sensitivity EIA Conjugate, 10 mL 
of Hsp70 High Sensitivity EIA Antibody, 10 mL of TMB Substrate and 10 mL 
stop solution 2. Stock solutions of wash buffer and Hsp70 Intermediate 
Standard were prepared as previously described in Chapter 4.2.1. The 
sensitivity of the kit was determined by interpolation at 2 standard deviations 
above the mean signal at background (0 ng / mL). The inter-assay coefficient 
of variation was 12.8% to 19.1% and the intra-assay coefficient of variation 
was 3.9% to 11.4% for this kit. All reagents were stored at 4˚C except the 
standard which was stored at -20˚C. 
 
Hsp70 singleplex multibead kit  
(ADI-985-016, ENZO Life Sciences, Exeter, UK) 
The kit included  200 μL of 25X Hsp70 Capture Bead, 1 vial of 
HSP/Chaperone Standard Cocktail, 400 μL of 25X Hsp70 Antibody and 400 
μL of 25X Streptavidin-PE Conjugate. The HSP/Chaperone MultiBead™ 
Buffer Pack was also used (ADI-987-002, ENZO Life Sciences, Exeter, UK). 
Hsp70 Capture Bead, Hsp70 Antibody, Streptavidin-PE Conjugate and the 
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HSP/Chaperone Standard Cocktail were prepared to a stock solution of 1X 
before use (as previously described in Chapter 4.2.4.3). All kit reagents were 
stored at 4˚C except the HSP/Chaperone Standard Cocktail which was 
stored at -20ºC.  
 
TaqMan® Gene Expression Master Mix 
(4369016, Applied Biosystems of Life Technologies Ltd, Paisley, UK) 
The TaqMan Gene Expression Master Mix contained AmpliTaq Gold® DNA 
Polymerase, UP (Ultra Pure), Uracil-DNA glycosylase, dNTPs with dUTP, 
ROX™ Passive Reference and optimised buffer components. All 
components were stored at 4˚C. 
 
Thymidine, [Methyl-3H] (3H-thymidine) 
(NET027E001MC, PerkinElmer, Buckinghamshire, UK) 
Thymidine, [Methyl-3H] was supplied as a 1 mL solution of 1mCi (37 MBq). 
10 µL of isotope was added to 90 µL of PBS giving a stock concentration of 1 
µCi.  Thymidine, [Methyl-3H] was stored at 4˚C. 
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2.   Cell culture 
 
Cell lysis buffer     
Cell lysis buffer was made up using 780 µL of dH2O added to 10 µL of 1M 
TRIS.HCl (121.1g TRIS added to 64 - 70 mL concentrated HCl, pH to pH7.4, 
then made to 1 L with dH2O), 10 µL of 100 mM sodium orthovanadate, 100 
µL of 10% sodium dodecyl sulfate and 100 µL of protease inhibitor cocktail. 
Lysis buffer stock solution was stored at -20°C. All reagents from Sigma-
Aldrich, Dorset, UK) 
 
Medium 199 (M199 medium)  
(11150-059, Gibco® of Life Technologies Ltd, Paisley, UK) 
Basal stock of M199 medium was prepared under asceptic conditions by 
adding 450 mL of autoclaved water, 50 mL of 10X M199, 10 mL Bicarbonate, 
5 mL of glutamine and 5 mL of a Penicillin (10,000 U)-Streptomycin (10 mg)-
L-Glutamine (200 mM) solution (Gibco® of Life Technologies Ltd, Paisley, 
UK). 80 mL of the basal stock was then added to 10 mL of FCS, 10 mL of 
newborn calf serum, 100 µL of heparin and 50 µL of endothelial cell growth 
supplement (Gibco® of Life Technologies Ltd, Paisley, UK). Basal stock of 
M199 medium and working M199 medium were stored at 4˚C. 
 
Medium 200 (M200 complete growth medium)  
(M-200-500, Gibco® of Life Technologies Ltd, Paisley, UK) 
Stock M200 medium prepared by adding 500 mL M200 to 5 mL low serum 
growth supplement 50X (2-003-10, Gibco® via Cascade Biologics of Life 
Technologies Ltd, Paisley, UK) and 1 vial (1 mL) of gentamicin and 
amphotericin B 500X (50-0640, Cascade Biologics of Life Technologies Ltd, 
Paisley, UK). Both low serum growth supplement and gentamicin and 
amphotericin B vial kept at -20 ˚C. Stock solution of M200 complete growth 
medium was stored at 4˚C.  
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Pulmonary Arterial Endothelial Cells   
(C-008-5C, Cascade Biologics of Life Technologies Ltd, Paisley, UK) 
Cells were cultured as previously described in Chapter 4.2.4.2.  Previous to 
culture, cells were stored at -150˚C. 
 
RPMI Media 1640 (RPMI medium)  
(21875-034, Gibco® of Life Technologies Ltd, Paisley, UK) 
To a 500 mL bottle of RPMI-1640, 5 mL of a Penicillin (10,000 U)-
Streptomycin (10 mg)-L-Glutamine (200 mM) solution and 10 mL of FCS 
were added (both from Gibco® of Life Technologies Ltd, Paisley, UK). Stock 
solution was stored at 4˚C. 
 
Trypsin/EDTA 
2.5% Trypsin (10X), no Phenol Red (15090, Gibco® of Life Technologies 
Ltd, Paisley, UK) 
Ethylenediaminetetraacetic acid disodium salt dihydrate (E5134, Sigma-
Aldrich, Dorset, UK) 
5 mL of 2.5% trypsin was added to 5 mL of 0.2% EDTA (made by adding 
0.2g EDTA with 100 mL of ddH2O, autoclaved) and 90 mL of PBS. 
Trypsin/EDTA solution was stored at 4˚C. 
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3. Flow cytometry reagents 
 
Flow cytometry antibodies and isotype controls 
Monoclonal antibodies used in staining of PBMCs isolated from human 
whole blood samples. All antibodies and isotypes were stored undiluted at 
4°C. 
Antibody Clone Reactivity 
Concentration/test 
number 
Catalogue 
number and 
Manufacturer 
Alexa Fluor® 700 
Mouse Anti-
Human CD3 
UCHT1 Human 
0.2 mg / mL 
(1 µL / test / 1 million 
cells) 
557943, BD 
Pharmingen™, 
Oxford, UK 
Pacific Blue™ 
anti-human CD4 
RPA-T4 
Human, Cross-
Reactivity: 
Chimpanzee 
0.5 mg / mL 
(4 µL / test / 1 million 
cells)  
300521, BioLegend, 
London, UK 
Anti-Human CD25 
PE-Cy7 
BC96 Human 
25 tests 
(5 µL / test / 1 million 
cells) 
25-0259-42, 
eBioscience, 
Hatfield, UK 
V500 Mouse Anti-
Human CD45 
HI30 Human 
25 tests 
(5 µL / test / 1 million 
cells) 
560779, BD 
Horizon™, Oxford, 
UK 
APC/Cy7 anti-
human CD69  
FN50 
Human, Cross-
Reactivity: 
Chimpanzee, 
Baboon, 
Cynomolgus, 
Rhesus, Pigtailed 
Macaque 
100 tests  
(20 µL / test / 1 million 
cells) 
310914,  
BioLegend, London, 
UK 
Alexa Fluor® 488 
anti-human CD127 
(IL-7Rα)  
HCD127 Human 
25 tests 
(5 µL / test / 1 million 
cells) 
317603,  
BioLegend, London, 
UK 
Anti-Human Foxp3 
APC 
236A/E7 Human 
100 tests  
(5 µL / test / 1 million 
cells) 
17-4777-42, 
eBioscience, 
Hatfield, UK 
Alexa Fluor® 488 
anti-human CD19  
HIB19 
Human, Cross-
Reactivity: 
Chimpanzee 
100 tests  
(5 µL / test / 1 million 
cells) 
302219, 
BioLegend, London, 
UK 
Anti-Human CD8a 
APC 
RPA-T8 Human 
100 tests  
(5 µL / test / 1 million 
cells) 
17-0088-42, 
eBioscience, 
Hatfield, UK  
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Monoclonal isotype controls used in staining of PBMCs from human clinical 
whole blood. 
 Antibody Clone 
Concentration/test 
number 
Catalogue number and 
Manufacturer 
Alexa Fluor® 700  mouse 
IgG1, κ 
MOPC-21 
0.2 mg / mL 
(1 µL / test / 1 million 
cells) 
557882, BioLegend, London, 
UK 
Pacific Blue™ mouse 
IgG1, κ 
MOPC-21 
0.5 mg / mL 
(4 µL / test / 1 million 
cells) 
400151, 
 BioLegend, London, UK 
Mouse IgG1, k PE-Cy7 P3.6.2.8.1 
100 
(5 µL / test / 1 million 
cells) 
25-4714-42, eBioscience, 
Hatfield, UK 
Mouse IgG1, κ APC P3.6.2.8.1 
100 
(5 µL / test / 1 million 
cells) 
17-4714-41, eBioscience, 
Hatfield, UK 
APC-Cy7™Mouse IgG1,  
κ 
MOPC-21 
100 tests  
(20 µL / test / 1 million 
cells) 
400128, 
 BioLegend, London, UK 
V500 mouse IgG1, κ X40 
0.2 mg / mL 
(5 µL / test / 1 million 
cells) 
560787, 
BD Horizon™, Oxford, UK 
AF488 mouse IgG1, ĸ  MOPC-21 
100 tests  
 (5 µL / test / 1 million 
cells) 
400129, BioLegend, London, 
UK 
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Monoclonal antibodies used in staining of mouse whole blood, all stored 
undiluted at 4°C. 
Antibody Clone Reactivity 
Concentration/test 
number 
Catalogue 
number and 
Manufacturer 
Alexa Fluor® 700 anti-mouse 
CD3   
17A2 Mouse 0.5 mg / mL 
(1 µL / test / 1 million 
cells) 
100216, 
BioLegend, 
London, UK 
FITC anti-mouse CD4 RM4-4 Mouse 
0.5 mg / mL 
(0.25 µL / test / 1 
million cells) 
116004, 
BioLegend, 
London, UK 
APC anti-mouse CD8a  53-6.7 Mouse 
0.2 mg / mL 
(0.25 µL / test / 1 
million cells) 
100712, 
BioLegend, 
London, UK 
PE/Cy7 anti-mouse CD25 PC61 Mouse 
0.2 mg / mL 
(1 µL / test / 1 million 
cells) 
102016, 
BioLegend, 
London, UK  
Monoclonal isotype controls used in staining of mouse whole blood. 
Antibody Clone 
Concentration/test 
number 
Catalogue number 
and Manufacturer 
Alexa Fluor® 700 Rat IgG2b, ĸ  RTK4530 
0.5 mg / mL 
(1 µL / test / 1 million 
cells) 
400628, BioLegend, 
London, UK 
FITC Rat IgG2b, ĸ  RTK4530 
0.5 mg / mL  
(0.5 µL / test / 1 
million cells) 
400606, BioLegend, 
London, UK 
PE/Cy7 Rat IgG1, κ  RTK2071 
0.2 mg / mL 
(1 µL / test / 1 million 
cells) 
400416, BioLegend, 
London, UK 
APC Rat IgG2a, ĸ  RTK2758 
0.2 mg / mL 
(0.25 µL / test / 1 
million cells) 
400512, BioLegend, 
London, UK 
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LIVE/DEAD® Fixable Dead Cell Stain Kit     
(L-23105, Invitrogen of Life Technologies Ltd, Paisley, UK) 
1 vial of component A (fluorescent reactive dye) was added to 50 μL of 
component B (anhydrous DMSO), mixed well and 1 µL of fluorescent dye 
stock solution added to a cell solution of 1 x 106 / mL. The fluorescent dye 
stock solution was stored at –20°C and protected from light.  
 
Foxp3 / Transcription Factor Staining Buffer Set  
(00-5523-00, eBioscience, Hatfield, UK) 
This kit contained 30 mL of eBioscience Fixation/Permeabilization 
Concentrate (4X), 100 mL of eBioscience Fixation/Permeabilization Diluent 
and 100 mL of eBioscience Permeabilization Buffer (10X). A 
fixation/permeabilization working solution of 1X was prepared by adding 1 
part eBioscience Fixation/Permeabilization Concentrate to 1 part 
eBioscience Fixation/Permeabilization Diluent. The permeabilization buffer 
was made by diluting 1 part eBioscience Permeabilization Buffer with 9 parts 
distilled water. All stocks and working solutions were stored at 4°C. 
 
Cell staining buffer  
Cell staining buffer was prepared by adding 10 mL of FCS to 90 mL of PBS 
after which it was stored at 4°C. 
 
Red Blood Cell Lysis Solution  
(130-094-183, Miltenyi Biotec Ltd, Surrey, UK) 
Working red blood cell lysis solution was prepared by diluting the 10X red 
blood cell lysis solution to 1X with ddH2O. The working red blood cell lysis 
solution was stored at 4°C. 
 
Normal mouse serum  
(ab7486, Abcam, Cambridge, UK) 
Normal mouse serum used as per chapter 2.2.2.1. 
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LSM 1077 Lymphocyte  
(J15-004, PAA, Austria) 
LSM 1077 Lymphocyte solution was used neat to separate PBMCs from 
whole blood solution as described in chapter 2.2.2.1. 
 
BD CELLFix™  
(340181, BD bioscience, Oxford, UK) 
A working solution of 1X CELLFix™ was prepared by adding 5 mL of 10X 
concentrate to 45 mL of distilled water and stored at 4°C. 
 
Anti-Mouse Ig, κ/Negative Control Compensation Particles Set 
(552843, BD bioscience, Oxford, UK) 
1 drop of reagent A (Anti-Mouse Ig, κ) was added to 1 drop of reagent B 
(FCS) before being added to each anti-human antibody. Compensation 
Particles Set was stored at 4°C. 
 
Anti-Rat and Anti-Hamster Ig κ /Negative Control Compensation 
Particles Set  
(552845, BD bioscience, Oxford, UK) 
1 drop of reagent A (Anti-Rat and Anti-Hamster Ig, κ) was added to 1 drop of 
reagent B (FCS) before being added to each anti-mouse antibody. 
Compensation Particles Set was stored at 4°C. 
 
ArC™ Amine Reactive Compensation Bead Kit  
(A-10346, Invitrogen of Life Technologies Ltd, Paisley, UK)  
ArC™ Amine Reactive Compensation beads were used as described in 
chapter 2.2.2.1. 
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4.   Animal study reagents 
 
Collagenase A from Clostridium histolyticum (Collagenase A) 
(10103586001, Roche, Welwyn Garden City, UK) 
A stock concentration of 0.5 mg / mL of collagenase A was prepared to a 
working concentration of 0.15% with HBSS (1X) solution (Life Technologies 
Ltd, Paisley, UK). Working collagenase A solution was stored at -20°C. 
 
Crotaline (monocrotaline) 
(C2401-500MG, Sigma Aldrich, Dorset, UK) 
 
Crotaline (C16H23NO6) was dissolved in 0.6 mL of 1M Hydrochloric Acid and 
vortexed for 40 minutes. Sterile water was added to make the volume to 5 
mL and the pH adjusted to 7.0 with sterile NaOH. A final solution to 10 mL 
was made with sterile water. And a dose of 60 mg / kg dose was given to 
rats weighing approximately 200g at the beginning of the procedure.  
Crotaline was stored at at 4°C prior to use. The control used in the MCT 
experiments was PBS at the same volume.  
 
LEAF™ Purified anti-mouse CD4 Antibody 
(100435, BioLegend, London, UK) 
LEAF™ Purified anti-mouse CD4 monoclonal antibody (stock solution of 
Stock solution of 1mg / mL) (clone GK1.5) was administered at a dose of 0.5 
mL per mouse per week for 4 weeks. This antibody was stored at 4°C. 
 
Normal Rat IgG Control, Rat IgG 
(6-001-A, R & D systems, Abingdon, UK)  
Normal Rat monoclonal IgG Control, Rat IgG (lyophilised and made up to 
1mg / mL in PBS) was administered at a dose of 0.5 mL per mouse per 
week for 4 weeks. This isotype control was stored at 4°C. 
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Paigen diet (atherogenic diet) 
(829110, Special Diet Services, Braintree, Essex, UK) 
Paigen diet (atherogenic) was made up by mixing distilled water with 500 g 
diet stock, until it reached the correct consistency. It consisted of 15% fat, 
1.25% cholesterol, and 0.5% cholic acid. After preparation, the diet stock 
was baked overnight on a flat ovenproof baking tray at 80°C, left to cool and 
broken up into smaller chunks before being used. Diet was kept unprepared 
at 4°C and prepared (after baking) at -20°C. 
 
Teklad Global 18% Protein Rodent Diet (Chow diet)  
(2018, Harlan Global Diets, Madison, USA)                                                                           
Chow diet consisted of 6.2% fat and 0% cholesterol. Diet was stored at room 
temperature.   
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5.  Immunohistochemistry buffers and 
reagents 
 
Primary antibodies used in immunohistological staining of mouse and 
rat tissue samples.  
All antibodies were stored at -20°C.  
Antibody Clone Description/ Reactivity 
Catalogue 
number and 
Manufacturer 
Dilution 
(in 
PBS) 
Antigen 
Retrieval 
step 
Anti-
Hsp70 
antibody 
C92F3A-5 
Mouse monoclonal 
Cross reactivity: Rat, 
Sheep, Rabbit, Chicken, 
Guinea pig, Hamster, 
Cow, Dog, Human, Pig, 
Caenorhabditis elegans, 
Carp, Fruit fly (Drosophila 
melanogaster), Monkey 
ab47455, 
Abcam, 
Cambridge, UK 
1:500 
Citrate 
buffer 
Anti-CD8 
antibody 
YTS169.4 
Rat monoclonal Cross 
reactivity: Mouse 
ab22378, 
Abcam, 
Cambridge, UK 
1:100 
Citrate 
buffer 
Anti-CD4 
antibody 
mAb51312 
Mouse monoclonal 
Cross reactivity: human 
ab51312, 
Abcam, 
Cambridge, UK 
1:100 
Citrate 
buffer 
Anti-IL2 
Receptor 
alpha 
Antibody 
(CD25) 
AP-
MABAP0710 
Rat monoclonal, Cross 
reactivity: mouse 
NB110-97867, 
Novus 
Biologicals, 
Cambridge, UK 
1:300 
Citrate 
buffer 
Anti-
Smooth 
muscle 
actin 
1A4 Mouse monoclonal 
M085, DAKO, 
Ely, UK 
1:150 N/A 
.  
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Secondary monoclonal antibodies used in immunohistological staining 
of mouse tissue samples.  
All secondary antibodies were used at a dilution of 1 in 200 in PBS and 
stored at 4°C.  
Antibody Catalogue number and 
Manufacturer 
Biotinylated goat anti-rat IgG BA9400 (Vector Laboratories, 
Peterborough, UK) 
Biotinylated goat anti-rabbit IgG BA1000 (Vector Laboratories, 
Peterborough, UK) 
Biotinylated goat anti-mouse IgG BA9200 (Vector Laboratories, 
Peterborough, UK) 
 
Acid alcohol 
Acid alcohol was prepared with 1% v/v HCl in 70% v/v IMS. This was stored 
at room temperature away from direct sunlight. 
 
Citrate Buffer  
500 mL of citrate buffer was made by adding 2.1g of citric acid monohydrate 
to 900 mL of dH20 before adjusting to pH6 with 13 mL of 2M NaOH (25 mL of 
H2O to 2g of NaOH pellets). This solution was then diluted a total volume of 
1000 mL using dH2O and stored at room temperature away from direct 
sunlight. 
 
Curtis’ Modified Van Gieson 
Curtis’ Modified Van Gieson was prepared by adding 10 mL of 1% w/v        
Ponceau S [aq] to 90 mL of saturated aq. Picric acid. 1 mL of glacial acetic 
acid was then added and it was stored at room temperature away from direct 
sunlight. 
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EDTA buffer  
EDTA buffer was made to a 1 mM solution by adding 0.186g of EDTA to 500 
mL of dH2O before being corrected to pH8. This was stored at room 
temperature away from direct sunlight. 
 
3% Hydrogen peroxide solution 
A 3% hydrogen solution was prepared using a 30% stock solution (30 % 
(w/w) in H2O) by diluting 1 mL of stock with 9 mL of PBS. Hydrogen peroxide 
stock solution was stored at 4°C. 
 
Milk blocking buffer  
5g of Marvel dried milk (from local supermarket) was added to 500 mL of 
PBS to make a 1% blocking buffer. Marvel dried milk powder was stored at 
room temperature. 
 
SIGMAFAST™ 3,3’-Diaminobenzidine tablets   
(D4418,Sigma Aldrich, Dorset, UK)  
1 Urea Hydrogen Peroxide tablet and 1 3,3’-Diaminobenzidine (DAB) tablet 
was added to 15 mL of water, mixed well and 2 drops of 30% hydrogen 
peroxide added prior to use to form an active DAB substrate solution. The 
DAB kit was stored at -20°C. 
 
TRIS/EDTA buffer  
TRIS/EDTA buffer was made by adding 1.21g of 10 mM TRIS, 0.37g of 1mM 
EDTA, 0.5 mL of 0.05% Tween20 and 999.5 mL of dH2O. The solution was 
then corrected to pH9 and stored at room temperature away from direct 
sunlight. 
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VECTASTAIN Elite ABC Kit (Standard*)   
(PK-6100, Vector Laboratories, Peterborough, UK) 
Working ABC reagent was prepared by adding 1 drop of Reagent A, 1 drop 
of Reagent B and 2.5 mL of PBS together. The kit was stored at 4°C. 
 
Other reagents 
All histological cassettes, moulds, paraffin wax and Millers Elastin stain were 
purchased from Raymond A Lamb Ltd (now Thermo Fisher Scientific, 
Epsom, UK) unless otherwise stated. All stains, Polysine™ glass slides, 
Potassium permanganate, coverslips, DPX resin, alcian blue and Carazzi’s 
Haematoxylin were purchased from VWR International Ltd (Lutterworth, UK) 
unless otherwise stated. Ethanol and xylene were also from Fisher Scientific. 
Oxalic acid purchased from Sigma Aldrich (Dorset, UK) 
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6. Patient treatment plans 
 
Patient ID PAH subtype Medication at baseline 
PAH 
specific 
medication 
given at 
Visit 1 
PAH 
specific 
medication 
given at 
follow-up 
13 IPAH 
GTN spray, Simvastatin, Omeprazole, 
Spironolactone, Metformin, Bisoprolol, 
Gliclazide, Isosorbide mononitrate, 
Bumetanide, Ramipril 
Bosentan N/A 
19 IPAH Frusemide, Trimethoprim Sildenafil 
Bosentan, 
Sildenafil 
32 IPAH 
Carbimazole, Seretide, Omeprazole, 
Bendroflumethiazide, Terbutaline, 
Chlorpheniramine 
Sildenafil Sildenafil 
35 IPAH 
Levothyroxine, Rosuvastatin, Bimatoprost, 
Liquifile 
Sildenafil N/A 
48 PAH-SSc 
Lansoprazole, Prednisolone, Calcichew, 
Ramipril 
Bosentan 
Bosentan, 
Sildenafil 
62 IPAH Simvastatin, Frusemide, Amlodipine Sildenafil N/A 
64 IPAH 
Amlodipine, Bisoprolol, Frumil, Diazepam, 
Valsartan, Citalopram, Frusemide 
Sildenafil N/A 
69 PAH-SSc Ramipril, Simvastatin, Lansoprazole, Diltiazem 
Bosentan, 
Sildenafil 
Bosentan, 
Sildenafil 
84 PAH-SSc 
Omeprazole, Ibruprofen, Amlodipine, 
Dermovate cream, Fucibet 
Bosentan Bosentan 
87 PAH-SSc 
Salbutamol, Warfarin, Loratidine, Nosonex, 
GTN spray, Gaviscon, Frusemide, Verapamil, 
Pregabalin, Quinine, Ramipril, Atorvastatin, 
Lansoprazole, Paracetamol 
Bosentan 
Bosentan, 
Sildenafil 
90 IPAH 
Methadone, Paracetamol, Clexane, 
Lansoprazole, Aspirin, Zopiclone, GTN spray, 
ISMN, Dipyridamole 
Bosentan Ambrisentan 
93 PAH-SSc 
Aspirin, Bendroflumethiazide, Nifedipine, 
Atorvastatin, Lansoprazole, Paracetamol, 
Naproxen 
Bosentan Bosentan 
94 PAH-SSc 
Digoxin, Warfarin, Omeprazole, Seretide, 
Salbutamol, Coamoxiclav, Paracetamol, 
Tiotropium, Carbocisteine 
none N/A 
96 IPAH 
Aspirin, Diltiazem, Levemir, Novorapid, 
Digoxin, Doazosin, Olmesartan, Omacor, 
Olmesartan, Venlafaxine, Warfarin 
none none 
131 IPAH Prednisolone, Lansoprazole, Clexane Sildenafil N/A 
155 PAH-SSc 
Azathioprine, Frusemide, Prednisolone, 
Lanzoprazole, Ramipril, Amlodipine, Aspirin 
Bosentan Bosentan 
163 IPAH 
Aspirin, ISMN, Lansoprazole, Simvistatin, 
Frusemide, Seretide, Ferrous sulphate 
Bosentan N/A 
164 PAH-SSc 
Frusemide, Ramipril, Omeprazole, Spiriva, 
Demovate cream, Diclofenac, Tramadol, 
Salbutamol 
Bosentan Bosentan 
165 IPAH Warfarin, Symbicort, Diltiazem none none 
171 IPAH 
Atorvastatin, Bisoprolol, Citalopram, 
Thyroxine, Lansoprazole, Bumetanide, 
Spironolactone 
Sildenafil Sildenafil 
175 PAH-SSc 
Bisoprolol, Digoxin, Spirinolactone, Warfarin, 
Ramipril, GTN spray, Simvastatin, Vitamin K 
none none 
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Cont… 
Patient ID PAH subtype Medication at baseline 
PAH 
specific 
medication 
given at 
Visit 1 
PAH 
specific 
medication 
given at 
follow-up 
183 PAH-SSc 
Simvastatin, Frusemide, Pantoprazole, 
Doxazosin, Tiotropium 
Sildenafil N/A 
184 PAH-SSc 
Citalopram, Omeprazole, Nifedipine, Ramipril, 
Ranitidine, Sildenafil 
Bosentan, 
Sildenafil 
Bosentan, 
Sildenafil 
189 PAH-SSc none Bosentan Bosentan 
193 IPAH 
GTN spray, Lansoprazole, ISMN, Digoxin, 
Thyroxine, Nicorandil, Frusemide, Eplerenone, 
Perindopril, Allopurinol, Warfarin 
Bosentan 
 
Sildenafil 
276 PAH-SSc 
Warfarin, Simvastatin, Atenolol, Omeprazole, 
Frusemide 
Bosentan none 
277 PAH-SSc 
Mycophenolate , Omeprazole, Diltiazem, 
Ramipril, Prednisolone, Amitriptyline, 
Paracetamol, Gabapentin 
none none 
280 IPAH 
Atorvastatin, Aspirin, Cod liver oil, 
Glucosamine 
Sildenafil Sildenafil 
344 IPAH 
Aspirin, Atorvastain, Clopidogrel, Perindopril, 
Ventolin, Spiriva, GTN, Enoxaparin 
Bosentan N/A 
346 PAH-SSc 
Lansoprazole, Furosemide, Simvastatin, 
Nifedipine, Tadalafil, FESO4 
Bosentan, 
Tadalafil  
N/A 
350 PAH-SSc 
Amlodipine, Ramipril, Fexofenadine, 
Pravastatin, Camellose 
Bosentan N/A 
353 IPAH Cerazette 
Bosentan, 
Sildenafil  
N/A 
380 IPAH 
Warfarin, Bumetanide, Spirinolactone, 
Simvastatin, Metformin, Bethistine, O2 therapy 
Sildenafil Sildenafil 
381 IPAH 
ISMN, Aspirin, Azathioprine, Prednisolone, 
Lansoprazole, Acetylcystene, Adcal d3, 
Carbocisteine, Alendroninc acid, O2 therapy 
Bosentan N/A 
383 IPAH none 
Ambrisentan, 
Sildenafil 
N/A 
430 PAH-SSc 
Spironolactone, Irbesartan, Bisoprolol, 
Simvastatin, aspirin, Frusemide, Felodipine, 
Lansoprazole 
Sildenafil N/A 
435 PAH-SSc 
Aspirin, Frusemide, Spironolactone, 
Omeprazole, O2 therapy 
Sildenafil N/A 
442 IPAH Lansoprasole, Adipine, Levothyroxine Sildenafil Sildenafil 
452 IPAH Adalat, Disodium, Bosentan N/A 
456 PAH-SSc 
Adalat, Adcal, Alendronic acid, Buprenorphine, 
Gaviscon, Sertraline, Folic acid, Gabapentin, 
Hydroxychloroquine, Metoclopramide, 
Paracetamol 
Sildenafil N/A 
460 IPAH 
Ramipril, Metformin, Atorvostatin, Humalog 
insulin, Seretide, Senna, Paracetamol, 
Salbutamol, Tiotropium, Certirizine, 
Coamoxiclav 
Bosentan, 
Sildenafil 
N/A 
467 IPAH Certirizine Sildenafil N/A 
 
Patient treatment plans from baseline and follow-up visits. 
Patient IDs, patient phenotype (IPAH or SSc-PAH) and treatments at 
baseline, visit 1 and follow-up visits are shown. N/A  shown when visit has 
not been completed.  
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